<Bundle xmlns="http://hl7.org/fhir"><id value="c1d4f9df-46be-4e7a-be98-37c7a7c51795" /><identifier><system value="http://ema.europa.eu/fhir/epiGuid" /><value value="c1d4f9df-46be-4e7a-be98-37c7a7c51795" /></identifier><type value="collection" /><timestamp value="2024-12-03T18:15:21.690675+01:00" /><entry><fullUrl value="da8ffe20-a826-4b65-9ad0-0ff93d02a1cd" /><resource><List><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) master document list</div></text><identifier><system value="http://ema.europa.eu/fhir/epiId" /><value value="EPI/24/129" /></identifier><status value="current" /><mode value="working" /><title value="all sections Spanish document" /><code><coding><system value="http://ema.europa.eu/fhir/documentType" /><code value="00001" /><display value="epiMasterList" /></coding></code><subject><reference value="subjectReference" /></subject><entry><item><reference value="referenceToDocument" /><display value="Ficha técnica o resumen de las características del producto" /></item></entry><entry><item><reference value="referenceToDocument" /><display value="Prospecto" /></item></entry></List></resource></entry><entry><fullUrl value="abff94af-62d6-40d9-a8ab-8a8ca7b25823" /><resource><Bundle><id value="abff94af-62d6-40d9-a8ab-8a8ca7b25823" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="abff94af-62d6-40d9-a8ab-8a8ca7b25823" /></identifier><type value="document" /><timestamp value="2024-12-03T18:15:21.6876898+01:00" /><entry><fullUrl value="abff94af-62d6-40d9-a8ab-8a8ca7b25823" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155532" /><display value="Ficha técnica o resumen de las características del producto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-03" /><author><reference value="systemUser" /></author><title value="Ficha técnica o resumen de las características del producto" /><section><title value="Ficha técnica o resumen de las características del producto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029791" /><display value="Ficha técnica o resumen de las características del producto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="6f6a820a-a26e-49ce-a96e-4ebe677cd462"><title value="0. Advertencia triángulo negro" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="Advertencia triángulo negro" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><img src="data:image/jpg;base64,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" width="24" height="22" alt="" /><span style="font-family:Times New Roman; font-size:11pt">Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas. Ver la sección 4.8, en la que se incluye información sobre cómo notificarlas.</span></p></div></text></section><section id="0d492add-b1a4-4dbf-a61d-c97afa732fd2"><title value="1. Nombre del medicamento" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029792" /><display value="Nombre del medicamento" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz 20 mg solución inyectable en jeringa precargada</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz 40 mg solución inyectable en jeringa precargada</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz 40 mg solución inyectable en pluma precargada</span></p></div></text></section><section id="76a394ed-98cf-4920-8d17-21523d7ee505"><title value="2. Composición cualitativa y cuantitativa" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029793" /><display value="Composición cualitativa y cuantitativa" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz 20 mg solución inyectable en jeringa precargada:</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Cada jeringa precargada con una dosis única de 0,4 ml contiene 20 mg de adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en jeringa precargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Cada jeringa precargada con una dosis única de 0,8 ml contiene 40 mg de adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en pluma precargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Cada pluma precargada con una dosis única de 0,8 ml contiene 40 mg de adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab es un anticuerpo monoclonal humano recombinante producido en células de Ovario de Hámster Chino.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Para consultar la lista completa de excipientes, ver sección 6.1.</span></p></div></text></section><section id="02d96719-8dc9-42d6-9f36-997396e69d52"><title value="3. Forma farmacéutica" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029797" /><display value="Forma farmacéutica" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Solución inyectable</span><span style="font-family:Times New Roman; font-size:11pt">(inyectable) en jeringa precargada</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Solución inyectable (inyectable) en pluma precargada (SensoReady)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Solución transparente a ligeramente opalescente, incolora a ligeramente amarillenta.</span></p></div></text></section><section id="9eb7ac7b-9f92-4faa-975d-0c4aea40affc"><title value="4. Datos clínicos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029798" /><display value="Datos clínicos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="a36ba221-7a7c-45ee-8073-909556efdbdc"><title value="4.1. Indicaciones terapéuticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029799" /><display value="Indicaciones terapéuticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis reumatoide</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz en combinación con metotrexato, está indicado para:</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt" ><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">el tratamiento de la artritis reumatoide activa moderada a grave en pacientes adultos, cuando la respuesta a fármacos antirreumáticos modificadores de la enfermedad incluyendo metotrexato haya sido insuficiente.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">el tratamiento de la artritis reumatoide activa, grave y progresiva en adultos no tratados previamente con metotrexato.</span></li></ul><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz puede ser administrado como monoterapia en caso de intolerancia al metotrexato o cuando el tratamiento continuado con metotrexato no sea posible.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab ha demostrado reducir la tasa de progresión del daño de las articulaciones medido por rayos X y mejorar el rendimiento físico, cuando se administra en combinación con metotrexato.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil poliarticular</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz en combinación con metotrexato está indicado para el tratamiento de la artritis idiopática juvenil poliarticular activa en pacientes a partir de 2 años que han presentado una respuesta insuficiente a uno o más fármacos antirreumáticos modificadores de la enfermedad (FAME). Hyrimoz puede ser administrado en monoterapia en caso de intolerancia al metotrexato o cuando el tratamiento continuado con metotrexato no sea posible (para consultar los datos de eficacia en monoterapiaver sección 5.1). No se ha estudiado el uso de adalimumab en pacientes menores de 2 años.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis asociada a entesitis</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la artritis asociada a entesitis activa en pacientes a partir de de 6 años que han presentado una respuesta insuficiente, o son intolerantes, al tratamiento convencional (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Espondiloartritis axial</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Espondilitis anquilosante (EA)</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de adultos con espondilitis anquilosante activa grave que hayan presentado una respuesta insuficienteal tratamiento convencional.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Espondiloartritis axial sin evidencia radiográfica de EA</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de adultos con espondiloartritis axial grave sin evidencia radiográfica de EA pero con signos objetivos de inflamación por elevada Proteína C Reactiva y/o Imagen por Resonancia Magnética (IRM), que presentan una respuesta insuficiente o son intolerantes a fármacos antiinflamatorios no esteroideos (AINEs).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis psoriásica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la artritis psoriásica activa y progresiva en adultos cuando la respuesta a la terapia previa con antirreumáticos modificadores de la enfermedad haya sido insuficiente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se ha demostrado que adalimumab reduce la progresión del daño en las articulaciones perifericas medido por rayos X en pacientes que presentaban el patrón poliarticular simétrico de la enfermedad (ver sección 5.1) y que mejora la función física de los pacientes.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la psoriasis en placas crónica de moderada a grave en pacientes adultos que sean candidatos para un tratamiento sistémico.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis pediátrica en placas</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la psoriasis crónica en placas grave en niños y adolescentes desde los 4 años de edad que hayan presentado una respuesta inadecuada o no sean candidatos apropiados para tratamiento tópico y fototerapias.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa (HS)</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de lahidradenitis supurativa activa (acné inverso) de moderada a grave en pacientes adultos y adolescentes a partir de 12 años de edad con una respuesta insuficiente al tratamiento sistémico convencional de hidradenitis supurativa (ver secciones 5.1 y 5.2).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la enfermedad de Crohn activa de moderada a grave en pacientes adultos que no hayan respondido a un tratamiento, completo y adecuado, con corticoesteroides y/o inmunosupresores, o que son intolerantes o tienen contraindicaciones médicas para dichos tratamientos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn pediátrica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la enfermedad de Crohn activa de moderada a grave en pacientes pediátricos (a partir de los 6 años de edad) que han presentado una respuesta insuficiente al tratamiento convencional incluyendo tratamiento nutricional primario y un corticoesteroide y/o un inmunomodulador, o que son intolerantes o tienen contraindicados dichos tratamientos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><a name="_Hlk53597433"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa pediátrica</span></span></a></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><a name="_Hlk53412902"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la colitis ulcerosa activa de moderada a grave en pacientes pediátricos (a partir de 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años) que han presentado una respuesta insuficiente al tratamiento convencional, incluidos corticoesteroides y/o 6-mercaptopurina (6-MP) o azatioprina (AZA),</span></a><a name="_Hlk55288298"><span style="font-family:Times New Roman; font-size:11pt">o que son intolerantes o están contraindicados para dichos tratamientos</span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado en el tratamiento de la colitis ulcerosa activa, de moderada a grave, en pacientes adultos que han presentado una respuesta inadecuada al tratamiento convencional, incluidos corticosteroides y 6-mercaptopurina (6-MP) o azatioprina (AZA), o que presentan intolerancia o contraindicaciones médicas a dichos tratamientos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uveítis</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado en el tratamiento de la uveítis no infecciosa intermedia y posterior y panuveítis en pacientes adultos que han presentado una respuesta inadecuada a corticoesteroides, que necesiten disminuir su tratamiento con corticoesteroides, o en aquellos en los que el tratamiento con corticoesteroides sea inapropiado.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uveítis pediátrica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado para el tratamiento de la uveítis pediátrica anterior crónica no infecciosa en pacientes desde los 2 años de edad que han tenido una respuesta inadecuada o son intolerantes a la terapia convencional, o en los que la terapia convencional no es adecuada.</span></p></div></text></section><section id="b9560dbd-4180-4c20-a874-0160f17d6f24"><title value="4.2. Posología y forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029800" /><display value="Posología y forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El tratamiento con Hyrimoz debe ser iniciado y supervisado por médicos especialistas con experiencia en el diagnóstico y el tratamiento de aquellas indicaciones autorizadas para Hyrimoz. Se aconseja a los oftlamólogos consultar con un especialista apropiado antes de iniciar el tratamiento con Hyrimoz (ver sección 4.4). A los pacientes tratados con Hyrimoz se les debe entregar la tarjeta de información para el paciente.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Tras un adecuado aprendizaje de la técnica de inyección, los pacientes pueden autoinyectarse Hyrimoz si el médico lo considera apropiado y les hace el seguimiento médico necesario.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Durante el tratamiento con Hyrimoz, se deben optimizar otros tratamientos concomitantes (por ejemplo, corticoesteroides y/o agentes inmunomoduladores).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text><section id="3aede193-a47c-440b-a5b7-f0085b883df3"><title value="4.2.1. Posología" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029801" /><display value="Posología" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis reumatoide</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes adultos con artritis reumatoide es 40 mg de adalimumab administrados en semanas alternas como dosis única en inyección por vía subcutánea. El metotrexato debe mantenerse durante el tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Glucocorticoides, salicilatos, fármacos antiinflamatorios no esteroideos, o analgésicos pueden mantenerse durante el tratamiento con Hyrimoz. Para la combinación con fármacos antirreumáticos modificadores de la enfermedad distintos del metotrexato, ver secciones 4.4 y 5.1.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En monoterapia, los pacientes que experimenten una disminución en su respuesta con Hyrimoz 40 mg en semanas alternas pueden beneficiarse de un aumento de la dosis a 40 mg de adalimumab cada semana u 80 mg cada dos semanas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los datos disponibles sugieren que la respuesta clínica normalmente se alcanza dentro de las 12 semanas de tratamiento. La continuación del tratamiento se debe reconsiderar en pacientes que no hayan respondido en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Interrupción del tratamiento</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Puede ser necesario la interrupción del tratamiento, por ejemplo antes de una cirugía o si se produce una infección grave.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los datos disponibles sugieren que cuando se vuelve a iniciar el tratamiento con adalimumab tras una interrupción de 70 días de duración o superior, se obtiene una respuesta clínica y un perfil de seguridad similar al observado antes de la interrupción del tratamiento.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA y artritis psoriásica</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes con espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA y para pacientes con artritis psoriásica es de 40 mg de adalimumab administrados en semanas alternas como dosis única en inyección por vía subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los datos disponibles sugieren que la respuesta clínica se consigue, por lo general, dentro de las primeras 12 semanas de tratamiento. La continuación con el tratamiento debe ser reconsiderada en los pacientes que no hayan respondido en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La posología recomendada de Hyrimoz para pacientes adultos es de una dosis inicial de 80 mg administrada por vía subcutánea, seguida de 40 mg administrados por vía subcutánea en semanas alternas comenzando una semana después de la dosis inicial.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La continuación del tratamiento mas allá de 16 semanas se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Tras 16 semanas, los pacientes con una respuesta inadecuada con Hyrimoz 40 mg en semanas alternas se pueden beneficiar de un incremento de la dosis a 40 mg semanales u 80 mg cada dos semanas. Los beneficios y riesgos de la continuación del tratamiento semanal con 40 mg u 80 mg cada dos semanas se debe reconsiderar cuidadosamente en pacientes con una respuesta inadecuada tras el incremento de la dosis (ver sección 5.1). Si se alcanza una respuesta adecuada con 40 mg semanal u 80 mg cada dos semanas, la dosis se puede reducir posteriormente a 40 mg en semanas alternas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La pauta posológica recomendada de Hyrimoz para pacientes adultos con hidradenitis supurativa (HS) es de una dosis inicial de 160 mg en el día 1 (administrada como 4 inyecciones de 40 mg en un día o 2 inyecciones diarias de 40 mg en dos días consecutivos), seguida de 80 mg dos semanas después, en el día 15 (administrada como 2 inyecciones de 40 mg en un día). Dos semanas despúes (día 29) continuar con una dosis de 40 mg semanal u 80 mg cada dos semanas (administrada como dos inyecciones de 40 mg en un día). Si es necesario se puede continuar el tratamiento con antibióticos durante el tratamiento con Hyrimoz. Durante el tratamiento con Hyrimoz se recomienda que el paciente utilice a diario un líquido antiséptico tópico en las lesiones de hidradenitis supurativa.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La continuación del tratamiento más allá de 12 semanas se debe reconsiderar, de forma cuiadosa en pacientes que no hayan mejorado en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Si se necesita interrumpir el tratamiento, se puede reintroducir Hyrimoz 40 mg semanalmente u 80 mg cada dos semanas (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se debe evaluar periódicamente el balance beneficio/riesgo del tratamiento continuado a largo plazo (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La pauta de dosificación inicial recomendado de Hyrimoz para pacientes adultos con enfermedad de Crohn activa de moderada a grave es de 80 mg en la semana 0 seguido de 40 mg en la semana 2. En caso de que sea necesaria una respuesta más rápida al tratamiento, se puede cambiar la posología a 160 mg en la semana 0 (administrada mediante 4 inyecciones de 40 mg en un día o con 2 inyecciones de 40 mg por día durante dos días consecutivos), seguido de 80 mg en la semana 2 (administrada mediante dos inyecciones de 40 mg en un día), siendo consciente del mayor riesgo de reacciones adversas durante el inicio del tratamiento.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Después de iniciar el tratamiento, la dosis recomendada es de 40 mg administrados en semanas alternas vía inyección subcutánea. De forma alternativa, si un paciente interrumpe el tratamiento con Hyrimoz y los signos y síntomas de la enfermedad recurren, se puede re-administrar Hyrimoz. Hay poca experiencia en la re-administración transcurridas más de 8 semanas desde la dosis previa.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los corticoesteroides se pueden reducir durante el tratamiento de mantenimiento, de acuerdo con las guías de práctica clínica.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Para algunos pacientes que han experimentado una disminución de su respuesta con Hyrimoz 40 mg en semanas alternas puede ser beneficioso un aumento de la dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Para algunos pacientes que no han respondido al tratamiento en la semana 4, puede ser beneficioso continuar con un tratamiento de mantenimiento hasta la semana 12. El tratamiento continuado se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido dentro de este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis de inducción recomendada de Hyrimoz para pacientes adultos con colitis ulcerosa de moderada a grave es de 160 mg en la semana 0 (administrada mediante 4 inyecciones de 40 mg en un día o con 2 inyecciones de 40 mg por día durante dos días consecutivos) y 80 mg en la semana 2 (administrada mediante dos inyecciones de 40 mg en un día). Después del tratamiento de inducción, la dosis recomendada es de 40 mg cada dos semanas mediante inyección por vía subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los corticoesteroides se pueden reducir durante el tratamiento de mantenimiento, de acuerdo con las guías de práctica clínica.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Para algunos pacientes que han experimentado una disminución de su respuesta con Hyrimoz 40 mg en semanas alternas, puede ser beneficioso un aumento de la dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los datos disponibles sugieren que la respuesta clínica se alcanza generalmente dentro de 2-8 semanas de tratamiento. El tratamiento con Hyrimoz no debería continuarse en pacientes que no respondan dentro de este período de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Uveítis</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes adultos con uveítis es de una dosis inicial de 80 mg, seguida de 40 mg administrado en semanas alternas comenzando una semana después de la dosis inicial. Hay experiencia limitada en el inicio del tratamiento con adalimumab en monoterapia. El tratamiento con Hyrimoz se puede iniciar en combinación con corticoesteroides y/o con otro agente inmunomodulador no biológico. El tratamiento concomitante con corticoesteroides puede ser ajustado de acuerdo con la práctica clínica comenzando dos semanas tras el inicio del tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se recomienda una evaluación anual del beneficio y riesgo del tratamiento continuado a largo plazo (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Poblaciones especiales</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Pacientes de edad avanzada</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No se requiere ajuste de dosis.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal y/o hepática</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab no se ha estudiado en estas poblaciones de pacientes, por lo que no hay recomendaciones de dosis.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Artritis idiopática juvenil poliarticular desde los 2 años de edad</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes con artritis idiopática juvenil poliarticular a partir de los 2 años de edad se basa en el peso corporal (tabla 1). Hyrimoz se administra en semanas alternas en inyección por vía subcutánea.</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto"><tr style="height:34.6pt"><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:368.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">1. Dosis de Hyrimoz para pacientes</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">con artritis idiopática juvenil poliarticular</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Pauta po</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">sológica</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">10</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg hasta &lt;</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">20</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg en semanas alternas</span></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">≥</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">40</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg en semanas alternas</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:184.35pt; border:none">
                                        </td>
                                        <td style="width:184.2pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los datos disponibles sugieren que la respuesta clínica se consigue, por lo general, dentro de las primeras 12 semanas de tratamiento. La continuación con el trata</span><span style="font-family:Times New Roman; font-size:11pt">miento se debe ser reconsiderar cuidadosamente en los pacientes que no hayan respondido en este periodo de tiempo</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No hay un uso relevante de adalimumab en pacientes menores de 2 años para esta indicación.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Artritis asociada a entesitis</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes con artritis asociada a entesitis en pacientes a partir de 6 años se basa en el peso corporal (tabla 2). Hyrimoz se administra en semanas alternas en inyección por vía subcutánea.</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto"><tr style="height:34.6pt"><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:368.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">2. Dosis de Hyrimoz para pacientes</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">con ar</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">tritis asociada a entesitis</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Pauta posológica</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">15</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg hasta &lt;</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">20</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg en semanas alternas</span><strong><span style="font-family:Times New Roman; font-size:11pt;">–</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">≥</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">40</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg en semanas alternas</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:184.35pt; border:none">
                                        </td>
                                        <td style="width:184.2pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No se ha estudiado el uso de adalimumab en pacientes con artritis asociada a entesitis menores de 6 años.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis pediátrica en placas</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes con psoriasis en placas desde los 4 a los 17 años de edad se basa en el peso corporal (tabla 3). Hyrimoz se administra mediante inyección por vía subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto"><tr style="height:34.6pt"><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:368.55pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">3. Dosis de Hyrimoz para pacientes pediátricos</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">con psoriasis en placas</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Pauta posológica</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">15</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg hasta &lt;</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Dosis inicial de</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">20</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg, seguida de</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">20</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg administrados en semanas alternas empezando una semana después de la dosis inicial</span></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">≥</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.2pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Dosis inicial de</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">40</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg, seguida de</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">40</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">mg administrados en semanas alternas empezando una semana después de la dosis inicial</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:184.35pt; border:none">
                                        </td>
                                        <td style="width:184.2pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La continuación del tratamiento más allá de 16 semanas se debe reconsiderar de forma cuidadosa en pacientes que no hayan r</span><span style="font-family:Times New Roman; font-size:11pt">espondido en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En el caso de que esté indicado el retratamiento con adalimumab, se deben seguir las indicaciones anteriores en cuanto a la dosis y la duración del tratamiento.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La seguridad de adalimumab en pacientes pediátricos psoriasis en placas ha sido evaluada durante una media de 13 meses.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No existe una recomendación de uso específica para adalimumab en niños menores de 4 años para esta indicación.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa en adolescentes (a partir de 12 años de edad, con un peso de al menos 30 kg)</span></span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No hay ensayos clínicos con adalimumab en pacientes adolescentes con HS. La posología de adalimumab en estos pacientes se ha determinado a partir de modelos farmacocinéticos y simulación (ver sección 5.2).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz es de 80 mg en la semana 0 seguida de 40 mg en semanas alternas comenzando en la semana 1 mediante inyección subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En pacientes adolescentes con una respuesta inadecuada con Hyrimoz 40 mg en semanas alternas, se puede considerar un incremento de dosis a 40 mg semanales u 80 mg cada dos semanas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Si es necesario se puede continuar el tratamiento con antibióticos durante el tratamiento con Hyrimoz. Durante el tratamiento con Hyrimoz se recomienda que el paciente utilice a diario un líquido antiséptico tópico en las lesiones de hidradenitis supurativa.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La continuación del tratamiento más allá de 12 semanas se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan mejorado en este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Si se necesita interrumpir el tratamiento, se puede reintroducir Hyrimoz según proceda.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se debe evaluar periódicamente el balance beneficio/riesgo del tratamiento continuado a largo plazo (ver datos en adultos en sección 5.1).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El uso de adalimumab en niños menores de 12 años para la indicación de enfermedad de hidradenitis supurativa no es apropiado.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn pediátrica</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes con enfermedad de Crohn desde los 6 hasta los 17 años de edad se basa en el peso corporal (tabla 4). Hyrimoz se administra en inyección por vía subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 4. Dosis de Hyrimoz para pacientes pediátricos con enfermedad de Crohn</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:250pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis de inducción</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:154pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis de mantenimiento a partir de la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">4</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:250pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></li></ul><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">En caso de que sea necesaria una respuesta más rápida al tratamiento, siendo conscientes de que el riesgo de acontecimientos adversos podría aumentar con el uso de una dosis de inducción mayor, puede usarse la siguiente dosis:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">m</span><span style="font-family:Times New Roman; font-size:11pt">g en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></li></ul></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:154pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:250pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></li></ul><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">En caso de que sea necesaria una respuesta más rápida al tratamiento, siendo conscientes de que el riesgo de acontecimientos adversos podría aumentar con el us</span><span style="font-family:Times New Roman; font-size:11pt">o de una dosis de inducción mayor, puede usarse la siguiente dosis:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; page-break-inside:avoid; page-break-after:avoid; padding-left:18.29pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></li></ul></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:154pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td></tr></table><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que tengan una respuesta insuficiente pueden beneficiarse de un aumento en la frecuencia de dosificación:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; widows:0; orphans:0; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg cada semana</span></li></ul><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">≥ 40 kg: 40 mg cada semana u 80 mg cada dos semanas</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El tratamiento continuado se debe reconsiderar, de forma cuidadosa, en pacientes que no hayan respondido en la semana 12.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El uso de adalimumab en niños menores de 6 años para la indicación de enfermedad</span><span style="font-family:Times New Roman; font-size:11pt">de Crohn no es apropiado.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa pediátrica</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz para pacientes de 6 a 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años con colitis ulcerosa se basa en el peso corporal (Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5). Hyrimoz se administra mediante inyección subcutánea.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">5. Dosis de Hyrimoz para pacientes pediátricos con colitis ulcerosa</span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:91.48%"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:40.1%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis de inducción</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:38.12%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis de mantenimiento</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">Comienza en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">4*</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:40.1%"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 (administrados como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) y</span></li><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 (administra</span><span style="font-family:Times New Roman; font-size:11pt">dos como una inyección de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg)</span></li></ul></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:38.12%"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></li></ul></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:40.1%"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 (administrados como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg al día en dos días consecutivos) y</span></li><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 (administrados como dos i</span><span style="font-family:Times New Roman; font-size:11pt">nyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día)</span></li></ul></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:38.12%"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 16.35pt; text-indent:0pt; padding-left:1.65pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas (administrados como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día)</span></li></ul></td></tr><tr><td colspan="3" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding:0.75pt; vertical-align:top"><p style="margin:0pt; line-height:115%; font-size:11pt"><a name="_Hlk53413143"><span style="font-family:Times New Roman; font-size:11pt">* Los pacientes pediátricos que cumplan 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años durante el tratamiento con Hyrimoz deben continuar con la dosis de mantenimiento prescrita.</span></a></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:88.35pt; border:none">
                                        </td>
                                        <td style="width:162.65pt; border:none">
                                        </td>
                                        <td style="width:154.6pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt"><a name="_Hlk53597628"><span style="font-family:Times New Roman; font-size:11pt"> </span></a></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El tratamiento continuado tras 8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas se debe reconsiderar, de forma cuidadosa, en pacientes que no muestran signos de respuesta transcurrido este tiempo.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El uso de Hyrimoz en niños menores de 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad para esta indicación no es relevante.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz puede estar disponible en distintas dosis y/o presentaciones en función de las necesidades individuales del tratamiento.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uveítis pediátrica</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La dosis recomendada de Hyrimoz en pacientes pediátricos con uveítis desde los 2 años de edad se basa en el peso corporal (tabla 6). Hyrimoz se administra en inyección por vía subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En uveítis pediátrica, no hay experiencia en el tratamiento con adalimumab sin un tratamiento concomitante con metotrexato.</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto"><tr style="height:34.6pt"><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:396.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">6. Dosis de Hyrimoz para pacientes pediátr</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">icos con uveítis</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:212.55pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">Pauta posológica</span></strong></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:212.55pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas en</span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">combinación con metrotexato</span></p></td></tr><tr style="height:22.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:184.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">≥</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">30</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt"> </span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:212.55pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas en</span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">combinación con metrotexato</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:184.35pt; border:none">
                                        </td>
                                        <td style="width:212.55pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Cuando se inicie la terapia con Hyrimoz, se puede administrar una dosis de carga de 40 mg para pacientes de &lt; 30 kg o de 80 mg para pacientes ≥ 30 kg una semana antes de empezar la terapia de mantenimiento. No hay datos clínicos disponibles sobre el uso de una dosis de carga de adalimumab en niños &lt; 6 años (ver sección 5.</span><span style="font-family:Times New Roman; font-size:11pt">2).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El uso de Hyrimoz en niños menores de 2 años de edad para esta indicación no es relevante.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se recomienda evaluar anualmente el beneficio y el riesgo en tratamientos continuados a largo plazo (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis psoriásica y espondiloartritis axial incluyendo espondilitis anquilosante</span></span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No hay un uso relevante de adalimumab en la población pediátrica para las indicaciones de espondilitis anquilosante y artritis psoriásica.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="bd881afc-0b7b-47d4-8354-a52266093af5"><title value="4.2.2. Forma de administración" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029803" /><display value="Forma de administración" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se administra mediante inyección subcutánea.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Las instrucciones completas para su uso se describen en el prospecto</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab está disponible en otras concentraciones y presentaciones.</span></p></div></text></section></section><section id="329d2b78-7605-4f97-b56e-2ea7653fbe9f"><title value="4.3. Contraindicaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029805" /><display value="Contraindicaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hipersensibilidad al principio activo o a alguno de los excipientes, incluidos en la sección 6.1.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tuberculosis activa u otras infecciones graves tales como sepsis, e infecciones oportunistas (ver sección 4.4).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Insuficiencia cardiaca moderada a grave (NYHA clases III/IV) (ver sección 4.4).</span></p></div></text></section><section id="7cc38aa7-77fc-4364-9cbf-6d9a363d4d06"><title value="4.4. Advertencias y precauciones especiales de empleo" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029806" /><display value="Advertencias y precauciones especiales de empleo" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Trazabilidad</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Con objeto de mejorar la trazabilidad de los medicamentos biológicos, el nombre y el número de lote del medicamento administrado deben estar claramente registrados.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Infecciones</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que están en tratamiento con antagonistas del TNF son más susceptibles de padecer infecciones graves. La función pulmonar alterada puede incrementar el riesgo de desarrollar infecciones. Los pacientes deben ser, por lo tanto, estrechamente monitorizados para la detección de infecciones (incluyendo tuberculosis), antes, durante y después del tratamiento con Hyrimoz. Dado que la eliminación de adalimumab puede tardar hasta cuatro meses, la monitorización se debe continuar durante este periodo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El tratamiento con Hyrimoz no se debe iniciar en pacientes con infecciones activas, incluyendo infecciones crónicas o localizadas, hasta que las infecciones estén controladas. Se debe considerar el riesgo y el beneficio antes de iniciar el tratamiento con Hyrimoz en pacientes que han estado expuestos a tuberculosis y en pacientes que han viajado a áreas de alto riesgo de tuberculosis o áreas endémicas de micosis, como histoplasmosis, coccidiomicosis o blastomicosis (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Otras infecciones oportunistas</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que desarrollen una nueva infección mientras estén bajo tratamiento con Hyrimoz deben ser estrechamente monitorizados y sometidos a una evaluación diagnóstica completa. La administración de Hyrimoz debe interrumpirse si un paciente desarrolla una infección grave nueva o sepsis, y se debe iniciar el tratamiento antimicrobiano o antifúngico apropiado hasta que la infección esté controlada. Los médicos deben tener precaución cuando consideren el uso de Hyrimoz en pacientes con antecedentes de infección recurrente o con condiciones subyacentes que puedan predisponer a los pacientes a infecciones, incluido el uso concomitante de medicamentos inmunosupresores.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Infecciones graves</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado infecciones graves, incluyendo sepsis, de origen bacteriano, micobacteriano, fúngicas invasivas, parasitarias, virales u otras infecciones oportunistas como listeriosis, legionelosis y pneumocistis en pacientes en tratamiento con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Otras infecciones graves observadas en los ensayos clínicos incluyen neumonía, pielonefritis, artritis séptica y septicemia. Se han notificado casos de hospitalizaciones o desenlaces mortales asociados a estas infecciones.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Tuberculosis</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se han notificado casos de tuberculosis, incluyendo reactivación y tuberculosis de nueva aparición, en pacientes en tratamiento con adalimumab. Las notificaciones incluyeron casos de tuberculosis pulmonar y extrapulmonar, es decir, diseminada.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Antes de iniciar el tratamiento con Hyrimoz, se debe evaluar en todos los pacientes la existencia de tuberculosis activa e inactiva (latente). Esta evaluación debe incluir una valoración médica detallada del paciente con antecedentes de tuberculosis o posible exposición previa a personas con tuberculosis activa y tratamiento inmunosupresor previo y/o actual. Se deberán realizar pruebas de detección adecuadas (es decir, prueba cutánea de la tuberculina y radiografía de tórax) en todos los pacientes (aplicando recomendaciones locales). Se recomienda anotar en la tarjeta de información para el paciente la realización y resultados de estas pruebas. Se recuerda a los médicos el riesgo de falsos negativos en la prueba cutánea de la tuberculina, especialmente en pacientes que están gravemente enfermos o inmunodeprimidos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Si se diagnostica tuberculosis activa, no se debe iniciar el tratamiento con Hyrimoz (ver sección 4.3).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En todas las situaciones descritas a continuación, el balance beneficio/riesgo del tratamiento con Hyrimoz debe ser cuidadosamente considerado.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Si se tienen sospechas de tuberculosis latente, se debe consultar con un médico con experiencia en el tratamiento de la tuberculosis.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Si se diagnostica tuberculosis latente, se debe iniciar el tratamiento con una profilaxis anti-tuberculosa antes de comenzar el tratamiento con Hyrimoz y de acuerdo con las recomendaciones locales.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se debe considerar también el uso de profilaxis anti-tuberculosa antes del inicio del tratamiento con Hyrimoz en pacientes con factores de riesgo múltiples o significativos a pesar de un resultado negativo en la prueba para la tuberculosis y en pacientes con antecedentes de tuberculosis latente o activa en los que no se haya podido confirmar el curso adecuado del tratamiento.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">A pesar de la profilaxis para la tuberculosis, se han producido casos de reactivación de la misma en pacientes tratados con adalimumab. Algunos pacientes que habían recibido un tratamiento satisfactorio para la tuberculosis activa han vuelto a desarrollar tuberculosis mientras estaban en tratamiento con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se deben dar instrucciones a los pacientes para que consulten con su médico si apareciesen signos/síntomas que sugieran tuberculosis (p. ej. tos persistente, debilidad/pérdida de peso, febrícula, apatía) durante o después del tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Otras infecciones oportunistas</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se han observado infecciones oportunistas, incluyendo infecciones fúngicas invasivas, en pacientes en tratamiento con adalimumab. Estas infecciones no se han identificado de forma sistemática en pacientes en tratamiento con antagonistas del TNF lo que ha originado retrasos en el tratamiento apropiado, en ocasiones con consecuencias mortales.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se tendrá en cuenta la posibilidad de una infección fúngica invasiva en aquellos pacientes que desarrollen signos y síntomas como fiebre, malestar, perdida de peso, sudoración, tos, disnea y/o infiltraciones pulmonares u otros síntomas de enfermedad sistémica grave con o sin shock conconmitante. En estos pacientes se debe suspender inmediatamente la administración de Hyrimoz. El diagnóstico y la administración de tratamiento antifúngico empírico en estos pacientes se debe realizar de acuerdo con un médico con experiencia previa en el cuidado de pacientes con infecciones fúngicas invasivas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Reactivación de Hepatitis B</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se han producido casos de reactivación de la hepatitis B en pacientes que estaban recibiendo antagonistas del TNF (Factor de necrosis tumoral), incluyendo adalimumab, los cuales son portadores crónicos del virus (por ejemplo, antígeno de superficie positivo), en algunos casos con desenlace mortal. Se debe analizar una posible infección previa con VHB en los pacientes antes de iniciar el tratamiento con Hyrimoz. Para aquellos pacientes con análisis positivo para infección de hepatitis B, se recomienda consultar con un médico especialista en el tratamiento de la hepatitis B.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se monitorizarán estrechamente los signos y síntomas de infección activa por VHB durante todo el tratamiento y hasta varios meses después de la finalización del tratamiento en aquellos portadores de VHB que requieran tratamiento con Hyrimoz. No existen datos adecuados acerca de la prevención de la reactivación del VHB en pacientes portadores del VHB que reciban de forma conjunta tratamiento anti-viral y un antagonista del TNF. En pacientes que sufran una reactivación del VHB, se debe interrumpir el tratamiento con Hyrimoz e iniciar un tratamiento anti-viral efectivo con el tratamiento de soporte apropiado.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Efectos neurológicos</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los antagonistas del TNF incluyendo adalimumab se han asociado en casos raros con la nueva aparición o exacerbación de los síntomas clínicos y/o evidencia radiográfica de enfermedad desmielinizante del sistema nervioso central, incluyendo esclerosis múltiple y neuritis óptica, y enfermedad desmielinizante del sistema nervioso periférico, incluyendo Síndrome de Guillain-Barré. Los médicos deberán considerar con precaución el uso de Hyrimoz en pacientes con trastornos desmielinizantes del sistema nervioso central o periférico preexistentes o de reciente aparición; si se desarrolla cualquiera de estos trastornos se debe considerar la interrupción del tratamiento con Hyrimoz. Existe una asociación conocida entre la uveítis intermedia y los trastornos desmielinizantes centrales. Antes del inicio del tratamiento con Hyrimoz y de forma regular durante el tratamiento se debe realizar una evaluación neurológica en pacientes con uveítis intermedia no infecciosa para valorar trastornos desmielinizantes centrales pre-existentes o en desarrollo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Reacciones alérgicas</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las reacciones alérgicas graves asociadas a adalimumab fueron raras durante los ensayos clínicos. Las reacciones alérgicas no-graves asociadas con adalimumab fueron poco frecuentes durante los ensayos clínicos. Se han recibido notificaciones de reacciones alérgicas graves que incluyeron anafilaxia tras la administración de adalimumab. Si aparece una reacción anafiláctica u otra reacción alérgica grave, se debe interrumpir inmediatamente la administración de Hyrimoz e iniciar el tratamiento apropiado.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Inmunosupresión</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un estudio de 64 pacientes con artritis reumatoide que fueron tratados con adalimumab, no se observó evidencia de descenso de hipersensibilidad retardada, descenso de los niveles de inmunoglobulinas, o cambio en el recuento de células efectoras T, B y células NK, monocitos/macrófagos, y neutrófilos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedades neoplásicas malignas y trastornos linfoproliferativos</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En las partes controladas de los ensayos clínicos de los antagonistas del TNF, se han observado más casos de enfermedades neoplásicas malignas, incluido el linfoma, entre los pacientes que recibieron un antagonista del TNF en comparación con el grupo control. Sin embargo, la incidencia fue rara. En el entorno posautorización se han notificado casos de leucemia en pacientes tratados con antagonistas del TNF. Existe un mayor riesgo basal de linfomas y leucemia en pacientes con artritis reumatoide con enfermedad inflamatoria de alta actividad, que complica la estimación del riesgo. Con el conocimiento actual, no se puede excluir un posible riesgo de desarrollo de linfomas, leucemia, y otras enfermedades neoplásicas malignas en pacientes tratados con antagonistas del TNF.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se ha notificado la aparición de enfermedades neoplásicas malignas, algunas mortales, entre niños, adolescentes y jóvenes adultos (hasta 22 años de edad) tratados con ag</span><span style="font-family:Times New Roman; font-size:11pt">entes antagonistas del TNF (inicio del tratamiento ≤ 18 años), incluyendo adalimumab en el entorno posautorización. Aproximadamente la mitad de los casos fueron linfomas. Los demás casos representan una variedad de enfermedades neoplásicas malignas e inclu</span><span style="font-family:Times New Roman; font-size:11pt">yen cánceres raros normalmente asociados con inmunosupresión. No se puede excluir el riesgo de desarrollar enfermedades neoplásicas malignas en niños y adolescentes tratados con antagonistas del TNF.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Durante la comercialización, se han identificado casos raros de linfoma hepatoesesplénico de células T en pacientes tratados con adalimumab. Estos casos raros de linfoma de células T cursan con una progresión muy agresiva y por lo general mortal de la enfermedad. Algunos de estos linfomas hepatoesplénicos de células T con adalimumab se han presentado en pacientes adultos jóvenes en tratamiento concomitante con azatioprina o 6 - mercaptopurina utilizada para la enfermedad inflamatoria intestinal. El riesgo potencial de la combinación de azatiopina o 6-mercaptopurina y Hyrimoz debe ser cuidadosamente considerado. No se puede descartar el riesgo de desarrollar linfoma hepatoesplénico de células T en pacientes tratados con Hyrimoz (ver sección 4.8).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">No se han realizado estudios que incluyan pacientes con historial de enfermedades neoplásicas malignas o en los que el tratamiento con adalimumab continue tras desarrollar una enfermedad neoplásica maligna. Por tanto, se deben tomar precauciones adicionales al considerar el tratamiento de estos pacientes con Hyrimoz (ver sección 4.8).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En todos los pacientes, y en particular en aquellos que hayan recibido un tratamiento inmunosupresor extensivo o pacientes con psoriasis y tratamiento previo con PUVA, se debe examinar la presencia de cáncer de piel de tipo no-melanoma antes y durante el tratamiento con Hyrimoz. Se han notificado también casos de melanoma y carcinoma de células de Merkel en pacientes en tratamiento con antagonistas del TNF incluyendo adalimumab (ver sección 4.8).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un ensayo clínico exploratorio que evaluaba el uso de otro antagonista del TNF, infliximab, en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave, se registraron más casos de enfermedades neoplásicas malignas, la mayoría del pulmón, o cabeza y cuello, en pacientes en tratamiento con infliximab en comparación con el grupo control. Todos los pacientes presentaban antecedentes de tabaquismo importante. Por tanto, se debe tener especial cuidado cuando se utilice cualquier antagonista de TNF en pacientes con EPOC, así como en pacientes con un elevado riesgo de sufrir enfermedades neoplásicas malignas por fumar en exceso.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Con los datos disponibles actualmente se desconoce si el tratamiento con adalimumab influye en el riesgo de desarrollar displasia o cáncer de colon. Se debe cribar para displasia a intervalos regulares antes del tratamiento y durante el curso de la enfermedad a todos los pacientes con colitis ulcerosa que presenten un riesgo incrementado de displasia o carcinoma de colon (por ejemplo, pacientes con colitis ulcerosa de larga duración o con colangitis esclerosante primaria), o que tengan antecedentes de displasia o carcinoma de colon. Esta evaluación deberá incluir colonoscopia y biopsias según recomendaciones locales.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Reacciones hematológicas</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En raras ocasiones se han descrito casos de pancitopenia, incluyendo anemia aplásica, con antagonistas del TNF. Se han descrito con adalimumab reacciones adversas del sistema hematológico, incluyendo citopenias significativas desde el punto de vista médico (ej. trombocitopenia, leucopenia). Se debe aconsejar a todos los pacientes que consulten inmediatamente con su médico en caso de presentar signos y síntomas de discrasias sanguíneas (ej. fiebre persistente, moratones, sangrado, palidez) cuando estén siendo tratados con Hyrimoz. En pacientes con anomalías hematológicas significativas confirmadas debe considerarse la interrupción del tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Vacunas</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un ensayo con 226 sujetos adultos con artritis reumatoide que fueron tratados con adalimumab o placebo se observó una respuesta de anticuerpos similar frente a la vacuna estándar neumocócica 23- valente y la vacuna trivalente para el virus de la gripe. No se dispone de datos sobre la transmisión secundaria de infecciones por vacunas vivas en pacientes tratados con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes pediátricos se recomienda, si es posible, una actualización del calendario de vacunaciones de acuerdo con las guías actuales de vacunación antes de iniciar el tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes en tratamiento con Hyrimoz pueden ser vacunados, excepto con vacunas de microorganismos vivos. No se recomienda la administración de vacunas de microorganismos vivos (p. ej., vacuna BCG) a lactantes expuestos a adalimumab en el útero durante los 5 meses siguientes a la última inyección de adalimumab de la madre durante el embarazo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia cardiaca congestiva</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un ensayo clínico con otro antagonista del TNF se ha observado empeoramiento de la insuficiencia cardiaca congestiva y aumento de la mortalidad debida a esta patología. También se han notificado casos de empeoramiento de la insuficiencia cardiaca congestiva en pacientes tratados con adalimumab. Hyrimoz debe utilizarse con precaución en pacientes con insuficiencia cardiaca leve (NYHA clases I/II). Hyrimoz está contraindicado en insuficiencia cardiaca moderada o grave (ver sección 4.3). El tratamiento con Hyrimoz debe interrumpirse en pacientes que desarrollen insuficiencia cardiaca congestiva nueva o presenten un empeoramiento de los síntomas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Procesos autoinmunes</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El tratamiento con Hyrimoz puede dar lugar a la formación de autoanticuerpos. Se desconoce el impacto del tratamiento a largo plazo con adalimumab sobre el desarrollo de enfermedades autoinmunes. Si un paciente desarrolla síntomas parecidos a los de un síndrome tipo lupus después del tratamiento con Hyrimoz y da positivo a los anticuerpos frente al ADN bicatenario, se debe interrumpir el tratamiento con Hyrimoz (ver sección 4.8).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Administración concomitante de FAME biológicos o antagonistas del TNF</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En ensayos clínicos se han observado infecciones graves con el uso concurrente de anakinra y otro antagonista del TNF, etanercept, sin beneficio clínico añadido en comparación con el uso de etanercept solo. Por la naturaleza de los efectos adversos observados en el tratamiento combinado de etanercept y anakinra, la combinación de anakinra y otros antagonistas del TNF puede producir una toxicidad similar. Por lo tanto, no se recomienda la combinación adalimumab y anakinra (ver sección 4.5).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Basándose en el posible incremento del riesgo de infecciones, incluyendo infecciones graves, y otras interacciones farmacológicas potenciales, no se recomienda la administración concomitante de adalimumab con otros FAME biológicos (por ejemplo, anakinra y abatacept) u otros antagonistas del TNF (ver sección 4.5).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Cirugía</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La experiencia de seguridad de intervenciones quirúrgicas en pacientes tratados con adalimumab es limitada. Si se planifica una intervención quirúrgica debe considerarse la larga semivida de eliminación de adalimumab. Los pacientes tratados con Hyrimoz que requieran cirugía, deben controlarse muy de cerca por la aparición de infecciones y tomar las medidas apropiadas. La experiencia de seguridad en los pacientes a los que se les ha practicado una artroplastia, mientras estaban en tratamiento con adalimumab, es limitada.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Obstrucción del intestino delgado</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Un fallo en la respuesta al tratamiento para la enfermedad de Crohn puede indicar la presencia de estenosis fibróticas establecidas que pueden requerir tratamiento quirúrgico. Los datos disponibles sugieren que adalimumab no empeora ni causa las estenosis.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Pacientes de edad avanzada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La frecuencia de infecciones graves en sujetos mayores de 65 años (3,7 %) tratados con adalimumab fue mayor que para aquellos menores de 65 años (1,5 %). Algunas de dichas infecciones tuvieron un resultado mortal. Se debe prestar una atención particular en relación al riesgo de infecciones cuando se trate a pacientes de edad avanzada.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ver Vacunas arriba.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Contenido de sodio</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene menos de 1 mmol (23 mg) de sodio por dosis de 0,8 ml y por dosis de 0,4 ml, esto es, esencialmente “exento de sodio”.</span></p></div></text></section><section id="e3927fa5-8357-4700-99d9-aa37d2d1d078"><title value="4.5. Interacción con otros medicamentos y otras formas de interacción" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029809" /><display value="Interacción con otros medicamentos y otras formas de interacción" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab ha sido estudiado en pacientes con artritis reumatoide, artritis idiopática juvenil poliarticular y artritis psoriásica tratados con adalimumab tanto en monoterapia como con metotrexato de forma concomitante. Cuando se administró adalimumab junto con metotrexato, la formación de anticuerpos fue inferior en comparación con el uso como monoterapia. La administración de adalimumab sin metotrexato resultó en un incremento de la formación de anticuerpos, del aclaramiento y redujo la eficacia de adalimumab (ver sección 5.1).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La administración conjunta de adalimumab y anakinra no está recomendada (ver sección 4.4 “Administración concomitante de FAME biológicos o antagonistas del TNF”).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La administración conjunta de adalimumab y abatacept no está recomendada (ver sección 4.4 “Administración concomitante de FAME biológicos o antagonistas del TNF”).</span></p></div></text></section><section id="82fc3962-7cb2-494d-be9a-8a87d8b553ef"><title value="4.6. Fertilidad, embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029811" /><display value="Fertilidad, embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mujeres en edad fértil</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las mujeres en edad fértil deben considerar utilizar un método anticonceptivo adecuado para prevenir el embarazo y continuar su uso durante al menos cinco meses tras el último tratamiento con Hyrimoz.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Embarazo</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Un gran número de embarazos (aproximadamente 2.100) seguidos de forma prospectiva y expuestos a adalimumab, resultando en nacimientos con vida conocidos, incluyendo más de 1.500 expuestos durante el primer trimestre, no indican un aumento en la tasa de malformación en el recién nacido.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un registro de cohortes prospectivo, fueron reclutadas 257 mujeres con artritis reumatoide (AR) o enfermedad de Crohn (EC) tratadas con adalimumab al menos durante el primer trimestre, y 120 mujeres con AR o EC no tratadas con adalimumab. La variable primaria fue la prevalencia de las principales anomalías congénitas que se dan al nacer. La tasa de embarazos que termina con, al menos, un recién nacido vivo con un defecto congénito grave fue de 6/69 (8,7%) en mujeres con AR tratadas con adalimumab y 5/74 (6,8%) en mujeres con AR sin tratamiento (OR no ajustado 1,31, 95% IC 0,38-4,52) y 16/152 (10,5%) en mujeres con EC tratadas con adalimumab y 3/32 (9,4%) en mujeres con EC no tratadas (OR no ajustado 1,14, IC 95% 0,31-4,16 ). El OR ajustado (teniendo en cuenta las diferencias basales) fue de 1,10 (IC del 95% 0,45 a 2,73) para AR y EC combinadas. No hubo diferencias claras entre las mujeres tratadas con adalimumab y las no tratadas para las variables secundarias de abortos espontáneos, defectos congénitos menores, parto prematuro, tamaño al nacer e infecciones graves u oportunistas, y no se notificaron nacimientos de niños muertos o neoplasias malignas. La interpretación de los datos puede verse afectada debido a las limitaciones metodológicas del estudio, incluyendo el pequeño tamaño de la muestra y el diseño no aleatorizado.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En un estudio de toxicidad para el desarrollo realizado en monos, no hubo indicios de toxicidad maternal, embriotoxicidad o teratogenicidad. No se dispone de datos preclínic</span><span style="font-family:Times New Roman; font-size:11pt">os sobre toxicidad postnatal de adalimumab (ver sección 5.3).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Debido a la inhibición del TNFα, la administración de adalimumab durante el embarazo podría afectar a la respuesta inmune normal en el recién nacido. Adalimumab solo debe usarse durante el emba</span><span style="font-family:Times New Roman; font-size:11pt">razo en caso de ser claramente necesario.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab puede atravesar la placenta al suero de niños nacidos de madres tratadas con adalimumab durante el embarazo. Como consecuencia, estos niños pueden tener un riesgo incrementado de infecciones. No se recomienda la administración de vacunas vivas (p. ej., vacuna BCG) a niños expuestos a adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">en el utero</span></em><span style="font-family:Times New Roman; font-size:11pt">hasta 5 meses después de la última inyección de adalimumab de la madre durante el embarazo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Lactancia</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La información limitada extraída de la literatura publicada indica que adalimumab se excreta a través de la leche materna en concentraciones muy bajas con una presencia de adalimumab en leche humana en concentraciones del 0,1% al 1% del nivel sérico materno. Administrada por vía oral, la inmunoglobulina G se somete a proteólisis intestinal y tiene una biodisponibilidad escasa. No se prevén efectos en neonatos/lactantes alimentados con leche materna. En consecuencia, Hyrimoz puede usarse durante la lactancia.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Fertilidad</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No hay datos preclínicos disponibles sobre el efecto de adalimumab en la fertilidad.</span></p></div></text></section><section id="2b97d0d2-ccdd-494f-983e-9917219585a8"><title value="4.7. Efectos sobre la capacidad para conducir y utilizar máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029815" /><display value="Efectos sobre la capacidad para conducir y utilizar máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La influencia de Hyrimoz sobre la capacidad para conducir y utilizar máquinas es pequeña. Se pueden producir vértigos y alteraciones de la visión tras la administración de Hyrimoz (ver sección 4.8).</span></p></div></text></section><section id="184f32b2-6958-4732-85fd-42e5b6d1b98d"><title value="4.8. Reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029816" /><display value="Reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resumen del perfil de seguridad</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab se ha estudiado en 9.506 pacientes en ensayos pivotales controlados y abiertos durante un máximo de 60 meses o más. Estos ensayos clínicos incluyeron pacientes con artritis reumatoide reciente o de larga duración, artritis idiopática juvenil (artritis idiopática juvenil poliarticular y artritis asociada a entesitis) así como con expondiloartritis axial (espondilitis anquilosante, y espondiloartritis axial sin evidencia radiográfica de EA), artritis psoriásica, enfermedad de Crohn, colitis ulcerosa, psoriasis, hidradenitis supurativa y uveítis. Los datos están basados en ensayos pivotales controlados que abarcaron 6.089 pacientes tratados con adalimumab y 3.801 pacientes con placebo o comparador activo durante el periodo controlado.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La proporción de pacientes que interrumpió el tratamiento debido a reacciones adversas durante la fase doble ciego y controlada de los ensayos pivotales fue 5,9 % para los pacientes tratados con adalimumab y 5,4 % para el grupo control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Las reacciones adversas notificadas más frecuentemente fueron infecciones (como nasofaringitis, infección del tracto respiratorio superior y sinusitis), reacciones en el lugar de inyección (eritema, picores, hemorragia, dolor o hinchazón), cefalea y dolor músculo esquelético.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se han notificado reacciones adversas graves con adalimumab. Los antagonistas del TNF, como adalimumab, afectan al sistema inmune, y su uso puede afectar a la defensa del cuerpo contra infecciones y cáncer.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se han notificado también en asociación con el uso de adalimumab infecciones mortales o que amenazan la vida del paciente (incluyendo sepsis, infecciones oportunistas y tuberculosis), reactivación del VHB y varios tipos de tumores (incluyendo leucemia, linfoma y linfoma hepatoesplénico de células T).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">También se han notificado reacciones hematológicas, neurológicas y autoinmunes graves. Estas incluyen notificaciones raras de pancitopenia, anemia aplásica, acontecimientos desmielinizantes centrales y periféricos y notificaciones de lupus, enfermedades relacionadas con lupus y síndrome de Stevens-Johnson.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En general, las reacciones adversas en pacientes pediátricos fueron similares en frecuencia y tipo a las observadas en pacientes adultos.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tabla de reacciones adversas</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La siguiente lista de reacciones adversas se basa en la experiencia de ensayos clínicos y en la experiencia pos-comercialización y se enumeran según</span><span style="font-family:Times New Roman; font-size:11pt">la clasificación por órganos y sistemas de MedDRA</span><span style="font-family:Times New Roman; font-size:11pt">(SOC) en la tabla 7: muy frecuentes (≥1/10); frecuentes (≥1/100 a &lt;1/10); poco frecuentes (≥1/1.000 a &lt;1/100); raras (≥1/10.000 a &lt;1/1.000) y frecuencia no conocida (no puede estimarse a partir de los datos disponibles). Las reacciones adversas se enumeran</span><span style="font-family:Times New Roman; font-size:11pt">en orden decreciente de gravedad dentro de cada intervalo de frecuencia. Las frecuencias incluidas son las más altas observadas en las diferentes indicaciones.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los casos en los que se incluye información adicional en las secciones 4.3, 4.4 y 4.8, aparece un asterisco (*) en la columna Clasificación por órganos y sistemas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 7</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">Reacciones adversas</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:459.3pt"><thead><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sistema de clasificación de órganos</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Frecuencia</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Reacciones adversas</span></strong></p></td></tr><tr style="height:1pt"><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Infecciones e infestaciones*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Infecciones del tracto respiratorio (incluyendo infecciones respiratorias del tracto inferior y superior, neumonía, sinusitis, faringitis, nasofaringitis y neumonia por herpesvirus)</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Infecciones sistémicas (incluyendo sepsis, candidiasis y gripe),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones intestinales (incluyendo</span><br /><span style="font-family:Times New Roman; font-size:11pt">gastroenteritis viral),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones de la piel y tejidos blandos</span><br /><span style="font-family:Times New Roman; font-size:11pt">(incluyendo paroniquia, celulitis, impétigo,</span><br /><span style="font-family:Times New Roman; font-size:11pt">fascitis necrotizante y herpes zoster),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infección de oidos,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones orales (incluyendo herpes simple, herpes oral e infecciones dentales),</span><br /><span style="font-family:Times New Roman; font-size:11pt">infecciones del tracto reproductor (incluyendo infección micótica vulvovaginal),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones del tracto urinario (incluyendo pielonefritis),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones fúngicas,</span><br /><span style="font-family:Times New Roman; font-size:11pt">infecciones de las articulaciones</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Infecciones neurológicas (incluyendo meningitis viral),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones oportunistas y tuberculosis</span><br /><span style="font-family:Times New Roman; font-size:11pt">(incluyendo coccidiomicosis, histoplasmosis, infecciones por el complejo mycobacterium</span><br /><span style="font-family:Times New Roman; font-size:11pt">avium),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">infecciones bacterianas,</span><br /><span style="font-family:Times New Roman; font-size:11pt">infecciones oculares,</span><br /><span style="font-family:Times New Roman; font-size:11pt">diverticulitis</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Neoplasias benignas, malignas y no especificadas (incluyendo quistes y pólipos)*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Cáncer de piel excluido el melanoma</span><br /><span style="font-family:Times New Roman; font-size:11pt">(incluyendo carinoma de células basales y carcinoma de células escamosas),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">neoplasia benigna</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Linfoma**,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">neoplasia de órganos sólidos (incluyendo cáncer de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mama, neoplasia pulmonar y neoplasia</span><br /><span style="font-family:Times New Roman; font-size:11pt">tiroidea),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">melanoma**</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Leucemia</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuencia no conocida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Linfoma hepatoesplénico de células T</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><br /><span style="font-family:Times New Roman; font-size:11pt">carcinoma de células de Merkel (carcinoma neuroendocrino de la piel)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Sarcoma de Kaposi</span></p></td></tr><tr style="height:1pt"><td rowspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos de la sangre y del sistema linfático*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Leucopenia (incluyendo neutropenia y agranulocitosis),</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Anemia</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Leucocitosis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">trombocitopenia</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Púrpura trombocitopénica idiopática</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Pancitopenia</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del sistema inmunológico*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Hipersensibilidad,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">alergias (incluyendo alergia estacional)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Sarcoidosis</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">vasculitis</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Anafilaxia</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del metabolismo y de la nutrición</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Lípidos elevados</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Hipocaliemia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">incremento de ácido úrico,</span><br /><span style="font-family:Times New Roman; font-size:11pt">sodio plasmático anormal,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hipocalcemia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hiperglucemia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hipofosfatemia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">deshidratación</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos psiquiátricos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Cambios de humor (incluyendo depresión)</span><br /><span style="font-family:Times New Roman; font-size:11pt">ansiedad,</span><br /><span style="font-family:Times New Roman; font-size:11pt">insomnio</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del sistema nervioso*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Cefalea</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Parestesias, (incluyendo hipoestesia), migraña,</span><br /><span style="font-family:Times New Roman; font-size:11pt">compresión de la raiz nerviosa</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Accidente cerebrovascular</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">temblor,</span><br /><span style="font-family:Times New Roman; font-size:11pt">neuropatía</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Esclerosis múltiple, trastornos desmielinizantes</span><br /><span style="font-family:Times New Roman; font-size:11pt">(por ejemplo, neuritis óptica, síndrome de Guillain</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Barré)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos oculares</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Alteración visual,</span><br /><span style="font-family:Times New Roman; font-size:11pt">conjuntivitis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">blefaritis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hinchazón de ojos</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Diplopía</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del oído y del laberinto</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Vértigo</span></p><p style="margin:0pt; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Sordera,</span><br /><span style="font-family:Times New Roman; font-size:11pt">tinnitus</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos cardiacos*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Taquicardia</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Infarto de miocardio</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">arritmia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">insuficiencia cardiaca congestiva</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Parada cardiaca</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos vasculares</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Hipertensión,</span><br /><span style="font-family:Times New Roman; font-size:11pt">rubor,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hematomas</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Aneurisma aórtico, oclusión vascular arterial, trombloflebitis</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos respiratorios, torácicos y mediastínicos*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Asma,</span><br /><span style="font-family:Times New Roman; font-size:11pt">disnea,</span><br /><span style="font-family:Times New Roman; font-size:11pt">tos</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Embolia pulmonar</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Enfermedad pulmonar intersticial,</span><br /><span style="font-family:Times New Roman; font-size:11pt">enfermedad pulmonar obstructiva crónica, neumonitis,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">derrame pleural</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Fibrosis pulmonar</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos gastrointestinales</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Dolor abdominal,</span><br /><span style="font-family:Times New Roman; font-size:11pt">náuseas y vómitos</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Hemorragia gastrointestinal,</span><br /><span style="font-family:Times New Roman; font-size:11pt">dispepsia,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">enfermedad de reflujo gastroesofágico,</span><br /><span style="font-family:Times New Roman; font-size:11pt">sindrome del ojo seco</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Pancreatitis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">disfagia,</span><br /><span style="font-family:Times New Roman; font-size:11pt">edema facial</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Perforación intestinal</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Trastornos hepatobiliares*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Enzimas hepáticas aumentadas</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Colecistitis y colelitiasis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">esteatosis hepática,</span><br /><span style="font-family:Times New Roman; font-size:11pt">incremento de la bilirrubina</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Hepatitis,</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">reactivación de la hepatitis B</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><br /><span style="font-family:Times New Roman; font-size:11pt">hepatitis autoinmune</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuencia no conocida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Insuficiencia hepática</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Trastornos de la piel y del tejido subcutáneo</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Muy</span><br /><span style="font-family:Times New Roman; font-size:11pt">frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Erupción (incluyendo erupción exfoliativa),</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Empeoramiento de la psoriasis existente o psoriasis de nueva aparición (incluyendo</span><br /><span style="font-family:Times New Roman; font-size:11pt">psoriasis pustulosa palmoplantar)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">urticaria,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">aumento de moratones (incluyendo púrpura), dermatitis (incluyendo eccema),</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">onicoclasis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">hiperhidrosis,</span><br /><span style="font-family:Times New Roman; font-size:11pt">alopecia</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">prurito</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco</span><br /><span style="font-family:Times New Roman; font-size:11pt">frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Sudores nocturnos,</span><br /><span style="font-family:Times New Roman; font-size:11pt">cicatrices</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raras</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Eritema multiforme</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">síndrome de Stevens</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Johnson</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span><br /><span style="font-family:Times New Roman; font-size:11pt">angioedema</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span><span style="font-family:Times New Roman; font-size:11pt">,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">vasculitis cutánea</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">reacción liquenoide en la piel</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuencia no conocida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Empeoramiento de los síntomas de la dermatomiositis</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos musculoesqueléticos y del tejido conjuntivo</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Dolor musculoesquelético</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Espasmos musculares (incluyendo incrementos plasmáticos de la creatina fosfoquinasa)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Rabdomiolisis,</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">lupus eritematoso sistémico</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Raros</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Síndrome tipo lupus</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos renales y urinarios</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Insuficiencia renal, hematuria</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Nicturia</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos del aparato reproductor y de la mama</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Disfunción eréctil</span></p></td></tr><tr style="height:1pt"><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Trastornos generales y alteraciones en el lugar de administración*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Muy frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Reacción en el lugar de inyección (incluyendo eritema en el lugar de inyección)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Dolor torácico,</span><br /><span style="font-family:Times New Roman; font-size:11pt">edema,</span><br /><span style="font-family:Times New Roman; font-size:11pt">pirexia</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1)</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Poco frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Inflamación</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Exploraciones</span><br /><span style="font-family:Times New Roman; font-size:11pt">complementarias*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Alteraciones en la coagulación y el sangrado (incluyendo prolongación del tiempo de tromboplastina parcial activada), presencia de autoanticuerpos (incluyendo anticuerpos de ADN bicatenario), incremento de la lactato deshidrogenasa plasmática</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuencia no conocida</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Aumento de peso</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2)</span></p></td></tr><tr style="height:43.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:156.35pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Lesiones traumáticas, intoxicaciones y complicaciones de procedimientos terapéuticos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Frecuentes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:236.05pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Alteración de la cicatrización</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr></thead></table><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">* Se incluye información adicional en las secciones 4.3, 4.4 y 4.8</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">** incluyendo los estudios de extensión abierta.</span></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 31.25pt; text-indent:0pt; text-align:justify; padding-left:4.75pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">incluyendo los datos de notificaciones espontáneas.</span></li><li style="margin:0pt 0pt 0pt 31.25pt; text-indent:0pt; text-align:justify; padding-left:4.75pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El cambio medio de peso desde el inicio para adalimumab fue de entre 0,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg y 1,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg en las indicaciones en adultos en comparación con entre (menos) -0,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg y 0,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg para el placebo durante un período de tratamiento de 4-6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses. También se ha observado un aumento de peso de 5-6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg en estudios de extensión a largo plazo con exposiciones medias de aproximadamente 1-2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años sin grupo de control, particularmente en pacientes con enfermedad de Crohn y colitis ulcerosa. El mecanismo que subyace a este efecto no está claro pero podría estar relacionado con el efecto antiinflamatorio de adalimumab.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El perfil de seguridad de los pacientes con hidradenitis supurativa en tratamiento semanal con adalimumab fue consistente con el perfil de seguridad conocido de adalimumab.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uveítis</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">El perfil de seguridad de los pacientes con uveítis en tratamiento con adalimumab en semanas alternas fue consistente con el perfil de seguridad conocido de adalimumab.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Descripción de reacciones adversas seleccionadas</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Reacciones en el lugar de inyección</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos controlados pivotales en adultos y niños, el 12,9 % de los pacientes tratados con adalimumab desarrollaron reacciones en el sitio de inyección (eritema y/o picores, hemorragia, dolor o hinchazón), comparado con el 7,2 % de los pacientes tratados con placebo o control activo. No se consideró necesario interrumpir el medicamento debido a las reacciones en el lugar de administración.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Infecciones</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos controlados pivotales en adultos y niños, la incidencia de infecciones fue de 1,51 por paciente/año en los pacientes tratados con adalimumab y 1,46 por paciente/año en los pacientes tratados con placebo y control activo. Las infecciones consistieron fundamentalmente en nasofaringitis, infecciones del tracto respiratorio superior y sinusitis. La mayoría de los pacientes continuaron con adalimumab tras resolverse la infección.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">La incidencia de infecciones graves fue de 0,04 por paciente/año en los pacientes tratados con adalimumab y 0,03 por paciente/año en los pacientes tratados con placebo y control activo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En ensayos controlados abiertos en adultos y pediátricos con adalimumab, se han notificado infecciones graves (incluyendo las mortales, que han ocurrido en casos raros), entre las que se incluyen notificaciones de tuberculosis (incluida la miliar y la localización extra-pulmonar) e infecciones oportunistas invasivas (por ejemplo: histoplasmosis diseminada o extrapulmonar, blastomicosis, coccidiomicosis, pneumocistis, candidiasis, aspergilosis y listeriosis). La mayoría de los casos de tuberculosis tuvieron lugar durante los primeros ocho meses del tratamiento y reflejan la exacerbación de una enfermedad latente.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Enfermedades neoplásicas malignas y trastornos linfoproliferativos</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No se han observado enfermedades neoplásicas malignas durante los ensayos con adalimumab en 249 pacientes pediátricos de artritis idiopática juvenil (artritis idiopática juvenil poliarticular y artritis asociada a entesitis) con una exposición de 655,6 pacientes/año. Adicionalmente, no se observaron enfermedades neoplásicas malignas en 192 pacientes pediátricos con una exposición de 498,1 pacientes/año durante ensayos de adalimumab en pacientes pediátricos con enfermedad de Crohn. No se han observado enfermedades neoplásicas malignas en 77 pacientes pediátricos con una exposición de 80,0 pacientes/año durante un ensayo de adalimumab en pacientes pediátricos con psoriasis en placas crónica. No se han observado enfermedades neoplásicas malignas en 93</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos expuestos a 65,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes/año durante un ensayo de adalimumab en pacientes pediátricos con colitis ulcerosa. No se observaron enfermedades neoplásicas malignas en 60 pacientes pediátricos con una exposición de 58,4 pacientes/año durante un ensayo de adalimumab en pacientes pediátricos con uveítis.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Durante las fases controladas de los ensayos clínicos pivotales con adalimumab en adultos que duraron un mínimo de 12 semanas en pacientes con artritis reumatoide activa de moderada a grave, espondilitis anquilosante, espondiloartritis axial sin evidencia radiográfica de EA, artritis psoriásica, psoriasis, hidradenitis supurativa, enfermedad de Crohn, colitis ulcerosa y uveítis, se observaron enfermedades neoplásicas malignas, diferentes a linfoma y cáncer de piel (tipo no melanoma), con una incidencia de 6,8 (4,4 – 10,5) por 1.000 pacientes/año (IC 95 %) en los 5.291 pacientes tratados con adalimumab, frente a una incidencia de 6,3 (3,4 – 11,8) por 1.000 pacientes/año en los 3.444 pacientes del grupo control (la duración media del tratamiento fue de 4,0 meses para los pacientes tratados con adalimumab y de 3,8 meses para los pacientes tratados del grupo control). La incidencia de cáncer de piel (tipo no melanoma) fue de 8,8 (6,0 – 13,0) por 1.000 pacientes/año (IC 95 %) en los pacientes tratados con adalimumab y 3,2 (1,3 – 7,6) por 1.000 pacientes/año en los pacientes control. De estos casos de cáncer de piel, el carcinoma de células escamosas se produjo con una incidencia de 2,7 (1,4 – 5,4) por 1.000 pacientes/año (IC 95 %) en los pacientes tratados con adalimumab y de un 0,6 (0,1 – 4,5) por 1.000 pacientes/año en los pacientes del grupo control. La incidencia de linfomas fue de 0,7 (0,2 – 2,7) por 1.000 pacientes/año (IC 95 %) entre los pacientes tratados con adalimumab y de 0,6 (0,1 – 4,5) por 1.000 pacientes/año en los pacientes del grupo control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Cuando se combinan los datos obtenidos en las fases controladas de estos ensayos clínicos y los ensayos de extensión abiertos en curso y completados, con una duración media aproximada de 3,3 años que incluyen 6.427 pacientes y más de 26.439 pacientes/año de tratamiento, la incidencia observada de enfermedades neoplásicas malignas, excluyendo linfomas y cáncer de piel (tipo no melanoma), es de aproximadamente 8,5 por 1.000 pacientes/año. La incidencia observada de cáncer de piel (tipo no melanoma) es de aproximadamente un 9,6 por 1.000 pacientes/año. La incidencia observada de linfomas es de aproximadamente 1,3 por 1.000 pacientes/año.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En la experiencia pos-comercialización desde enero de 2003 a diciembre de 2010, principalmente en pacientes con artritis reumatoide, la incidencia registrada de enfermedades neoplásicas malignas es aproximadamente de 2,7 por 1.000 pacientes tratados/año. La frecuencia registrada para cáncer de piel (tipo no melanoma) y linfomas es de aproximadamente 0,2 y 0,3 por 1.000 pacientes tratados/año, respectivamente (ver sección 4.4).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Durante la comercialización se han notificado casos raros de linfoma hepatoesplénico de células T en pacientes tratados con adalimumab (ver sección 4.4).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Autoanticuerpos</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Se analizaron muestras séricas a distintos tiempos de los pacientes para la detección de autoanticuerpos en los ensayos I-V de artritis reumatoide. En dichos ensayos, el 11,9 % de los pacientes tratados con adalimumab y el 8,1 %de los pacientes tratados con placebo y control activo que tuvieron títulos de anticuerpos anti-nucleares basales negativos dieron títulos positivos en la semana 24. Dos pacientes de los 3.441 tratados con adalimumab en todos los ensayos de artritis reumatoide y artritis psoriásica desarrollaron signos clínicos que sugerían un síndrome tipo lupus de reciente aparición. Los pacientes mejoraron tras interrumpir el tratamiento. Ningún paciente desarrolló lupus, nefritis o síntomas a nivel del sistema nervioso central.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;">Efectos hepatobiliares</span></em></p><p style="margin:0pt; text-align:justify"><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos controlados fase 3 de adalimumab en pacientes con artritis reumatoide y artritis psoriásica con un rango de duración del periodo de control</span><span style="font-family:Times New Roman; font-size:11pt">de 4 a 104 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 3,7 % de los pacientes tratados con adalimumab y en un 1,6 % de los pacientes del grupo control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos controlados fase 3 de adalimumab en pacientes de 4 a 17 años con artritis idiopática juvenil poliarticular y en pacientes de 6 a 17 años con artritis asociada a entesitis, se produjo un aumento de ALT ≥ 3 SLN en un 6,1 % de los pacientes tratados con adalimumab y en un 1,3 % de los pacientes del grupo control. La mayoría de los aumentos de ALT se produjeron con el uso en combinación con metotrexato. No se produjeron aumentos de la ALT ≥ 3 SLN en los ensayos de fase 3 de adalimumab en pacientes con artritis idiopática juvenil poliarticular de 2 a &lt; 4 años de edad.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos controlados fase 3 de adalimumab en pacientes con enfermedad de Crohn y colitis ulcerosa con un rango de duración del periodo de control de 4 a 52 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 0,9 % de los pacientes tratados con adalimuma</span><span style="font-family:Times New Roman; font-size:11pt">b y en un 0,9 % de los pacientes del grupo control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos Fase 3 de adalimumab en pacientes con enfermedad de Crohn pediátrica en los que se evaluó la eficacia y la seguridad de dos regímenes de dosificación ajustados por peso corporal en manteni</span><span style="font-family:Times New Roman; font-size:11pt">miento tras un tratamiento de inducción ajustado por peso corporal hasta 52 semanas de tratamiento, se observaron aumentos de la ALT ≥ 3 sobre el límite normal en el 2,6 % (5/192) de los pacientes, 4 de los cuales recibieron inmunosupresores concomitantes</span><span style="font-family:Times New Roman; font-size:11pt">inicialmente.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos controlados fase 3 de adalimumab en pacientes con psoriasis en placas con un rango de duración del periodo de control de 12 a 24 semanas, se produjo un aumento de ALT ≥ 3 SLN en un 1,8 % de los pacientes tratados con</span><span style="font-family:Times New Roman; font-size:11pt">adalimumab y en un 1,8 % de los pacientes del grupo control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">No se produjeron aumentos de ALT ≥3 SLN en los ensayos clínicos fase 3 de adalimumab en pacientes pediátricos con psoriasis en placas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En ensayos controlados con adalimumab (dosis inicial de 160 mg en la semana 0 y 80 mg en la semana 2, seguido de 40 mg semanales a partir de la semana 4), se produjeron aumentos de ALT ≥ 3 SLN en un 0,3 % de los pacientes tratados con adalimumab y un 0,6 % de los pacientes del grupo control, en pacientes con hidr</span><span style="font-family:Times New Roman; font-size:11pt">adenitis supurativa con una duración del periodo control de 12 a 16 semanas.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ensayos clínicos controlados con adalimumab (dosis inicial de 80 mg en la semana 0 seguido de 40 mg en semanas alternas comenzando en la semana 1) en pacientes adultos con</span><span style="font-family:Times New Roman; font-size:11pt">uveítis hasta 80 semanas con una exposición media de 166,5 días y 105,0 días para pacientes en tratamiento con adalimumab y pacientes control respectivamente, se produjeron aumentos de ALT ≥ 3 SLN en un 2,4% de los pacientes en tratamiento con adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">y en un 2,4 % en los pacientes control.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En el ensayo controlado de fase</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3 de adalimumab en pacientes con colitis ulcerosa pediátrica (N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">93), que evaluó la eficacia y la seguridad de una dosis de mantenimiento de 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en semanas alternas (N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31) y de una dosis de mantenimiento de 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) cada semana (N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">32), tras una dosis de inducción ajustada al peso corporal de 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1, y de 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la</span><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 (N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">63),</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">o una dosis de inducción de 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0, placebo en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1, y 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 (N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30), se produjeron aumentos de ALT ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">SLN en un 1,1% (1/93) de los pacientes.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En los ens</span><span style="font-family:Times New Roman; font-size:11pt">ayos clínicos de todas las indicaciones, los pacientes con ALT elevada fueron asintomáticos y en la mayoría de los casos estos aumentos fueron transitorios y se resolvieron en el curso del tratamiento. Sin embargo, en pacientes que han recibido adalimumab, se han notificado además casos de fallo hepático así como afecciones hepáticas menos graves que pueden preceder a la insuficiencia hepática, tales como hepatitis, incluida la hepatitis autoinmune, en el periodo de post comercializacion.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tratamiento concomitante con azatioprina/6-mercaptopurina</span></span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">En estudios de enfermedad de Crohn con pacientes adultos, se vieron mayores incidencias de neoplasias malignas y efectos adversos relacionados con infecciones graves con la combinación de adalimumab y azatioprina/6-mercaptopurina comparado con adalimumab solo.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text><section id="33ee68ea-3b14-4f9b-a5b7-1cf55171b206"><title value="4.8.2. Notificación de sospechas de reacciones adversas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029818" /><display value="Notificación de sospechas de reacciones adversas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante notificar sospechas de reacciones adversas al medicamento tras su autorización. Ello permite una supervisión continuada de la relaci</span><span style="font-family:Times New Roman; font-size:11pt">ón beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del sistema nacional de notificación incluido en el</span><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">Apéndice V</span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p></div></text></section></section><section id="fee8869e-607f-48e2-b365-ea0bd1137648"><title value="4.9. Sobredosis" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029819" /><display value="Sobredosis" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">No se observó toxicidad limitante de la dosis durante los ensayos clínicos en pacientes. El nivel de dosis más alto evaluado ha sido la administración intravenosa repetida de dosis de 10 mg/kg, que supone aproximadamente 15 veces la dosis recomendada.</span></p></div></text></section></section><section id="b748e93d-f122-4f6d-95ae-b00e110697ed"><title value="5. Propiedades farmacológicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029821" /><display value="Propiedades farmacológicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="0b4c039f-36b2-4524-b16a-c7a589dacf4f"><title value="5.1. Propiedades farmacodinámicas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029822" /><display value="Propiedades farmacodinámicas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Grupo farmacoterapéutico: Inmunosupresores, inhibidores del Factor de Necrosis Tumoral alfa (TNF-α), Código ATC: L04AB04</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz es un medicamento biosimilar. La información detallada sobre este medicamento está disponible en la página web de la Agencia E</span><span style="font-family:Times New Roman; font-size:11pt">uropea de Medicamentos</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">http://www.ema.europa.eu</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Mecanismo de acción</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab se une específicamente al TNF (Factor de necrosis tumoral) y neutraliza su función biológica al bloquear su interacción con los receptores p55 y p75 del TNF en la superficie celular.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab también modula la respuesta biológica inducida o regulada por el TNF, incluyendo cambios en los niveles de las moléculas de adhesión responsables de la migración leucocitaria (ELAM-1, VCAM-1, e ICAM-1 con una CI</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:sub">50</span><span style="font-family:Times New Roman; font-size:11pt">de 0,1-0,2 nM).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Efectos farmacodinámicos</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras el tratamiento con adalimumab, se observó una rápida disminución de los niveles de los componentes de fase aguda de inflamación (proteína C reactiva, PCR) y velocidad de sedimentación globular (VSG)) y de las citoquinas plasmáticas (IL-6) en comparación con el inicial en pacientes con artritis reumatoide. Los niveles plasmáticos de metaloproteinasas de la matriz (MMP-1 y MMP-3) que participan en la remodelación tisular responsable de la destrucción del cartílago también disminuyeron tras la administración de adalimumab. Los pacientes tratados con adalimumab generalmente experimentaron mejorías en los signos hematológicos de inflamación crónica.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes con artritis idiopática juvenil poliarticular, enfermedad de Crohn, colitis ulcerosa e hidradenitis supurativa se ha observado un rápido descenso en los niveles de Proteína C reactiva (PCR), después del tratamiento con adalimumab. En pacientes con enfermedad de Crohn se observó una reducción e</span><span style="font-family:Times New Roman; font-size:11pt">n el número de células que expresan marcadores inflamatorios en el colon, incluyendo una reducción significativa en la expresión del TNF-α. Los estudios endoscópicos de la mucosa intestinal han mostrado evidencias de cicatrización de mucosa en pacientes tratados con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Eficacia clínica y seguridad</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis reumatoide</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab se evaluó en más de 3.000 pacientes en el conjunto de los ensayos clínicos de artritis reumatoide. La eficacia y seguridad de adalimumab en el tratamiento de la artritis</span><span style="font-family:Times New Roman; font-size:11pt">reumatoide fue evaluada mediante cinco ensayos aleatorios, doble ciego y controlados. Algunos de estos pacientes fueron sometidos a tratamiento durante un máximo de 120 meses.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide I se evaluaron 271 pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años, que no habían respondido a la terapia con al menos un fármaco antirreumático modificador de la enfermedad y mostraban una respuesta no suficientemente eficaz al metotrexato a dosis entre 12,5 y 25 mg (10 mg</span><span style="font-family:Times New Roman; font-size:11pt">si no toleraban el metotrexato) semanales y cuyas dosis de metotrexato se mantuvieron fijas de 10 a 25 mg semanales. Se administraron dosis de 20, 40 y 80 mg de adalimumab o de placebo en semanas alternas durante un periodo de 24 semanas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide II se evaluaron 544 pacientes con artritis reumatoide activa moderada a grave con edades ≥ 18 años, que no habían respondido a la terapia con al menos un fármaco antirreumático modificador de la enfermedad. Se administraron dosis de 20</span><span style="font-family:Times New Roman; font-size:11pt">o de 40 mg de adalimumab mediante inyección subcutánea en semanas alternas con placebo en las semanas intermedias, o cada semana durante un periodo de 26 semanas; el placebo se administró cada semana durante el mismo periodo. No se permitió la terapia con ningún otro fármaco antirreumático modificador de la enfermedad.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide III se evaluaron 619</span><span style="font-family:Times New Roman; font-size:11pt">pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años, y que mostraban una respuesta ineficaz al metotrexato a dosis entre 12,5 y 25 mg o mostraron intolerancia a 10 mg de metotrexato semanales. Había tres grupos en este ensayo. Al prime</span><span style="font-family:Times New Roman; font-size:11pt">ro se le administraron inyecciones de placebo durante 52 semanas. Al segundo se le administraron 20 mg de adalimumab semanales durante 52 semanas. Al tercero se le administraron 40 mg de adalimumab en semanas alternas, con inyecciones de placebo en las semanas intermedias. Una vez completadas las primeras 52 semanas, 457 pacientes fueron incluidos en una fase de extensión abierta en la cual se administraron 40 mg de adalimumab/MTX en semanas alternas durante un máximo de 10 años.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis r</span><span style="font-family:Times New Roman; font-size:11pt">eumatoide IV se evaluó fundamentalmente la seguridad en 636 pacientes con artritis reumatoide moderada a grave con edades ≥ 18 años. Los pacientes podían bien no haber sido tratados previamente con fármacos antirreumáticos modificadores de la enfermedad o</span><span style="font-family:Times New Roman; font-size:11pt">bien seguir con su tratamiento reumatológico anterior, siempre y cuando hubiese sido un tratamiento continuado durante al menos 28 días. Estos tratamientos incluyen metotrexato, leflunomida, hidroxicloroquina, sulfasalazina y/o sales de oro. Los pacientes se aleatorizaron a los grupos de tratamiento con 40 mg de adalimumab o placebo en semanas alternas durante un periodo de 24 semanas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide V se evaluaron 799 pacientes adultos sin tratamiento previo con metotrexato con artritis reumatoide temprana moderada a grave (duración media de la enfermedad menor de 9 meses). Este ensayo evaluó la eficacia de adalimumab 40 mg administrado en semanas alternas en terapia combinada con metotrexato, adalimumab 40 mg administrado en semanas alternas en monoterapia y la monoterapia con metotrexato en la reducción de los signos, síntomas y velocidad de progresión del daño articular en la artritis reumatoide durante 104 semanas. Tras completar las primeras 104 semanas, se incluyeron 497 pacientes en una fase de extensión abierta en la que se administraron 40 mg de adalimumab en semanas alternas hasta un periodo de 10 años.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La variable primaria de los ensayos de artritis reumatoide I, II y III, y la secundaria del ensayo de artritis reumatoide IV era el porcentaje de pacientes que alcanzaron una respuesta ACR 20 en la semana 24 o en la 26. La variable primaria del ensayo de artritis reumatoide V era el porcentaje de pacientes que alcanzaron una respuesta ACR 50 en la semana 52. Los ensayos de artritis reumatoide III y V tenían otra variable primaria adicional a las 52 semanas, el retraso en la progresión de la enfermedad (detectado por medio de rayos-X). El ensayo de artritis reumatoide III tenía también la variable primaria de cambios en la calidad de vida.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Respuesta ACR</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El porcentaje de pacientes tratados con adalimumab que alcanzaron respuestas ACR 20, 50 y 70 fue constante durante los ensayos de artritis reumatoide I, II y III. Los resultados de los pacientes que recibieron dosis de 40 mg en semanas alternas se resumen en la tabla 8.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 8</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuestas ACR en ensayos controlados con placebo</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:38.75pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.2%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">respuesta</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Ensayo de artritis reumatoide I</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">**</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Ensayo de artritis reumatoide II</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">**</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Ensayo de artritis reumatoide III</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">**</span></p></td></tr><tr style="height:44.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo/ MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">60</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">/ MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">63</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:9.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">110</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">113</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo/ MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">200</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">/ MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><br /><span style="font-family:Times New Roman; font-size:11pt">n =</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">207</span></p></td></tr><tr style="height:54.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.2%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">13,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">65,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:9.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">19,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">46,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">29,5</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">63,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">58,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td></tr><tr style="height:37.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.2%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">52,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:9.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">8,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">22,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">9,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">9,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">39,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">41,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td></tr><tr style="height:37.35pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.2%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">70</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">meses</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">23,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:9.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">12,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NA</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:10.36%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">4,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">20,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">23,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:51.75pt; border:none">
                                        </td>
                                        <td style="width:48.1pt; border:none">
                                        </td>
                                        <td style="width:87.45pt; border:none">
                                        </td>
                                        <td style="width:45.05pt; border:none">
                                        </td>
                                        <td style="width:84.95pt; border:none">
                                        </td>
                                        <td style="width:48.1pt; border:none">
                                        </td>
                                        <td style="width:87.3pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Ensayo de artritis reumatoide I a las 24 semanas, Ensayo de artritis reumatoide II a las 26 semanas, y Ensayo de artritis reumatoide III a las 24 y 52 semanas</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">40 mg adalimumab administrados en semanas alternas</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">MTX = metotrexato</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">** p&lt;0,01, adalimumab versus placebo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los ensayos de artritis reumatoide I-IV, todos los componentes individuales de los criterios de respuesta ACR (número de articulaciones doloridas e inflamadas, valoración por parte del médico y del paciente de la actividad de la enfermedad y dolor, resultados del índice de discapacidad (HAQ) y valores PCR (mg/dl)) mejoraron a las 24 o 26 semanas en comparación con placebo. En el ensayo de artritis reumatoide III, estas mejorías se mantuvieron durante 52 semanas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la fase de extensión abierta del ensayo III de AR, la mayoría de los pacientes con respuesta ACR mantuvieron esta respuesta a los 10 años. De 207 pacientes que fueron aleatorizados a adalimumab 40 mg en semanas alternas, 114 pacientes continuaron con adalimumab 40 mg en semanas alternas durante 5 años. De estos, 86 pacientes (75,4 %) tenían respuesta ACR 20; 72 pacientes (63,2 %) tenían respuesta ACR 50; y 41 pacientes (36 %) tenían respuesta ACR 70. De 207 pacientes, 81 continuaron con adalimumab 40 mg en semanas alternas durante 10 años. De estos, 64 pacientes (79,0 %) tenían respuesta ACR 20; 56 pacientes (69,1 %) tenían respuesta ACR 50; y 43 pacientes (53,1 %) tenían respuesta ACR 70.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide IV, la respuesta ACR 20 en pacientes tratados con adalimumab y cuidados estándar fue mejor de forma estadísticamente significativa que en pacientes tratados con placebo y cuidados estándar (p &lt; 0,001).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los ensayos de artritis reumatoide I-IV, los pacientes tratados con adalimumab alcanzaron respuestas ACR 20 y 50 estadísticamente significativas en comparación con placebo tan solo una a dos semanas después de iniciar el tratamiento.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide V con pacientes con artritis reumatoide temprana sin tratamiento previo con metotrexato, la terapia combinada con adalimumab y metotrexato resultó en a una respuesta ACR significativamente mayor y más rápida que en la monoterapia con metotrexato y en la monoterapia con adalimumab en la semana 52 y dichas respuestas se mantuvieron en la semana 104 (ver tabla 9).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 9</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuestas ACR en el ensayo de artritis reumatoide V</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:26.85pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:18.84%"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">MTX</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">n =</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">257</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">n</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">274</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt 3.15pt 0pt 0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">/MTX n</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">268</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Valor p</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Valor p</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Valor p</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></strong></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">62,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">54,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">72,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,013</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,043</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">104</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">56,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">49,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">69,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,002</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,140</span></p></td></tr><tr style="height:13.2pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">45,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">41,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">61,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,317</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">104</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">42,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">36,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">59,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,162</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">70</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">27,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">25,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">45,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,656</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">104</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.56%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">28,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">28,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:17.72%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">46,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.82%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.74%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.6%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,864</span></p></td></tr><tr style="height:107.85pt"><td colspan="7" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">             </span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con metotrexato y la terapia combinada con adalimumab/metotrexato usando el test de Mann</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Whitney U.</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">             </span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la terapia combinada con adalimumab/metotrexato usando el test de Mann</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Whitney U.</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt; vertical-align:-0.5pt">             </span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la monoterapia con metotrexato usando el test de Mann</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">Whitney U.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:81.65pt; border:none">
                                        </td>
                                        <td style="width:48.7pt; border:none">
                                        </td>
                                        <td style="width:70.1pt; border:none">
                                        </td>
                                        <td style="width:102pt; border:none">
                                        </td>
                                        <td style="width:51.8pt; border:none">
                                        </td>
                                        <td style="width:49.55pt; border:none">
                                        </td>
                                        <td style="width:48.9pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la extensión abierta del ensayo de artritis reumatoide V, se mantuvieron las respuestas ACR tras un seguimiento de hasta un periodo de 10 años. De los 542 pacientes que fueron aleatorizados a recibir adalimumab 40 mg en semanas alternas, 170 pacientes continuaron con adalimumab 40 mg en semanas alternas hasta completar 10 años de tratamiento. Entre esos, 154 pacientes (90,6 %) obtuvieron respuestas ACR 20; 127 pacientes (74,7 %) obtuvieron respuestas ACR 50; y 102 pacientes (60,0 %) obtuvieron respuestas ACR 70.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 52, el 42,9 %de los pacientes en tratamiento con la terapia combinada adalimumab/metotrexato alcanzó la remisión clínica (DAS28 &lt; 2,6) comparado con el 20,6 % de los pacientes en monoterapia con metotrexato y el 23,4 % de los pacientes en monoterapia con adalimumab. La combinación adalimumab/metotrexato era clínica y estadísticamente superior a la monoterapia con metotrexato (p &lt; 0,001) y a la monoterapia con adalimumab (p &lt; 0,001) a la hora de reducir la gravedad de la enfermedad en pacientes diagnosticados con artritis reumatoide reciente moderada a grave. La respuesta a las dos monoterapias fue similar (p = 0,447). De los 342 sujetos inicialmente aleatorizados a recibir adalimumab en monoterapia o la combinación adalimumab/metotrexato que se incluyeron en la extensión abierta del estudio, 171 sujetos completaron 10 años de tratamiento con adalimumab. Entre esos, se reportó que 109 sujetos (63,7 %) estaban en remisión a los 10 años.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Respuesta radiográfica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide III, en el que los pacientes tratados con adalimumab habían tenido artritis reumatoide durante una media de 11 años, se valoró radiográficamente el daño estructural en las articulaciones y se expresó como el cambio en el Índice Total de Sharp modificado y sus componentes, el índice de erosión y el índice de estrechamiento del espacio articular. Los pacientes tratados con adalimumab/metotrexato demostraron una progresión radiográfica significativamente menor que los pacientes tratados sólo con metotrexato a los 6 y 12 meses (ver tabla 10).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la extensión abierta del estudio de artritis reumatoide III, la reducción en la frecuencia de la progresión del daño estructural se mantuvo durante 8 y 10 años en un subgrupo de pacientes. A los 8 años se evaluaron radiográficamente 81 de los 207 pacientes tratados con adalimumab 40 mg en semanas alternas. De los pacientes analizados, 48 no mostraron progresión del daño estructural, definido como un cambio desde el basal en el índice total de Sharp modificado de 0,5 o menos. A los 10 años, 79 de 207 pacientes originalmente tratados con 40 mg de adalimumab en semanas alternas se evaluaron radiográficamente. De estos, 40 pacientes no mostraron prograsion del daño estructural definido por un cambio desde el basal en el índice total de Sharp modificado de 0,5 o menos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 10</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">cambios radiográficos medios durante 12 meses en el ensayo de artritis reumatoide III</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:38.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.42%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo/MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.02%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">/MTX</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en</span><br /><span style="font-family:Times New Roman; font-size:11pt">semanas</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.78%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Placebo/MTX</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><br /><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">/MTX</span><br /><span style="font-family:Times New Roman; font-size:11pt">(IC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.14%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Valor P</span></p></td></tr><tr style="height:25.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.42%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice total de</span><br /><span style="font-family:Times New Roman; font-size:11pt">Sharp</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,7</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.02%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.78%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,4,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.14%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></p></td></tr><tr style="height:17.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.42%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice de erosión</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.02%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.78%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,9,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2,2)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.14%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td></tr><tr style="height:13.2pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.42%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice JSN</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.64%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,0</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.02%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.78%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,3,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1,4)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.14%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,002</span></p></td></tr></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">metotrexato</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">IC 95 % para las diferencias en el cambio de los índices entre metotrexato y adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">basado en análisis de rango</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span><span style="font-family:Times New Roman; font-size:11pt">Estrechamiento del espacio articular</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide V, el daño estructural en las articulaciones se valoró radiográficamente y se expresó como cambio en el Índice Total de Sharp modificado (ver tabla 11).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 11</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">principales cambios radiográficos en la semana 52 en el ensayo de artritis reumatoide V</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt" ><tr style="height:48pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:77pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">MTX</span><br /><span style="font-family:Times New Roman; font-size:11pt">n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">257</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">(IC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><br /><span style="font-family:Times New Roman; font-size:11pt">n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">274</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">(IC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:93.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">/MTX</span><br /><span style="font-family:Times New Roman; font-size:11pt">n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">268</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">(IC</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">95</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Valor p</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Valor p</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">Valor p</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></p></td></tr><tr style="height:25.95pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:77pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice</span><br /><span style="font-family:Times New Roman; font-size:11pt">total de Sharp</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">5,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(4,2</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">7,3)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,7</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4,3)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:93.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,5</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2,1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,0020</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td></tr><tr style="height:25.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:77pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice de erosión</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(2,7</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4,7)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,0</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2,4)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:93.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,4</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1,2)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,0082</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:77pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">índice JSN</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:66pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,2</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1,3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,5</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">2,1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:93.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1,0)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,0037</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,151</span></p></td></tr></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con metotrexato y la terapia combinada con adalimumab/metotrexato usando el test de Mann-Whitney U.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la terapia combinada con adalimumab/metotrexato usando el test de Mann-Whitney U.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">valor p se refiere a la comparación del par de valores correspondientes a la monoterapia con adalimumab y la monoterapia con metotrexato usand</span><span style="font-family:Times New Roman; font-size:11pt">o el test de Mann-Whitney U.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En las siguientes 52 semanas y en las 104 semanas de tratamiento, el porcentaje de pacientes sin progresión (cambio de la línea base del Índice Total de Sharp ≤ 0,5) fue significativamente mayor con la terapia combinada adalim</span><span style="font-family:Times New Roman; font-size:11pt">umab/metotrexato (63,8 % y 61,2 % respectivamente) en comparación con la monoterapia con metotrexato (37,4 % y 33,5 % respectivamente, p &lt; 0,001) y con la monoterapia con adalimumab (50,7 %, p &lt; 0,002 y 44,5%, p &lt; 0,001 respectivamente).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la extensión abierta del ensayo de artritis reumatoide V, el cambio medio desde la basal en el Índice Total de Sharp modificado a los 10 años fue de 10,8, 9,2 y 3,9 en los pacientes inicialmente aleatorizados a recibir metotrexato en monoterapia, adalimumab en monoterapia y la combinación adalimumab/metotrexato respectivamente. La proporción correspondiente de pacientes sin progresión radiográfica fue de 31,3 %, 23,7 % y 36,7% respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Calidad de vida y rendimiento físico</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La calidad de vida relacionada con la salud y el rendimiento físico se evaluaron usando el índice de discapacidad del Cuestionario de Evaluación del Estado de Salud HAQ (Health Assessment Questionnaire) en los cuatro ensayos originales controlados, siendo éste uno de los objetivos fundamentales a la semana 52 en el ensayo de artritis reumatoide III. En los cuatro ensayos, todas las dosis/pautas de adalimumab mostraron de forma estadísticamente significativa superioridad en la mejoría en el índice de discapacidad del HAQ desde el nivel basal hasta el mes 6 comparado con placebo, y en el ensayo de artritis reumatoide III se observó lo mismo a la semana 52. Los resultados del Cuestionario de Salud Abreviado SF 36 (Short Form Health Survey) para todas las dosis/pautas de adalimumab en los cuatro ensayos respaldan estos hallazgos, con unos resultados del resumen del componente físico PCS (Physical Component Summary) estadísticamente significativos, así como unos resultados estadísticamente significativos en la escala de dolor y de la vitalidad para la dosis de 40 mg en semanas alternas. Se ha observado una disminución estadísticamente significativa de la fatiga, medida mediante la escala de valoración funcional del tratamiento de enfermedades crónicas FACIT (Functional Assessment of Chronic Illness Therapy) en los tres ensayos en los que se evaluó (ensayos de artritis reumatoide I, III, IV).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide III, la mayoría de los pacientes que consiguieron mejora en la función física y continuaron el tratamiento, mantuvieron la mejora durante las 520 semanas (120 meses) de tratamiento abierto. La mejora en la calidad de vida se midió hasta la semana 156 (36 meses) manteniéndose a lo largo de este periodo de tiempo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de artritis reumatoide V, la mejoría en el índice de discapacidad del Cuestionario HAQ y del componente físico del SF 36 mostró una mejora superior (p &lt; 0,001) para la combinación adalimumab/metotrexato frente a la monoterapia con metotrexato y la monoterapia con adalimumab en la semana 52, que se mantuvo en la semana 104. Entre los 250 sujetos que completaron la extensión abierta del estudio, las mejorías en la función física se mantuvieron durante los 10 años de tratamiento.</span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Espondiloartritis axial</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Espondilitis anquilosante (EA)</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó el tratamiento con adalimumab 40 mg cada 2 semanas mediante dos ensayos aleatorizados, doble-ciego controlados con placebo de 24 semanas de duración en 393 pacientes con espondilitis anquilosante activa (la media de partida de la actividad basal de la enfermedad según el índice funcional de Bath [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] fue de 6,3 en todos los grupos) que habían presentado una respuesta inadecuada a la terapia convencional. 79 pacientes (20,1 %) fueron tratados concomitantemente con un fármaco antirreumático modificador de la enfermedad, y 37 pacientes (9,4 %) con glucocorticoides. Tras el periodo doble-ciego se continuó con un periodo abierto durante el cual los pacientes recibieron adalimumab 40 mg cada dos semanas por vía subcutánea, durante 28 semanas adicionales. Los pacientes (n = 215; 54,7%) que no consiguieron una puntuación de 20 en el índice ASAS (Assessment in Ankylosing Spondylitis, o Evaluaciones en Espondilitis Anquilosante) a las semanas 12, 16 o 20 recibieron prematuramente terapia de rescate con Adalimumab 40 mg subcutáneo administrado en semanas alternas y, posteriormente fueron considerados como no-respondedores en los análisis estadísticos doble ciego.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de espondilitis anquilosante más amplio (I), con 315 pacientes, los resultados mostraron una mejora estadísticamente significativa de los signos y síntomas de la espondilitis anquilosante en pacientes tratados con adalimumab comparado con placebo. La primera respuesta significativa fue observada en la segunda semana y se mantuvo durante 24 semanas (tabla 12).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 12</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta de eficacia en el ensayo I de espondilitis anquilosante</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">controlado con placebo.</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">reducción de signos y síntomas</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:52.1pt" ><thead><tr style="height:33.05pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:155.15pt"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">107</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">a</span><strong><span style="font-family:Times New Roman; font-size:11pt;">dalimumab</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">208</span></strong></p></td></tr></thead><tbody><tr style="height:12.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">42</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:12.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 42.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p></td></tr><tr style="height:12.65pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 36.85pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">58</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:13.55pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 36.85pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">51</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:11.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:12.65pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 36.85pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:12.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">38</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:13.55pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:11.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">70</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:12.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 36.85pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%**</span></p></td></tr><tr style="height:12.65pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:12.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:12.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:12.65pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">BASDAI</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:12.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 36.85pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:12.65pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:13.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.15pt"><p style="margin:0pt 31.35pt 0pt 0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:95.35pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">42</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr></tbody></table><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">***, ** estadísticamente significativa a p &lt; 0,001, &lt; 0,01 para todas las comparaciones entre adalimumab y placebo en las semanas 2, 12 y 24.</span></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">evaluaciones en espondilitis anquilosante</span></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">índice de Bath para la actividad de la enfermedad espondilitis anquilosante.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes tratados con adalimumab tienen una mejoría significativamente mayor en la semana 12, la cual se mantiene hasta la semana 24 tanto en el SF36 como en el Cuestionario de Calidad de Vida de Espondilitis anquilosante (ASQoL).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron tendencias similares (no todas estadísticamente significativas) en un ensayo de espondilitis anquilosante más pequeño aleatorizado, doble ciego, controlado con placebo (II) de 82 pacientes adultos con espondilitis anquilosante activa.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Espondiloartritis axial sin evidencia radiográfica de EA</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la seguridad y eficacia de adalimumab en dos ensayos aleatorizados, doble ciego, controlados con placebo en pacientes con espondiloartritis axial no radiográfica (EspA ax-nr). El ensayo EspA ax-nr I evaluó pacientes con EspA ax-nr activa. El ensayo EspA ax-nr II era un estudio de retirada de tratamiento en pacientes con EspA ax-nr activa que alcanzaron la remisión durante la fase abierta del tratamiento con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ensayo EspA ax-nr I</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo EspA ax-nr I, se evaluó el tratamiento con adalimumab 40 mg en semanas alternas en un ensayo aleatorizado, doble ciego, controlado con placebo de 12 semanas de duración en 185 pacientes con EspA ax-nr activ</span><span style="font-family:Times New Roman; font-size:11pt">a (la media de partida de la actividad basal de la enfermedad según el índice funcional de Bath [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] fue de 6,4 en pacientes tratados con adalimumab y 6,5 en aquellos en placebo) que presentaron respuesta insuficiente o intolerancia a ≥ 1 AINEs, o contraindicación para AINEs.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Al inicio del ensayo treinta y tres (18 %) pacientes fueron tratados concomitantemente con un fármaco antirreumático modificador de la enfermedad, y 146 (79 %) de los pacientes</span><span style="font-family:Times New Roman; font-size:11pt">con AINEs. Tras el periodo doble ciego se continuó con un periodo de extensión abierto durante el cual los pacientes recibieron adalimumab 40 mg en semanas alternas por vía subcutánea durante un periodo adicional de 144 semanas. Los resultados de la semana 12 mostraron una mejoría estadísticamente significativa de los signos y síntomas de la EspA ax-nr activa en pacientes tratados con adalimumab comparado con placebo (tabla 13).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 13</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta de eficacia en el ensayo de EspA ax-nr controlado con placebo</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta doble</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">‑</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">ciego en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">12</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">94</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">91</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">31</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%**</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5/6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">31</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASAS remisión parcial</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">BASDAI</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">35</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASDAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c,d,e</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1,0***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">ASDAS enfermedad inactiva</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">hs</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">CRP</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d,f,g</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">4,7***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">SPARCC</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">h</span><span style="font-family:Times New Roman; font-size:11pt">MRI articulaciones sacroilíacas</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d,i</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">3,2**</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44.86%"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">SPARCC MRI espinal</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d,j</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.56%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">0,2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:27.58%"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">1,8**</span></p></td></tr></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Sociedad internacional de Evaluación de las Espondiloartritis</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">índice de Bath para la actividad de la enfermedad espondilitis anquilosante.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">puntuación de la actividad de la enfermedad de espondilitis anquilosante</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span><span style="font-family:Times New Roman; font-size:11pt">cambio medio a partir del valor basal</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">e</span><span style="font-family:Times New Roman; font-size:11pt">n = 91 placebo y n = 87 adalimumab</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">f</span><span style="font-family:Times New Roman; font-size:11pt">Proteína C-Reactiva de alta sensibilidad (mg/L)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">g</span><span style="font-family:Times New Roman; font-size:11pt">n = 73 placebo y n = 70 adalimumab</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">h</span><span style="font-family:Times New Roman; font-size:11pt">Consorcio de Canadá de Investigación de Espondiloartritis</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">i</span><span style="font-family:Times New Roman; font-size:11pt">n = 84 placebo y adalimumab</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">j</span><span style="font-family:Times New Roman; font-size:11pt">n = 82 placebo y n = 85 adalimumab</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">***, **, * Estadísticamente significativa a p &lt; 0,001; &lt; 0,01 y &lt; 0,05, respectivamente, para todas las comparaciones entre adalimumab y placebo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Durante la fase de extensión abierta, las mejoras de los signos y síntomas del tratamiento con adalimumab se mantuvieron hasta la semana 156.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Inhibición de la inflamación</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los pacientes tratados con adalimumab se mantuvo una mejoría significativa de los signos de inflamación en las Articulaciones Sacroilíacas y Espinal, medido por PCR hs y RMN, hasta las semanas 156 y 104 respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Calidad de vida y rendimiento físico</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La calidad de vida relacionada con la salud y el rendimiento físico se evaluaron usando los cuestionarios HAQ-S y SF-36. Adalimumab mostró, de forma estadísticamente significativa, superioridad en la mejoría en el índice total del HAQ y en el índice del componente físico (PCS) del SF-36 desde el nivel basal hasta la semana 12 comparado con placebo. Se mantuvieron las mejoras en la calidad de vida relacionada con la salud y la función física durante la fase de extensión abierta hasta la semana 156.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ensayo EspA ax-nr II</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">673 pacientes con EspA ax-nr activa (la med</span><span style="font-family:Times New Roman; font-size:11pt">ia de partida de la actividad basal de la enfermedad [BASDAI] fue de 7,0) que tuvieron respuesta inadecuada a ≥ 2 AINEs, o intolerancia o contraindicación a AINEs participaron en la fase a bierta del Estudio EspA ax-nr II durante el cual recibieron adalimu</span><span style="font-family:Times New Roman; font-size:11pt">mab 40 mg cada dos semanas durante 28 semanas. Estos pacientes también presentaban evidencia objetiva de inflamación en RMN en las articulaciones sacroilíacas o vertebral o PCR-us elevado. Los pacientes que alcanzaron remisión sostenida durante al menos 12 semanas (n=305) (ASDAS &lt; 1,3 en las semanas 16, 20, 24, y 28) durante la fase abierta fueron posteriormente aleatorizados para continuar recibiendo tratamiento con adalimumab 40 mg cada dos semanas (n=152) o placebo (n=153) durante 40 semanas adicionales en la fase de doble ciego controlada con placebo (duranción total del estudio 68 semanas). A los pacientes que recayeron durante la fase de doble ciego se les administró tratamiento de rescate con adalimumab 40 mg cada dos semanas durante al menos 12 semanas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La variable primaria de eficacia fue la proporción de pacientes sin recaída antes de la semana 68 del estudio. Se definió re</span><span style="font-family:Times New Roman; font-size:11pt">caída como ASDAS ≥ 2,1 en dos de las visitas consecutivas con cuatro semanas de diferencia. Durante la fase de doble ciego, una mayor propoción de pacientes tratados con adalimumab no tuvo brote de enfermedad, comparado con los tratados con placebo (70,4%</span><span style="font-family:Times New Roman; font-size:11pt">vs 47,1%, p&lt;0,001) (Figura 1).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Figura 1: Curvas de Kaplan-Meier que resumen el tiempo de recaída en el</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Ensayo EspA ax-nr II</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAE3AiMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD7LooooAKMjOO9Fcl4ut759X8M3VneXkaRakizQQH93IjA5MmBnAx64557UAdbketZPiTX7Pwv4bvte1BJXtbKMyyLCu5yB6DjJrzzxZe6heeNreSxGrAxCCOxEMcyRGUXJFx5gA2keXjl+Mcj1qf4yv4nHw98QJaW2ltpH2UeZJLNIJxyM4UIVPt81AF3/hav/VO/Gn/grH/xdH/C1f8AqnnjT/wVj/4uvRe1FAHnX/C1f+qeeNP/AAVj/wCLo/4Wr/1Tzxp/4Kx/8XXojbth2YLds1yLT/Eve2zTfDJXPGby4Bx/36oAyf8Ahav/AFTzxp/4Kx/8XR/wtX/qnnjT/wAFY/8Ai61fP+J3/QN8Mf8Agbcf/GqPP+J3/QN8Mf8Agbcf/GqAMr/hav8A1Tzxp/4Kx/8AF0f8LV/6p540/wDBWP8A4utXz/id/wBA3wx/4G3H/wAao8/4nf8AQN8Mf+Btx/8AGqAMr/hav/VPPGn/AIKx/wDF0f8AC1f+qeeNP/BWP/i61fP+J3/QN8Mf+Btx/wDGqPP+J3/QN8Mf+Btx/wDGqAMr/hav/VPPGn/grH/xdJ/wtX/qnnjP/wAFY/8Ai6i1vUPijvhs4bTRLV/9cZoJbmQEKf8AVk+Scbv5A1Sute+KFy9tcQ6XplqtvGtw0Ia6P2jIP7o/ueo/mRQBpf8AC1f+qeeM/wDwVj/4ul/4Wr/1Tzxp/wCCsf8AxdcB428c/FPRrh9XisbOCGwAdreJphHPGD+8Y+ZEuQB1ORjj1rovCvxW1LVtMstWvNOP2XWE8ywRdisuc7d3zHILDbkcjgkDdwAbv/C1f+qeeNP/AAVj/wCLo/4Wr/1Tzxp/4Kx/8XW7o3iK8mtxa6lZn7fFcGGbYyKuzkrN977hx2yc9uDWn/bBChjYy83HkkCSPIX/AJ6fe+7+vtQBx/8AwtX/AKp540/8FY/+Lo/4Wr/1Tzxp/wCCsf8AxddJqXi/S9HV/wC1BLbMNzRqV3GZFxl1254+bvg8Hir1jr2l6ilr9nukMl1GZo4icOVBwTt6jBOD70Acb/wtX/qnnjT/AMFY/wDi6P8Ahav/AFTzxp/4Kx/8XXotFAHnX/C1f+qeeNP/AAVj/wCLo/4Wr/1Tzxp/4Kx/8XXotFAHnX/C1f8AqnnjT/wVj/4uoF+JFmt698vwx8XC7dBG040hd7KOilt+ce1emUUAedf8LV/6p540/wDBWP8A4uj/AIWr/wBU88af+Csf/F16LRQB51/wtT/qnfjT/wAFY/8Ai6qWnxC03T5Z5bD4V+KrSS4bfM0OjIhlb1YhuT7mvUKKAPOv+Fq/9U88af8AgrH/AMXR/wALV/6p540/8FY/+Lr0WigDzr/hav8A1Tzxp/4Kx/8AF0f8LV/6p540/wDBWP8A4uvRaKAPOv8Ahav/AFTzxp/4Kx/8XR/wtX/qnnjT/wAFY/8Ai69FooA86/4Wr/1Tzxp/4Kx/8XR/wtX/AKp540/8FY/+Lr0WigDzr/hav/VPPGn/AIKx/wDF0f8AC1f+qeeNP/BWP/i69FooA86/4Wr/ANU88af+Csf/ABdH/C1f+qeeNP8AwVj/AOLr0WigDzr/AIWr/wBU88af+Csf/F0f8LV/6p540/8ABWP/AIuvRaKAPOv+Fq/9U88af+Csf/F0f8LV/wCqeeNP/BWP/i69FooA86/4Wr/1Tzxp/wCCsf8AxdH/AAtX/qnnjT/wVj/4uvRaKAPOv+Fq/wDVPPGn/grH/wAXR/wtX/qnnjT/AMFY/wDi69FooA86/wCFq/8AVPPGn/grH/xdH/C1f+qeeNP/AAVj/wCLr0WigDzr/hav/VPPGn/grH/xdH/C1f8AqnnjT/wVj/4uvRaKAPOv+Fq/9U88af8AgrH/AMXR/wALV/6p540/8FY/+Lr0WigDzr/hav8A1Tzxp/4Kx/8AF0f8LV/6p540/wDBWP8A4uvRaKAPOv8Ahav/AFTzxp/4Kx/8XR/wtX/qnnjT/wAFY/8Ai69FooA86/4Wr/1Tzxp/4Kx/8XR/wtX/AKp540/8FY/+Lr0WigDzr/hav/VPPGn/AIKx/wDF1FcfFyG1tpbm4+H/AIyjhiUu7tpgwqgZJPz16VWL4t/5EfXv+wfP/wCi2oA2I3EkSSLnDAMM+9FR2n/HlB/1zX+VFAE1FQNeWaXiWT3UK3UillhLgOwHcL1IpkOpWFxf3FhBdxSXdsAZoQ3zxg9CR6HBoAtUhUHqKWuX8Q+ONJ8N6lBY30N1Izx+dNJBHuS2i3hPMkOeF3MBxk9TjAJoA6fav92uH+L3/JH/ABJ/16n+YrT1fxppmja7b6TcW91I0ixvLNFGGjtlkfZGXOc/M3AwD74HNZHxeli/4VJ4jjMih/sp+XPPUUAd6OlFA6UUAFFFFABRRRQAUUUUAFFFFABjmiiigDH8QaDb6/p4s7hYTGW+cSxCQOmQWQ8jg4APqK5Ow+DfgK2kma58NaZOrMGjRbfYsXHRfmPcZr0SigDjP+FVfDvO7/hEbDPrsP8AjUc/wm+Hk9tLB/wi1nH5ild8YIZcjGQc8Gu3ooA8c8SfB6RdPsm0PxRrEsOnjP8AZt/M15DcqFwIypZcD8a89v4fHvw51GylhWfXLdNRivJzDayCZYS5Vo/vthSWOFHBJPpX1LWTqnhvQ9ZLnUtNhuGcBWZl5IHTn2yfzoA4vSPisl1ZD7Z4R8S/ak/1gg0uRlwfusPYjBrQ/wCFlWv/AEKHiv8A8FL1SW8bwvqd/wD2bDFNZW0ixyQ7okkkZ/uop4wsYKjns554rsrvUNThF59n0WW5MMSvCFmjX7QxzlBk/LjjlsDmgDmv+FlWv/QoeK//AAUvTLH4u+Bri4u7XUNV/sK7tHEctrqw+yyglQwO1jkjBHNdDqmt3WmWt9dSaW7wW1sJkcSoPOfn92ATkHgcnj5uvWsDTdYX+1JbHxDp9tNK6xyJdxIsqsZG2iLC5b5TwWIxjBzQBp6f8QvBWravFpOleJbC+vJEaRYoJg52rjJ46da6P7Tb/wDPeP8A76Fecav8PfDfjO5luLi30q98m6PluYDvgKlVeMYIGPkwfqavD4N/DTHPhGyz9D/jQB3P2m3/AOe8f/fQo+02/wDz3j/76FcN/wAKb+Gf/Qo2f5H/ABo/4U38M/8AoUbP8j/jQB3P2m3/AOe8f/fQqvp+rWGqCY2Nws3kSGKTb2Yf561xF58GPh3JZTR2vhexhnZSEkZWYKcdcZ5rz3w5eaX8L/iddONPgsPCmr2i20M2nwST77mF2yWjTe6khm5xg4oA+hqK4b/hbHgf/n91H/wTXv8A8Zo/4Wx4H/5/dR/8E17/APGaAO5orhv+FseB/wDn91H/AME17/8AGans/id4Kv7t7WDVpI5kha4K3VnPbAouNxBlRQcZHAOeaAOyorM0XXdN8QaeL7TLgTRZKsM/MjDqrDsR6Vp0AFFFFABRRSBlbODnFAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWL4t/5EfXv+wfP/wCi2rarF8W/8iPr3/YPn/8ARbUAalp/x4wf9c1/lRRaf8eMH/XNf5UUAePfFC48dJ4w+xeBPD9jqN9e6X5ZuH1JLS4t8O2DGCcsMnJ7cDNavwzHxBl12+n8d+FLfRWjsYbeCaK9F29zh3Lb2HcZH51D4503x/qPxGgj8DeLLLw7KdOHmtd6d9oEwEjcKxGBjPTPetrwHovxL0rUr+Tx94usvEEMkSLbfZbQW/lMCd2QOuQRz7Uobff+oS/y/Q76uI8XeA28T6xBeR6u9jDJALO/iWEP9ptxIJAgJPyHcDzzwx9q7eimB5zrfw4uvEHiLTNU1PWIZI7KbeyLZ7ZJI1l8yKPeH6KcdQc4yME1m/Gjwb4YvvAmveJLzRbabV4bUeXdsvzrtIxg+1esVw3xe/5I/wCJP+vU/wAxQB3I6UUDpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAERt7dmLNChJ5JKjNS0UUANZFkXa6hh6GmrBChysSqemQMVJR2oAxLi402LxXY27wxG8MEpjkz8yKSmQB/tY/8AHa281yV/4SlvtXbU2uIRcCQNFKY23xp8oKfewQQpzx3NbUOg6XC1g8drtbT4Gt7c7m/dxsFBXrz91evpQBpbh60uay4PD+lWz2Lw22xrBWS3+Ynywwww68/jRD4f0mA2JitdpsGd7f5m+QuCG785yetAGpkGohb24YMIUBHOQtZb6PNaqp0W6+ykH/VSgvEd0m5zjIO48gHPGelTWl3K2u39jNdRyGNY5Y4liZTGjAj5m6MSyt0xgUAaeB6UYHpRRQAYHpXN+MPC1n4m0Ywy2dpNcwnfA1zbpKAw5x8wOASBnFdJRQB474c+Da6JqFw1vrGr6baXZM08VhfeQnncDcqIuBnBz+FdX/wri2/6G7xV/wCDV/8ACu3ooA4j/hXFt/0N3ir/AMGr/wCFH/CuLb/obvFX/g1f/Cu3ooA4K6+HsMNnNNF4p8WTSIhZY11VsscdBkVxHhzwX8V9MlW1tviJMqToZJ5rzSFkPmDHVjJliRxn/ZFe6UUAeZ/8In8Wv+ip2n/gjT/45R/wifxa/wCip2n/AII0/wDjlemUUAeZ/wDCJ/Fr/oqdp/4I0/8AjlYnibSPi9pul+XbfFCye8usxQK+kJEu7aTkvvO0ADrg84r2ejHNAHhUnj74jx2Uc02iaY0mkKEvBHqfF5JgA7B5fI5zx3I9DXQeHvE3xHZJdOPhvTdSnhAlM39rjlXJI6RdiCPpivVNo9KXAHQUAcP/AG18S/8AoR9M/wDBx/8Aaqgbxl4t0zU7aLxH4JlhsZ1f/SNLma+ZGGMBkVAQDzz7V39FAHK6D8QPDHiK9nsLG9eK+gnNtJaXUTQzK4QPyjAHGCOeh59K6qvM/FHwm0nxP4jvNduYokvZYo4YpopZoWRUJYZ8t1DHczHJ9h2q6PhB4JxzBqmf+wvd/wDxygDv6gvLy3sLKa9u5RFbwqXdz0UCuH/4VB4I/wCeGqf+De7/APjlZ2q/Bfw1cpCun/bY9rFnE+p3bhuOP+WvY4P4UAdhJ4z8MxC6L6vAPspUTfN9wsMr+dSW/i3w7daomlwatBJeOAViDfMQV3D9K8ci/ZxsUubWR9QEiRM5lUz3I84NnGSJeMcY+lcf4y+FsHww8Nx+KI9XmuNTtbmB0eF5ySomQsWUuQVGeePTAzQB9X0V832f7UOmSTQxzaUiIQpdkaRtgzhv+WfbrX0Jpep2WsaTa6pp04ntLqNZYpB0dSMg0AXKKKKACiiigAooooAKxfFv/Ij69/2D5/8A0W1bVYvi3/kR9e/7B8//AKLagDUtP+PGD/rmv8qKLT/jxg/65r/KigDzD4kaTY+LfEdt4Y1rx1c+GbBbb7StvaXK20l6+4g/OeSFAHyj+9k9qsfDOxt/D2qap4W0vxtP4p021ijmX7TOs8lk7FgYzIvUEDIB5H41ifG6xn8QC00dfhzY+LrKziN/eSXV0beSCMEjbCVwd5AbvjjmpPgdDLFZag+meCYPB3haVUfTbKR915ccndPNnkZ4ABPSiHX+v6/4AT6f1/X/AAT2SvKfiP4m1rR/ESQ6frJ08Q2Iure32If7QmM6xmE7gSflI4XB+YHtXq1QT2VncyxS3FrFNJC26NnQMUPqCehoA8p8Z+MtTs/iBpFno+solkgh+1RRyRHez3HlsuGBaQjBBVSpU8nPSn/GjVvEkPgfXtPtfCv2rSntRv1H7aibMkZ/dkZOPrzXpx0rTDPHOdOtjLExdHMS5Rj1IOOCa5L4vf8AJH/En/Xqf5igDuR0ooHSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzi88eXWn+OH+1bV8Mg/ZZLoqAkEy8szPnhTnHttr0esn/hGtCIZTpduQzbyNgwW9cUAaBurdYUmaZFjfG1icA56fnUwORmuQ1rw1NdX8K2tvv0/99LND5+3zJnxtbkHG3BIwRyfatTSdN1KHT9MGo6ncPc2ykTfOrC4JGPmO0Zx1GMfjQBt0VlfZ9ZgS4itryGVfJ/cPcqS/mksfm24BXG0ADB4PNcnrOpeIrPV59VjdVt7CIRi2aOULOTzI5YAgKOMdT8p9aAPQaKwfDXivSPFdh9s0mZnjGM70KH64POMgj8DW9ketABRRketGR60AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWNrHhjR9emil1O3klaL7my4kjx/wB8MM/jWzRQB57efC7wPp+k3txZ6M0UiWzhWF3OcAKSBy9XfhPBFbfB/wAKRQqVT+zoTgsT1UHv9a2/FV/Hp3hPUriQbj5DoqZwXYggKPck14j8N/i5daP4N0/Qdf8ACesRXFlaxW0K29i773AwFP17EehoA+iKK8tj+K1zNYxWf/CI67HrbuITG+nSCJWJ+8T127fmr0fTb5dQ0+K6C7CwwynqrDhlPuCCKALdFFFABRRRQAVi+Lf+RH17/sHz/wDotq2qxfFv/Ij69/2D5/8A0W1AGpaf8eMH/XNf5UUWn/HjB/1zX+VFAHg3xy0zwte+KtMn17wx4j1tYLQtdS6RO0Udjb7zmRwv3uc8egNWPgHotno+o67t8Haz4XuZoYXSHUr43Qngy2x1J+6eoK9uK7Lx58KdP8e6tHqF/wCKvEOjpHbfZmi0m9+zpKpJJ3/Kd3XFT+A/hlZ+A9Qvry18T6/rf2yFIj/bF59pMYUkjYcDAO7kUQ0/EJanfVh6z4t8P+H761stW1Bbee6/1a7GbjcFyxUEIMsBlsDJ61uV59428Far4h1hrjTrm2it72yGn3nnbtyRiUSb48dW+8MHjkHtggHR6x4u0PQb22s9UnuIZblkWMraTSIS7bVBdEKqSeOSKw/i6c/CDxIB/wA+p/mK0bjRdX1bWdKl1KS3j0/T5pJ/JiJYzOPlhJyOwJY/7WMdK4740eDPDl94G17xLdaf5mqQ2o2T+a4xtIxwDj9KAPWh0ooHSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsvXtMuNX0iSwtr37G0hG6Ty9+RnJGMjrWpRQBxmn+BIrHVpL5b3yklWIPHaK8BcxkFcsHJIznI77mz1rf/shtxb+0rwZuRc8Sdgf9X0+57frWpRQBmNpLMtwo1O9XzrhbjIk+5jHyLxwhxyPc0Ppcmy5231zumlWYfvMbMbfkXjhTt5Hua06KAOGvfFGr2eoMTbQPFYxqt3EkyjzJm/hQtg/L8pJIwQ3qK6VdcsTEzN5qFJ1tXHkudshxx05HI+YfL71oNbwMxZoUJPUlRmn7VxjaMUARrdW7bMTxnzMlcMPmx1x606OaKVA8Uiup6FTkGoF07T08jZZQL9nBWHEYHlg9QvHGe+Kp3Hh/T5ottvGbF1gkt45LU+W0SvgttxwDkA5x1oA1qKx5dNv4PJl0/UHMqLFCy3OZEdFbLHAI+cjI3fTiuG8WeOtY02dXtoo7NNNhN1qcLssjbevlrjq2MHj19aAPUaKq6ffW+paZbahaP5kFxGssbYxlSMirVABRRQSAMnpQAUVDbXVveWyXNrMk0L8q6NkH8amoAKKKKACiiigCnqOl2OrWwt9Qt1niDBwrEjBHQ8Vmr4P8OLNHMumqJYtux97ZXb0xzxjtW9RQBl/2Bpf2j7R9nbzv+enmvu6Y65zVy0sraxhaK1j8tGYuRknLE5JJPUmrFFABRRRQAUUUUAFYvi3/AJEfXv8AsHz/APotq2qxfFv/ACI+vf8AYPn/APRbUAalp/x4wf8AXNf5UUWn/HjB/wBc1/lRQB5H8VtN8C+IvEdloPxI8STaVo32fzra2N39lgupdxDF34yVG3C5HXNWfhJZ+EdG1HV9B8A+I59Z8PW8ccmxrn7TFaTEtlI5PQgAlcnH41B8bdU8L6bpEaeLPseqw3ACWOhtZLc3F1cZPMYzkdQM9q1fg3pPibSfBir4g0LSPDqTHzLfSdNg2G3U95Dnlzx9KIbMJ9D0uiivM/H3i7XNC114dNuobeGz08X7RSxhjesZ1j8pSenB7ZOWX8QD0yuG+L3/ACR/xJ/16n+YrI8V+Nta0zx9p2m2SldISKCS8lTyy2ZZjGBhuTggA7eRnPbFHxk1i4h+HXiDTV0PUJo3tebyNUMK5I6ksDx9KAPUB0ooHSigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxPEGl3WpxW8NvHA0PmhrhZJDGXUA4AIU/xYP0FbdFAHPeHtBl0rT4La4lkAtVeGFEuXkHlEjG4kDcwxgHHStGLSYYRaBbi6b7KjIu+dm3g45fJ+Y8cE9Oa0KKAKEOlxQ/ZNtxdN9l3bd87Hfn+/z83tnpWfqmgyz6QtrY3ErSKzf6+5cB1c/OGPJPykgZBxx6Vv0UAcjp+h6hpMpaOEvAl0JYLeK9chN/Em7KgMoyWCnOD0xxW8+oXCRlv7MuCRP5RAKfd/56fe+7+vtWhRQBmR69pksNpMk5KXcbTQkow3KoBJ5HHUday4PHXh6402PUI7phbyyBFZ0K8EZDkHohGDuPY1u6haNeadcWscxt2ljKCRRkrkYyK5C++HkGoXF1LLeRqLuzSxmRbdcNCpJC+uDkg+ooArt8XvB6zvAbi5EqNtKeQc59Pz4+tb2leNNB1jU5tPs7vM8MayEOu0EH0J646EdiK4X/AIUZo5uhcvqjvJ5Xktvt0O8Y7+vIB9MgVynin4R67/otno0l1KLBzJDdqkQeUsMuHJ6jtj1OenFAH0LHNFMu6KRXH+yc0+vIPhlofirwxqwsb7TTHp9xE0krNIpaJ+CqgAnKjkZ6+ue3r9ABRRRQAUUUUAFFFFABWL4t/wCRH17/ALB8/wD6LatqsXxb/wAiPr3/AGD5/wD0W1AGpaf8eMH/AFzX+VFFp/x4wf8AXNf5UUAc1q/g7wjrHjSy13VIhJrlrbmK0ZblopI0zlioVgfxq9pdno1vrt59h1Kae9SJY54Jb15zEMkg7XYlc8+mcV5t8WLnx1pmuSX3g/wnBfibThA+qyanFYvZNvYgK0nXOckdOBV74V3njbVdXvNR8X+E4NHAsYYLe7i1GO+N5h3JLOnpnp70R1/H9Qlp/XoesVQvtF0nUrm2utQ023uprVt8LyxhjGfUE9Og/Kr9Z1/rmj6XdW1rqGo29rPdNthSWQKZD0wAevUfnQBC/hnQJLqG6fR7Rp4JGmjkMKlkdjksDjgk8/Wud+Lv/JH/ABJ/16n+Yrp7zXtH0/ULbT77UYLe7uv9TC74aTnHA+tcx8Xf+SP+JP8Ar1P8xQB3I6UUDpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUHgUUUAefTa19n+IEOpTGAWkrf2WiA5mLZLbsY+7uHr05r0GsLxDq1loiWd5f6nDp9t5+1/Mj3eb8rfKMdD3z6Ka1LG+ttSsYr2zkEkEq7kbBGR9DyKALNFFFABRRRQAUUUUAFYvi3/AJEfXv8AsHz/APotq2qxfFv/ACI+vf8AYPn/APRbUAalp/x4wf8AXNf5UUWn/HjB/wBc1/lRQB4T8brnwpN4t0vTvG3hrxR4j0uK0M8NnosDSxCUuQXl2sOcDA+pq78Dbzw0uqa7png/w74k8P6QsUM/2LW4WjVZSWBMQZicEAZ564rtPH/xEj8EtaWtj4Z1PxLrN6paKx02LcwjXq7t/CuSBn1NWPAXjyLxtaXRuPD+peHtVsyq3FhqUWyRQ2SrKf4lODz6g0Q6hI7OvM/H3hDXNe1xptNtbe4hu7AWLSyyBTZsJ1k81RjngdsHKr+HplFAHnev6J4k1LxPpurafYy2V1bEQG5W8Xy/IEoZt8e3LblHGDwT7Vm/Gbw61z4C1/Wf7e1aAR2o/wBChnUW7YI6rtyc9+a9Wrhvi9/yR/xJ/wBep/mKAO5HSigdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmvFfh248Rpb2vmxfY13edDICPMBGCAR04JH4mpvDGj32iWMlndXSTx7y0e3Pyj0JPX1+pNb9FABRRRQAUUUUAFFFFABWL4t/wCRH17/ALB8/wD6LatqsXxb/wAiPr3/AGD5/wD0W1AGpaf8eMH/AFzX+VFFp/x4wf8AXNf5UUAed+O/CXj/AFfxHFq/g34hQ+EYI7UQ3G/TorsykMWBzJ90DPasX4UXWpy+OPENprHxUsvH15a2sCO1pZRW62nzv8pMfysT+YxW38XPCnh3xJ4egbxR4vn8PafBICwN55Fvcf7Mgyu4fQg0z4TaToGjaVJZ+GtF0uHT8M6alpcyzQ3IaVyE3feJUEfeojpcJHplec+OvGWtaDrawaUtr9msLMajerOpLzxmYR+XGQflb7xyc9hjnNejVk6p4b0PWry1vNU0yG6ntDmF5FyV5Bx7jIBweMgUAcj47+JFp4VvdK0uK6so7y7mhaY3c6xrFbtIEZhkgljk4A9CT0rM+M3ia3tfAOvaI2marJLLajFxDYSvbjJHWUDaPfJ4r0CbwzoNxCYbjS7eZDN5/wC8Tcd+7fnJ/wBrmuc+LoA+D/iP/r1P8xQB3Q6UUDpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWL4t/5EfXv+wfP/AOi2rarF8W/8iPr3/YPn/wDRbUAalp/x4wf9c1/lRRaf8eMH/XNf5UUAeJfGBbSbxtpi6t8L9Y8f2UFmXit7Rd8FvIXILOp4LEAAZ7Zq38GTbx69r0Om/DbVfAenvDDL9jvRtjlkywLxr0HGAce1dJ448A+JfFWuwX+ifETU/CsMUHlPFYxq/nNuJ3Nu9M1T+HOg6n4e8W61p+r+PtW8U3S28R8vUrYxeQu5vmQ4wwPqPSiGn4hLX8D1Cq1xqFlazQw3N1FDJO2yJHcKZG9FB6mrNeYfELwjrWva+txp2mxXiT2Is453kVTYSCdZPOAPJ4X+HnKigD0WbUbG2uobW4vIYp5/9VG8gDSfQdTXIfF7/kj/AIk/69T/ADFVPFmka5r1/pX2bw8Y5bW8jkN28sBTy45c/P8A8tMEDcAhHJGe9U/jJpepS/DvxBfR+IbqC0W1+axSGIxvgjOWKlufY0AeoDpRQOlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYvi3/kR9e/7B8//AKLatqsXxb/yI+vf9g+f/wBFtQBqWn/HjB/1zX+VFFp/x4wf9c1/lRQB5t8QLr4oR+JLeHwHrnhawtfswaePXWfcz7jgoEHTHXNHw5/4WFJ4m1Ofx9rHhrUJPskSW40JnIQb2Lbw4z3GPxrmPjVZ/Da48U6XL428B6x4okS2JkuLETGPTrfdzJJ5bDjP14Bqf4F6d4Usb7XG0H4b6l4GuZY4maG+mkk+1wEt5cg3k4P3sjtSh/mE/wDI9voorg/GPjm98N6wLWz0yK7gtbUX188kxRlhMojHlgKdzZJOCQMD3pgd5XDfF7/kj/iT/r1P8xVrxP4i1vRdR05rPT7O60+4lihcNcsty7O+0+WgQg7R8xyRwD0xXLfGjxl4XsfAmveG7vWreHV5rUeXaMTvbcRjt3oA9YHSigdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfFv8AyI+vf9g+f/0W1bVYvi3/AJEfXv8AsHz/APotqANS0/48YP8Armv8qKLT/jxg/wCua/yooA8m+L3hjQb2Qa94j+J2peDLBLU20kdndiBbkZJIYHl+uAAKwfgLdWV94l8QXOj694r8Q6ULaGOHUdfzslId8iHIHA7/AIV33xCh+F13d6PZeP30pL6ab/iWteBfNDj+4SD3x14ziq/wx8SaHrv9pW3hbxRZ67pFhIyfu7dopopXkZ2DcAMvPylQBx360Q0uEtV/X9dD0esDWvB+g+IL+2vtUtDNNbjapEjIHXcG2uAQHXcoOGyMit+kJA60AcxceA9Butcttama/N7aljE630yhdzbmGN2ME9umOOnFZfxejj/4VF4kfYu77Kecc9RXd7lz1rh/i7/yR/xJ/wBep/mKAO5HSigdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfFv/ACI+vf8AYPn/APRbVtVi+Lf+RH17/sHz/wDotqANS0/48YP+ua/yootP+PGD/rmv8qKAPBvj5p+qJdLqq/8ACEwaXNYmxkuvE4cvG5Yn9xt6NjnPsK1/gjHr15Je67qH/CHS6dNaQ2trN4WDiNtjNkSbudwyMVP8VNS8FeHvEllrnxE8L3Gr6R9n8m3u1tPtUVpJuJYMn8JYbcNg/dxVj4S3nhPWdT1fXfAnhq40TQbiOOMvJbfZo7yVS2XSP0AIBbAz+FENmE/6/A9Zryb4l6Vrd94ms5LGxv7rNoI9OltmOy0vPOUmR8EBR5fc8YDDvg+s0UAcLrdvPq2s+GNStra/R7HVjHMjbkXyxFKpcrnBUttwx9R61z3xo07xZJ4I168s/Edrb6MtqPMsXsN8j4I3Yl3jGf8Ad4r1vA9K4X4vf8kg8Sf9ep/mKAO6HSigdKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfFv/Ij69/2D5/8A0W1bVYvi3/kR9e/7B8//AKLagDUtP+PGD/rmv8qKLT/jxg/65r/KigDxD42+K10bXrG1m+Jp8G+RaNeW9utr5wv5QxAWTg/Jxgj/AGvan/AnxKvizUNa1q/8cxeI9bnhhM9nZwtFaabHltkcYYDJ65PfFUPjp4oh0PxbpcbeKtN8PvFaG5CXWjm+bUMOQIScHy168jnJrvfh346+HnjK7vP+EKEBubeCNrsw2jQbQxOFOVXPIaiGzfqE/wCvwPRK5DxP46tfDOppZS6dc3QWAXVzLDt220JkEYdskE/MegycA119cn4l8C2HibVLe+ub66tgsfkXMUJAW7h3hxG+RnG4Z4weSO9ABrfjW30XXIdNbTri5TZDJcXEZULbrLJ5cZIJycsD06CuX+M3i7wvZ+ANf8PXniDT7fV5bUeXZSXCrM+4jGEJyc10N94Bg1HWYdRutbvnw4M0PyBLhElMkUbfLkBGPGOSOCTUHxW0n+0Phlr6Wmm/bL97UiNY4d8rEEcDjJNAHdDpRXEf8LL0f/oCeJP/AAS3P/xFH/CzNH/6AniT/wAEtz/8RQB29FcLN8UdCt4JJ5tI8RRxRqXd20W4AUDkk/JSQfFPQLq2iubbSfEU0Mqh45E0a4KspGQQdnTFAHd0VxH/AAszR/8AoCeJP/BLc/8AxFH/AAszR/8AoCeJP/BLc/8AxFAHb0VxH/CzNH/6AniT/wAEtz/8RVe9+LXhrTbRru/07xBawKyqZJdHuFUFmCqMle5IH40Ad/RXEf8ACzNH/wCgJ4k/8Elz/wDEUf8ACzNH/wCgJ4k/8Etz/wDEUAdvRXEf8LM0f/oCeJP/AAS3P/xFH/CzNH/6AniT/wAEtz/8RQB29FcDcfFjw3aSW8d1pviCF7mTyoVfRrgGR8E7R8vJwCfwqf8A4WZo/wD0BPEn/gluf/iKAO3oriP+FmaP/wBATxJ/4Jbn/wCIo/4WZo//AEBPEn/gluf/AIigDt6K4j/hZmj/APQE8Sf+CW5/+IqFvit4dW9jsm0vxCLmRGkSI6NcbmVSASBt6AsPzFAHe0VxH/CzNH/6AniT/wAEtz/8RR/wszR/+gJ4k/8ABLc//EUAdvRXEf8ACzNH/wCgJ4k/8Etz/wDEUf8ACzNH/wCgJ4k/8Etz/wDEUAdvRXBJ8VvDsl5NZx6X4ha4hVWkiGjXG5A2dpI2cZwfyqb/AIWZo/8A0BPEn/gluf8A4igDt6K4j/hZmj/9ATxJ/wCCW5/+Io/4WZo//QE8Sf8Agluf/iKAO3oriP8AhZmj/wDQE8Sf+CW5/wDiKgtvix4bvBKbTTfEE4hkaGTZo1wdjrwyn5eCPSgDvqK4j/hZmj/9ATxJ/wCCW5/+Io/4WZo//QE8Sf8Agluf/iKAO3oriP8AhZmj/wDQE8Sf+CW5/wDiKRviboqqWbRfEgUDJJ0W54/8coA7iiuBs/ix4b1GxhvrDTfEFzazqHjli0a4ZXU9CCF5FT/8LM0f/oCeJP8AwS3P/wARQB29FcR/wszR/wDoCeJP/BLc/wDxFH/CzNH/AOgJ4k/8Etz/APEUAdvRXBXXxW8O2NnNeXml+Ibe2gQySSyaNcKqKOSSdnAqVfidororpoviRlYZBGi3PI/74oA7iiuI/wCFmaP/ANATxJ/4Jbn/AOIo/wCFmaP/ANATxJ/4Jbn/AOIoA7eiuI/4WZo//QE8Sf8Agluf/iKhuPit4ds0R7rS/EMKySLEpfRrgbmY4VR8nUmgDvaK4j/hZmj/APQE8Sf+CW5/+Io/4WZo/wD0BPEn/gluf/iKAO3oriP+FmaP/wBATxJ/4Jbn/wCIo/4WZo//AEBPEn/gluf/AIigDt6K4KT4reHYbmC1m0vxCk9xuEUbaNcBpNoycDZzgc1N/wALM0f/AKAniT/wS3P/AMRQB29FcR/wszR/+gJ4k/8ABLc//EUf8LM0f/oCeJP/AAS3P/xFAHb0VxH/AAszR/8AoCeJP/BLc/8AxFQD4seGzqDaeNN8QG7WMTGH+x7jeEJIDY29MgjPtQB31FcR/wALM0f/AKAniT/wS3P/AMRR/wALM0f/AKAniT/wS3P/AMRQB29FcR/wszR/+gJ4k/8ABLc//EUf8LM0f/oCeJP/AAS3P/xFAHb0VwFv8WvDV1cXVtbad4glmtHEc8aaPcExMQGAYbeDgg/jVj/hZmj/APQE8Sf+CW5/+IoA7eiuI/4WZo//AEBPEn/gluf/AIij/hZmj/8AQE8Sf+CW5/8AiKAO3rF8W/8AIj69/wBg+f8A9FtWF/wszR/+gJ4k/wDBLc//ABFZviD4gabf+F9VsbbQvEjT3FpLFGDotwMsyED+D1NAHodp/wAeMH/XNf5UUtsCtnCrDBCKCD24ooAjm0+xuJ/PuLOCaXbt3yRhjj05pYLCxtZmmtrOGGRl2s0cYUkenFWKKACiiigAooooAKKKKAKmqQ2t1pN3a3sgjtp4XjlYttwpBB57cGm6TZ2mnaLZafYtutbaBIYju3ZRVAHPfgVg+PtKutW8ORQ2+n/2nHDeQXFxYkr/AKVEkgZ4/mIU5A6E4OMVL4F0u80fwda2V7b/AGWQPK624YHyI2kZkj44+VSF4444oA6aiiigArI8SaFp/iTQpNK1QuLVpI5WKNtIMbrIvP1UVr1xvxF0jxBrvhWTTNDMBWYMLmKWVojNHtOEDAHGTjPqMjIzQB2KMrRqysGUjII5BpaxfClvf2fg7R7PU4UgvILOKKWNG3BWVACM9+lbVABRRRQBj6zpel6le6RLqE2yaxuxc2o8wLukCMuMd+GPFbFeRfE7wn4i1/xlol/peli6hskHlyZjwkvnxud+5gyLtj+9H82cg8cH1tM7Fz1xQA6iiigArHubTSRrsHiC4ukjntYZLNWaUKgDshYH3yi1rsoZCp6EYryHUfDF1pvhHUtLs/BMWtC41eeS2ilEUq28TjBmxIwyfvcZySeaAPXwQwBByD3orN0C1Fh4a0yxVJkFvbRxBbggyDaoGGwSM8c4OK0qACgnHWioLy1hvbGa0uF3RSoUZQSMgjB5FAGbFa6PZazd6+LuNJdRSKB3aUbG2btoX3+Y1sggjI5rwO78AeJR4X8KW0WkvNJpVpcQxWqmBkt7hpVMUkgkyCgUEHb8wHTrXvFusi20aygCTaN23pnvQBJRRRQBFPcW9rEZbmeOGMdWkYKB+JrL0bTdJ0WS8t7K4Blv7mW/kRpAWLOcsQPTNZHxCt5rrw0IrbwlF4muDMvl28yxskRwR5pEhAO0E8A5OfxrhfDngnUtN8TaPJFoVwiW0sEi6jdPEZYrdLYxtbttYkEuc7VyuD14oA9qooooAKrXk1qkXkXVxHD5+Y1DuFLE9hnqas1538TdJm1iKxsoPCH9s+dujlvkSFpLKPIJMfmMuHOBgjpjPbFAHXeHtH0/w1oFh4c05z9nsoBFCkj7n2Lxk+v1rWrzDRfD/i+3+Lz+ItUhtZrOaymtxPHOxMaeZGYo9hHBwpJ5OSWOegr0+gAooooAydes9L1rSLzw7qVwqx6jA8DxrIFdkIwdvfpV60e18hYbaZJVh/dHawbBAxg+9ec+NdHn1Xxtpn2fwaZ1iMU0mtxLD5qFHJSIMzB1XPLEA8EgDJ4p/B/wpr/hmTVP7X0z7Ek8cPLGPLyru342Mdy8jDt8575wKAPWqKKKACsfVrPSdYWK2vLpc2U8V4VWUAoyNuUt6DIrYPSvKNU8P3jePNT1qHwV9qtDp80E8Drbqt+5ZSu0hstnbz5nAA475APU4Z4biFZreZJo26OjBgfxFSVxvw50yfS/DEq3WkNo9xcXUlxJZ7Y0jhLY+WNUYgJx65JyT1rsqACiikb7poAyLu10m+1Wy1aW6QzaO0m0rKNsZdNrB/wPetWKaKeJZYZFkjYZDIcgj614bq/gbWdSutdksPDs2n6fdy2rT2ii2jkuBHMzyKm0lGBBzuk+YnjOOnqHgax1HTfBljZ6pbJbXEQYCJQg2JuOwNs+XdtxnbxnOKAOlooooAKxPsGjw+KZfEb3SrfS26aed0oC7VZnC4/vZc/pV7Vl1FtIul0h4UvzGwgacExq+OC2OcZr5/j+HfjOKPWYNS0CLVDdTXP2WUXKyNHcSxQgXRL7cYaNuQNwycDFAH0bRTIVZYEVvvBQD9afQAUUVj+J7fWrvw3dWugXEVvfygIksjFQqkjcQQDg7c4ODg4oAZpej6XpOp6vq1rN+81e4SWdmkBUuqiMBfThQMetbdeBxeB/iCnh7RrI6dYfZ9M1ETxWgvH3Kftm8yk7cN+76Z5wW6kgD3tc7Ru60ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXL+LNX1jTbjTbbRrfzpbppAwEPmH5VyON64575rqKpajqGn6ZCl1qNxHbx7givIcDcxwB+NAE9q08lnC91GIp2RTIinIVscjP1qagHIyKKACiiigArk/EWu6vpuqPaWcdpsbTp7mJ53KjzUKgBjwAvzV1lZOo6xollPJDqF1Aksdu1w6ueViH3mI9KAOO0fxxfX1/ocDXFpKbyaSC5iVQHXaGw6bZGyuVAyAR1yRin6z4z1Ky1e4toTawxxzNGiTgl7gq0a7F5HzHeSOvAHHWups9U8PzXNlHayQC4uEc26bNrsq/ewCM4FQXmr+GLHUXhvJ7eO5klAYMOd+FAJ464ZRn3FAF3w9qMuq6Db3syBJH3KwHQlWK5HscZH1rUbdsO0At2Bqtp7WbadC2n7PspX93sGFx7VZZlRSzHCjkk9qAPOLjxrrVr/ZclyLOOOW7uLa5VCGf5Ljyk8tWZWYEA5IBPtV6y8XXk2m+IJvMtbr7BMI4JoPuMrAYJwzDgk55BwOQMitr+3/DM0toUuoJmuGf7OUXfuKttcggcYbgmp473w/c6VftHLbPZQO8V1tA2KwALK3vgjNAHJWPjTUptTaF/s0qrMsbRRqQ8GZjFtfn72MN24B4716MOgrnYNY8L3d6IYp7eSeKVQRt5EnKg9OTwRn14rou1AGJ4p1O+0fw/LqFhHFJJEybllzjaWAOMd+a4+98dX1jresWF7qNhZpbsTbPsEoKhgu18SAq5JwAQO/XBrvdU1DT9Ns/P1OeOGAsE3SHgknAH51nahqvhmxuJYNQmtUm2rJJGyhmIJIUkYyeQcUAYut+LNQ0/T9OdYreOW4tvPllZi8UfzRqTkdQPM3Z9F/GrvhPxFd6zPNFdeTJtjEizQZCOPMdMjOeDsyOe9aF5qPh2Cztb27nthAVLQuQCNuOce2CB+IqbR7zRr5pZtKeJyVXcUGDt5C/hwR+BoA1q5PVPE19pWuarbvYm6trawjuoEtkZ5ZHZ2TaQB0yB06DJNdZWXcazpFveXkM1zGLi1hWWdRyyISQCQOcEg0AcRoHj7U9XvdIjmjtrc3axCS1ZHWViyOzOm7HyKVx0555HFWbjxvqEOrWFjHp7mO71CS2efynZYkDtGoyBjcSueSMCultte8OXF9aw291bvcTxh4do5KsCRg44yATj2pg1jw9FfSacksf2iV2Zo0QklujHgde2aAL2g38mp6DaX0qBJJk3MB0z049vStF92w7MFu2elV7B7WTTrd7HZ9lKDytn3duOMe2KsMyqpZjgDqTQBwDeLtTW20sS3emw391ey2xtHyPMVLgxsysWGMKM9DkkDvVuLxDrEPhXWdauvJuooHIs3jhaLzVGAXILH5d2cHuBnvWr/bXhmcWMxntpFupWitpNuQ7htpAOODu4+tXH1DR7iy1CNp4JLezJiulyCsfy5Kt+B6UAcf4j8bax4f0jxBN/ZwvLixdFthAjupUxby0hAOAOf0HvXUeHdYk1Zb8PGVFrceSrFSu8GNJAcHkY8zB9waLPXtAvZ3srW8ieTf5LIP7wyMdP9lh+BFa8NtBbhvJjCBmLNtGMk9TQBk+JNTvtLt7GazjidZb2GCXzCchHcKSMd+e9cx4i8Zaxo8OpbYbYPb3qQRk8jy2i8zLFioz26jrxk9e11DUNPsVgXULiOLz5ViiDn77k8Ae9Zk3iDw5i5W4uImEEgScMhO1ucZGPY89OKAMfVfF0trb20kl1bachsFvGmuIywZmYKEVcqc5J791qjceNdQhkCi4064kSxF3cWsTZeI7QQAdx37ucYHAwc+vU6pqHhu2+zXGpSWxLoTCXUMSpK5xwcgkr+lTWv8AYWrLvtoraYBUOVQH5SAy/h0NAGqjbo1bGMjODXIeIPEeqaTfXsSJbJAkEckUsm47N0oRmfp8q5zgdh19OxrIutY0WG5ube5niM0EYeaPG5lRjgZA7GgDE8OeJdU1W9sUuEtWtrm2uXE0O7940UyoGGeisGyOv1rMvvHF9bXUcsKwSB7i5hNjj9/iIuqt97PzGP8Aukc8kV1Nh4g0C8uktNPuoppfLBCxqcKp98YHTpSpeeH49WW3SS2F7NI6qBjczKPnx9O9AHO+FPGN5rd1ZRXMaFp2mR/LUYQqqsMEMwIw2Dz17Cuq169utO8P3t9ZxpJPDGXVZDheO55HTr1FQ2F9oN3qGzT5beSeIyw5jx8pVh5ij6Ern8K1bh4Y7aSS4KiFVJcv0x3zQB55pnjrUL250RWa2K3tzJBJGU2yMgLBZlG8kKSo7EdckVa1PxdfWeoQRwyW3z6l9jNrJ/rWT5RvHzZ6nsp4IzgZNb8OteHGlsWhntwblR9mcLwynOADjHOOlSQ3mgzWr6xbyW8sJlKmdMEFwdh59cgCgDlfDnjTVNW1Bbe7tY8C5SB2jXChmR2Kg7ju2lBk8Z3dBXolc42t+F4THMLi3ylw0KmNd2JduSOB1xW5a3dvewefbSCRNxXI7EHBH4EEUAcj458WXvhmbTEs4Y3W4kbzC4z8oxwORzz0GTxwpp8eu61Hb+INQm8m6sLBG8gpCY2kkUEsPvHKjgZ4yd3pXSahd6ba/ZxqEkKGWVY4RJj5nPQD3rOuvEnhu3iuYbi/t9kUptpl64fbuKkf7pyfagDlbr4g6jZatqtj/YtzOLO1VoCttLmeTdtLcKQI8nqM8Amuj8I6/Prtm8s8WwiKGTOxl+/GGIw3PBJ/DFaNxqWj6Vbq1xcQ28SQ+YGY8CMYGc+nI/OoU1jQbS7uIY7iNJMLJNtHABAAJOMdCv4YoA268zbx3rTXXiuGC2tmOkxTS24fIz5bY+bBJ5AzyFz2yOa9MByMisS41nw9ajUpJ7u1jFmFN4xIHlg9N9AFLWfEVxphgaOykuv9Fe4McKlnkYFVCgAHu3JwcAVz+l+Ldf1iz0+7hktIxJZvc3cTWzr5O3cowxYH5mHAI6BjXZR6ho1zqyWQlQ3sSlkUrghSBnB/EZx7VWm1zw3mWzmuoACr7wwwpVc7hnGDgBuPY0Aaum3TXul2t40ZjM0SybD1XIziqfiXVJtE8L6hq1vbm5ltYjIsY43H/DufYU7S9c0nVSY9Nu45ti52rwQM46H3q5fXVrZWE13eypFbRKWkdzgKPegDznT/AIgaheXdhDutcvJHE8bJh7lmlZGMRDEEIFDEgsCPSrmpeMdTs9chUfZo7Jrx7Z0ODNwyqMKXBOSSeAcDHFdHba54auJrSOC4gLyZWDCYwckFQccHg8cGlk1Hw5a6k0cjwJctNtJ2f8tMKOuMA4Kj8qAKWn69qEuqx2t5FF89/PaDysnCpH5isc/TB9yK6usHTtb8OatqIOn3lvc3CbgpTqOMnH1A698e1b1AHGeKPFN9o3iCysLf7OqSrG3lzA77otMsZSPHdQdx69Rx3qh4q8Y6no9/J9lFsltbSqk3mkGRlKbiUUsu45IGBz14NdbqOr6LY6jZ2mo3MEd1O37hZPvZyFyPTkgfU4qvqGoeHbC9LX8kCTnbuZlzjrtyccd+aAObsfHF9fa9d2rafJb28FxbRxrNDIkkqSO8Zb5gB1UMAM/KD+HoNYaavoF9fxxrNFJcxTBVDLgq+GAxkegYA/WtygAooooAKKKKACiiigAooooAKwPEXhay8Tm2i1KWQ2kIc+SjFd7MNoYkc8AsMe9b9FAFawtns9PgtZLhrhokCGVhgvgYyferNFFABRRRQAVhav4ch1a9+1NKqt9kltCkkQkRhIVJLKeo+Xp3ya3aKAOU0XwZDpB0xvtxkawknkVUjCR/vBgqq5OxR2GTVW98Ey3mpXdwupGCK4lYyIIwxkjYozJk/dO5OGGeDjGea7WigDM0HTn0nRILGSTzHQszMOmWYsce2Sa0yAwweRRRQBxd54ChuvsSi+WMW11NdCT7OpmXzJjKVjkzmPk7T1yK0pvDKDS9Ztbe4IfUbk3YLLwj7UAHHUfIPzNdFRQBxEPgeSG7SU6k0kYmVkQxhfJjEvnFcj7xLYGeOO1dsBgAUtFAGbrmkxa5o82myymJZdvzqMkYYH+lctqPw2tLvWr3WLXVrq3vbsDLOTIsbBs7lwVI4+UYPA/Ku7ooA4u78DobLSrGyvXhjsLf7Okjje3BRlc9id0YyO4J6VoeH/DkujX1xcS3n2lpIwhfbt3MXd2bHbl+B2A6mukooAKwNS8PSXmpXmo2t8La5ubRLT5oRIoCuzZIyM53EdR9a36KAOJsfh/BZappF2NTlePTY1Hl7SpmdQyqzENjADEAYyMDmkbwO0mq29813Cv2S5kuI2W3HnENIZNglzlVJYgjByPSu3ooAz9FsG0vRLWwZ/MaJMMwGAT1OPbJrQIBGDRXm3iP4kat4d8V6DoM3hWNzr99NZWUrX5T/VjO9x5Z2g9sEmjyDzNq58FG4hsbVdWeG0tryS9ZUiG9naUygK2flALFTwcj0PNRQeAbPTvD+saVp97cbNRYOPNbd5bADn1OSMnuazoviRqH/CyNJ8DXnhkWt9qGnSagXN5lYgjFSn3OeRwfSqvg/wCKOpeMbEX9j4Xijt11N9OlQ3+6VNjhGlCeXgqCwJ5BxQtf687fmG39eVzU0/wCdO1eS/TUWlE90txIhXGNrM+M5+Y7mxnj5RjGea7uvN/DPxWtNa8VeKfDep6TJpN7oAMvMwkF3CGZfMTgd1xj3rm4/j00nw3n8af8IkyQw62NENs16N+/cF352Yxk9KFr/Xnb8wem/wDXX8j1rWNJj1i2ghkkMZhuIrhWAySUcMB+OK5y48F6lK+pTxeI/Kn1CRDIfsuUMa5AQqHByQcFgRkAcda5xvjholrDq1vqWl3MOsafq0eirZQuJRdXMgygjfjIxySQMY6V09t46hi8fQeCNdsf7O1a7tTeWhjm82G4QHDKGwpDL3BHToaFrt/Wl/yB6f18h+teEH1OaJoLxLdxarBvER/dMjhldAGBH8Q69x6c3PDfhtNADRxzNJEkMVvHvOWKxg/MT6ksf0qDxD440nw7c3lvOktxLYafJqd2sIyYYEzgn3YggDvg+lc5qHxUax8AXvjKLQ4r/T7fTv7SSS1vlkjkXIzGW2/LIN3TGOOtK+l/6/rRjtrb+v61PTKwtV0Ge9uLm8sNSNhdzW32ZZPKDhPm3bsZGT261z1l471m88P/ANtL4Zga2fTBqEflX5bDFVcQvmMbWKuD3FYcXxu02b4MXnxDXQ5xNZSy21xpRlAljljJ3oWx2Ubs46U37t79BLW1up0+n+BVsdbstUa8thJaxbD9msxC8pwR8z7iSvOdpzzzmrUPhNTGkM1y6pDdXNwjJwxE28kZ7EGQ4I9BVW8+IOn6T8Jl+IWs25tbT7Et4bdH3t8wBVAcDJ5FVPG/xITwn4GsvGOn6LLr2m3GyRxbSYkSFl3eYBg7gFySMih6Xv0Ba2t1LmgeBrfw7qUDWd5NJawyTTKkpyQzqq4z6AKfqTXYsAylTyD61zvh/wAV23iaaC40hYbjSbmxjvYbxJslw5I2lNvBG055qt4d+IHh/wATSeJE02ZmPh27e0ux1JKru3KB1B5A91ND03Ba7CQeEbm3uNISPVkew09ebaW23eY+Sd+4MMEZ44OKtz+Gl/sZrGC4O77eL9SwwN3nebtOO3asPw78Rx4n0S31zSdH+2adcwSXEb210sjpswfLkXA2SEdFyRkYyK7DR9X0/XtEs9Z0ucXFleRiWKQd1P8AWnYDnda8Dw6va3UIuoovtN19q3SWyytEfLWPMZJGxgFyG7E9DWzoGktpFlPDJM0rzXEk7MTn7x4H5Y/HNa9FIChqulx6rbRQySGPy54pwwGTlHDY/HGK5zXPAcOs/bymoPayXtyJ2kVPmjXyVhZVIYEZVevP0NdlRQBzt14aiuJmjSQx2z6a2nkHkqP4SPpz+lYl18O421HUb211Bo21CBreQeWAfmRY2JbqQFXKr2Yk5rvaKAGxoI4ljHRRisTUPDVvqCayjztGNVtVtXwo/d4DjcPU/P8ApW7RQBz9toF7D4mbVZtUS4tlh8mG2a3w0PTJD7u+Oflz054rFXwLdzL9lutZDackMsEdv9ny6b937wPu+9hscqehHc13VFAHK6H4XudM159Uu9Q+2TvG6vII/LDs5TJ2gkABY0A69znmtzV9Oj1bRbvTZCoW4jMeXXcBnocZGcHnqKvUUAcVpXga40q5sWTW/tFvBI9xPFPAXM0zkkyBi/B5wM7sY9eaml8KX8upbl1SNLBbtrlrZ7cyebuIPJ3DBBzjqOnGRXX0UAcRofgT+xdVsbr+05LtbONYYtyBCsUcbpEnHUgSuS3c44GK7eiigDmtc8KLrOrQXo1CS2TakdzCIwwnRJBIoBPKncOo6gn2Iran4W1C+1G4e31WO2trmWOWaKS380ShV27D8wwOAf5111FAHIxeFtQW7kkvNUjvPOvIpy4tzG8ccbb1jB3EYBx2HG7ua66iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorO1b+2Psyf2PLaQyBiZHuomkAQA9FVlyc470m7AaNFec+GPHV9L4L03xd4uvdNs9N1CNVUW9vIrRzNJsVfvNuB+g5ro7Pxx4Z1C5gtrTUWklnJWNfIkXc4TzCnK/f2fNt647VWwHR0VxelfEvwzqOi2mpzTzWK3I3LHPBICi+Z5YZjtwoLYGTxnjPFXJviB4Rt9Qexl1YC4S4a0ZRDIQJgu7y8hcbscgdT2zSA6iiuWt/GGh6hqGnzWXiCEWs9rcTmB4GVpBGyqzFmxs2HIKkZ57Ypz+PvCUe4S6t5brPHbmN4ZFffIMoNpXOGAODjB7UAdPRXIW/xD8P3muafptlJNNHe209yLnyXWOIROEdXyvykEnOcYxz1rZ0zxHo2sXT2theeZOkSz+W0bRs0bfddQwG5T/eGRQBrUUUUAMaaJZFiaRFd/uqWwT9BTftNvtkb7RHiM4c7h8p9/SsnUPC+k6l4n0zxFdRyG/wBMDC3ZXwo3DByO/Ws7/hXvhv8As/XrHyZ/J16Y3F4PNOWcsW49OTQB1H2iDci+cmZOUG4fN9PWvLviL4d1jX/iJ4A1vSYYZ7Hw7fyXF87XCIUVkCgAE8muw/4QjQTf6FfeVN52hReTZnzDhVwBz69Kh/4V94b+wa7ZeTP5OuyeZeDzTljnPHpR1T7B0aOU1Xw5rU/7Rmi+M4LWKTSLfR5bIv8AaEDu7NuG1Scke9c78MfAnirwPBdXM/hgNrFzqFyRcC8jMS200quSw3ZLKF6Ade9epf8ACD6B9s0G78qbzdBj8uzPmHCjGPm9aw/GfjHWdA8WWml2U2lw202mXV+XvY3JLQlPkyHGN2/rg4x0NJPlt8/82Nrm/D/JGHN8NL/UviH4e8Zsp06Sya9h1C3DqxvLd5WlhXIOPvEE/jXBP8JvHUnwY1Lwm2jwm/ufFZ1hV+1R7fs5kV+Tn72BjFeqaX8Qbm41LSLzWIl0nTL/AEBdTkt5UJkglaRF256n7+AMZ6V058ZeHP7ON+NQLRB5UKrDIZFMf+sBjC7ht78cU/h17fpL/NC+L5/5f5M4vx98LINb0TQpvClnaaZqOiavFrMUJGxLh1++jkZ5Yfxc8ip5PBmreI/jRo/jzV7YaZZ6FYyQWtsZFklllk+8zbcgKBwOck+ldXceMfD4aG3g1aLz7sBLaTy2aJpGTei7gNu4ryFJBIrn/BfxL0XWPDFlJrGrQRauLEXd0nltGuM4LJkYYAkDCk4JAprR/wBdrfkD1X9d7/mZF5pGs2Hxg8W31vbxTnxBocEWn/aP9S8sJcPExwQMhwcdxn0rjdY+C+p2+leMYvBOknRbTXtJa2fRjeBoJLtnB81MkhFAyO2c9BXvOm6xpetNcLYzebLZyBJo5I2SSFiMjKsARkHI45FaVTbS3r+N/wDMd9b+n4W/yPIfDvh3X/DfgU+G7Twx9n8+wBunkvIyJLoQxxbU+Y8HYWJOPpzWB4h+Euom2+JE2hyxyJ4ntVaz05plVYLl1xM5JOBnaOR6mvYPEnhHQfFkFvBrtrJcR27F4wk8kWCRg/cIzXN/8KZ+Hv8A0Cbj/wAD7j/4unL3rt9RR921uhlJ4U1bWPB3h/wjrEMdpp9npXk3ZLxzLJN5flbMbugUsQfUj0rO+Gnh3xh4c8F6P4R8TafFeW+k30kUNwLmJg9mVcJuGeo3YxzxXTf8KZ+Hv/QJuP8AwPuP/i6P+FM/D3/oE3H/AIH3H/xdNu7b7iSskuxz/h/4faj8PrvxgPCd0LjTNVWNtMsjMo+wOzP5oXcfujcGAz7Vn6b8PfF3hH4uzeIPC6wXmjatpP2W+BZIvLuI1xFJtyd3QA/U9a7D/hTPw9/6BNx/4H3H/wAXXYaLouneH9Ii0rSoWhtIc7UaRpCMnJ5Yk/rS2K/r+vuPJdG+HSeFvHkfjqx01fC1sLGY63aW9z5lteylRtKIOmDk5wOwxya634OaFqXhv4Q6HperRtDeKkkzxP1i8yRnCH3AYCr3hbxpB4m1bXtMns/sr6bMrQ7zkXFsw+ScexZXH/Aaz/8AhYNn/wAJ81n/AGhGNBTR3v2la3dSXEyICrEfOp3HG0HJprou/wDwWL+v0PQKK4bU/GiNq/h7+x72NrC7vbizvfMgYPG0cLuRhsFSCvII5zU0PxB8L2Oi2U2peIo7p5bL7d58VrIolhBAMuwA7VyRn0pAdnRXMx+PPCk1x9nj1TdJ58VuB5MnLy58vB24Ktg4b7px1qOX4ieEIQfM1Uhh552C3lL/ALltsvyhc/KTzx70AdVRXMQ+P/CNwWWDV1lIWJ1CxSEyrJwhT5fnBII+XPSsC++JWmWPiyxkm1SL/hGrrSpbwTLbuzh0mRCTgEgAFs5AxjmjrYD0aio7e4gu7WK6tpVmgmUPHIhyrKRkEH0qSgAormPG/i6LwZ4eOrSWcl7iRd0UfVYgcySfRUyx+gHerPijxRY+F/CF14kuAbiCFFaNIzzMzEBFB9yQM+9AG9RWBDdeJreSzm1KHTzay7muvKLKbMBSepJEgzwThfXFRSeOvCcW/wA7WYomSWOEpIrK26T/AFfBGSGwcHoaAOkornofGvhm4tYrmDUvNjkLgbInLLsfY25duVwxAOQOaVvGvhdLZLmTWIkheOaRXYMBthOJe38J6jrQB0FFczD4+8I3ARotZjZWZVDeW4A3MFUkkcAkgAngnoap6541isPE2gaPp8kNwb7UTY3JKMRHiJ3O1x8u4bRkdeafkB2VFZNl4j0TUb8WNnqCS3DIZUXBHmoDgshIw4B4JXOK1qQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHcLI1tKsW0yFSF3HAzjvRRSeugHnVt4D1qD4TaN4QN1ZNeafdW8zS5fy3WK4EvHGcnGKkuPBPiK58d2uvS6nYyWtpqZvYVeN/MSJrcxGIYO0YJznv36Ciiq63/AK6f5C6W/r+tTn7j4W+LJvDqaD/bemPZxQGKJXik+Vhcear8HkkfKc9O3U1unwNrrao941zYHd4hj1kgFx8iwiMp068ZoopLT+vNP9BvX+vKxnJ8MNXuP9HvdQtI7Z4dWhdoSxcfbJRIpAIx8uMH1q3B4C182mltef2BHe2eoWtzLJY2rQCeOHdjceSWO7p0HbrRRQtLW6W/DUHrfzv+JXh+GGqPNKLzUbVYLpNUt5xFu3CK7lEgKnj5lxjniul8O+FNQsdbs9a1i6t5byy0tdKQ2wIWRAwYuwPQnavHOOeeaKKFp/Xr/mweu/8AX9WR2NFFFABRRRQAUUUUAFclqXhm81D4l6P4kb7I9hY2NxavFJkuzSNG24DGOPL/AFooo63DyM7xd4R8Q6x4hbVNE1G0sSNOFmhk3bs+ekh6DgFVK5ByM5HSsbT/AId+KdF1CLVtL1XSlvI7u7cwSQSGB4LgozKfmzuVkGD379aKKFp/XzB6/wBeVjStPAOp2niy6vHn0e90y7mS8Zrix3XUE4jVD5bZwFO0Ed1yQKyZvhLe6h4d0rS77VIIZtCtWgsJ4FJ3v5iSK8gPb90oKgnqeaKKAO40DQLiw13WNf1CSH7fqwgWSODJjQRKVGCcEk7ienoO1dHRRQAUUUUAFFFFABWbr1vqV5oN3aaTLFDdzJ5aySsVCA8E5AJzjOPeiijcDjLv4dSQeKbDUtBuBa2jabLpV/HNcyyM8LAbPL3ZwUOSOg5NZEPw78aR21qq69pkU9jo/wDZEMqRPmVRLG4ZuflJWPacZxnIooo/r8/82H9fl/kizYfDvX7LULa4+16a0cWr3GplEEi4EsBj2DOc4Jzn/Go4Phvr0Wi2dg15p7Nb+HZ9FLZfBeRlIf7vQbelFFK1/wCvK35Dvrf+t7/mPvfh34guL5L6G90+Oe3g0xYVbeVaS1dmO7gfKwcgY5GKfpfw98Q2GrC+mv8AT7jjUshVdObp1cevClf1oooave/W/wCO4lpb5fgVF+G/iy3fRGstV06L+z9NtdPmU+Zi4ETksMgAgEHtzxjoasaP8N9d0e2sUjv9OmeGwvNNceW6oI55vNDgc5I6beAfWiim9fx/H/hwWn9dj0TQ9Kh0Lw9p2i2zM8NjbpbozdSFUAE/lWhRRTbu7sS00OY1jSdWvdZnmW0068sZLM2ohuZXQgMT5mQEIORtH4VjW/gC7vvg7H4E8Raksk8UQiju4MsU2Puhb5sZK4XPriiikM159J8Sa14YvtE1y6soPtVpJatcWW4ly6Fd2GA29c4yfrXL2/gTxDLpempe2/h+1vbK/s55JbKFk+0pAxOWO3O454XoOeeaKKfW/wDWgdLET/DPWJZ5Zvttra3X9o3N7b31rJIk1uJZhIU4GHUjgo3B4qtL8NfEzxGzW+037NEuqRxOxfe63eSC3GAVJ6DOcUUVNtLD63LviDwD4n1ezs7OK/09beCxtYdj7wEmhlDlhgfMGAAGfu9hzRH8PfEUd1ZWbahYy6Xaa1NqySneJysyyh4yOmQ0pw2egHFFFU9Xf+u5K0Vl/WljU8N+Bb3Srnw2dRvYZ4/DdtNaWkkQIedZNoBkz0IVRwM5PPFd9RRRcYUUUUgCiiigAooooAKKKKAP/9k=" width="547" height="311" alt="" /></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Nota: P = Placebo (Número en riesgo (con brote)); A = Adalimumab (Número en riesgo (con brote)).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Entre los 68 pacientes que recayeron en el grupo de retirada del tratamiento, 65 completaron 12 semanas de tratamiento de rescate con adalimumab, de los cuales 37 (56,9%) volvieron a entrar en remisión (ASDAS &lt; 1,3) después de 12 semanas de volver a empezar con el tratamiento en fase abierta.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Antes de la semana 68, los pacientes que continuaron con el tratamiento con adalimumab mostraron una mejoría mayor estadísticamente significativa de los signos y síntomas de la EspA ax-nr activa comparado con los pacientes asignados a la retirada del tratamiento durante la fase de doble ciego del ensayo (Tabla 14).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 14</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta de eficacia en la fase controlada con placebo del Ensayo EspA ax-nr II</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:100%" ><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">doble ciego</span></strong></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta en la semana 68</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N=153</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N=152</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a,b</span><span style="font-family:Times New Roman; font-size:11pt">20</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">47,1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">70,4%***</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a,b</span><span style="font-family:Times New Roman; font-size:11pt">40</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">45,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">65,8%***</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ASAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Remisión parcial</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">26,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">42,1%**</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ASDAS</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">Inactividad de la enfermedad</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">33,3%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">57,2%***</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:61.34%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">brote parcial</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.56%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">64,1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:20.1%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40,8%***</span></p></td></tr><tr><td colspan="3" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">evaluación de la Sociedad Internacional de Espondiloartritis</span></p><p style="margin:0pt 0pt 0pt 1pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">base definida como punto de partida de la fase abierta cuando los pacientes presentan enfermedad activa.</span></p><p style="margin:0pt 0pt 0pt 1pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">Puntuación de actividad de enfermedad de Espondilitis Anquilosante</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span><span style="font-family:Times New Roman; font-size:11pt">brote parcial definida como ASDAS ≥ 1,3 pero &lt; 2,1 en 2 visitas consecutivas.</span></p><p style="margin:0pt 0pt 0pt 1pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">***, ** estadísticamente significativa p &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001 y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,01, respectivamente, en todas las comparaciones entre adalimumab y placebo.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:277.7pt; border:none">
                                        </td>
                                        <td style="width:84pt; border:none">
                                        </td>
                                        <td style="width:91pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis psoriásica</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab, 40 mg admin</span><span style="font-family:Times New Roman; font-size:11pt">istrado en semanas alternas, se ha estudiado en pacientes con artritis psoriásica activa moderada a grave en dos ensayos controlados con placebo (ensayos de artritis psoriásica I y II). El ensayo de artritis psoriásica I de 24 semanas de duración, incluyó a 313 pacientes adultos con una respuesta inadecuada a la terapia con antiinflamatorios no esteroideos, y de éstos el 50 % estaban tomando metotrexato. El ensayo de artritis psoriásica II, de 12 semanas de duración, incluyó a 100 pacientes con respuesta inadecuada a la terapia con fármacos antirreumáticos modificadores de la enfermedad (DMARD). Una vez finalizados ambos estudios, 383 pacientes se incluyeron en un ensayo de extensión abierto, en el que se administraron 40 mg de adalimumab en semanas alternas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">No existe suficiente evidencia acerca de la eficacia de adalimumab en pacientes con artropatía psoriásica similar a la espondilitis anquilosante, debido al bajo número de pacientes estudiados.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 15</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta ACR en ensayos de artritis psoriásica controlados con placebo</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:126pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Ensayo I de artritis psoriásica</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:126.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Ensayo II de artritis psoriásica</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">respuesta</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">placebo N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">162</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">151</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">placebo N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">49</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">51</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">58</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">39</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">57</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">50</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">39</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">ACR</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">70</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:1pt"><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">14</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:89.7pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%***</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N/A</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:89.7pt; border:none">
                                        </td>
                                        <td style="width:63pt; border:none">
                                        </td>
                                        <td style="width:65.2pt; border:none">
                                        </td>
                                        <td style="width:63pt; border:none">
                                        </td>
                                        <td style="width:65.2pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">*** p &lt; 0,001 en todas las comparaciones entre adalimumab y placebo</span></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">* p &lt; 0,05 en todas las comparaciones entre adalimumab y placebo</span></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">N/A no aplicable</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las respuestas ACR en el ensayo de artritis psoriásica I eran similares con o sin terapia concomitante con metotrexato</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las respuestas ACR se mantuvieron en el ensayo de extensión abierto hasta la semana 136.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los ensayos en artritis psoriásica se evaluaron los cambios radiográficos. Se obtuvieron radiografias de manos, muñecas y pies al inicio del ensayo y en la semana 24 durante el periodo doble ciego, en el que los pacientes estaban en tratamiento con adalimumab o con placebo, y también en la semana 48, durante la fase abierta del ensayo en la que todos los pacientes estaban en tratamiento con adalimumab. Se utilizó un Índice Total de Sharp modificado, que incluía las articulaciones interfalángicas distales (es decir, no es idéntico al Índice Total de Sharp usado para la artritis reumatoide).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El tratamiento con adalimumab redujo la progresión del daño articular periférico en comparación con el tratamiento con placebo. Esta reducción fue medida como el cambio en el Índice Total de Sharp modificado respecto a la situación basal (media ± SD) 0,8 ± 2,5 en el grupo de placebo (en la semana 24) frente a 0,0 ± 1,9, p &lt; 0,001, en el grupo de adalimumab (en la semana 48).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">De los pacientes en tratamiento con adalimumab que en la semana 48 de tratamiento no mostraron progresión radiográfica respecto a la situación basal (n = 102), el 84 % tampoco mostró progresión radiográfica tras 144 semanas de tratamiento. En la semana 24 del ensayo, los pacientes tratados con adalimumab mostraron una mejoría estadísticamente significativa en el rendimiento físico comparados con el grupo placebo. Esta mejoría en el rendimiento físico se evaluó con los cuestionarios HAQ y de salud abreviado SF 36 (Short Form Health Survey). La mejora en el rendimiento físico continuó durante la fase abierta de extensión del ensayo hasta la semana 136.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se valoró la seguridad y eficacia de adalimumab en pacientes adultos con psoriasis en placas (superficie corporal afec</span><span style="font-family:Times New Roman; font-size:11pt">tada (BSA) ≥ 10 % e índice de gravedad y área de psoriasis (PASI – Psoriasis Area and Severity Index) ≥ 12 o ≥ 10) que eran candidatos para tratamiento sistémico o fototerapia en ensayos doble ciego aleatorizados. El 73 %de los pacientes reclutados en los ensayos de psoriasis I y II habían recibido previamente tratamiento sistémico o fototerapia. Se estudió también la seguridad y eficacia de adalimumab en pacientes adultos con psoriasis crónica en placas de moderada a grave con psoriasis de mano y/o pie con</span><span style="font-family:Times New Roman; font-size:11pt">comitante que eran candidatos para tratamiento sistémico en un ensayo aleatorizado doble-ciego (Ensayo de Psoriasis III).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo clínico Psoriasis I (REVEAL) se evaluaron 1.212 pacientes dentro de tres periodos de tratamiento. En el periodo A los pacientes recibieron placebo o una dosis inicial de 80 mg de adalimumab seguido de 40 mg en semanas alternas, comenzando en la semana 1 después de la dosis inicial. Después de 16 semanas de tratamiento, los pacientes que alcanzaron como mínimo una respuesta PASI 75 (mejora de la puntuación PASI de al menos el 75 % respecto al valor inicial), entraron en el periodo abierto B y recibieron 40 mg de adalimumab en semanas alternas. Los pacientes que mantuvieron una respuesta PASI 75 en la semana 33 y que habían sido aleatorizados inicialmente a tratamiento activo en el periodo A, fueron re-aleatorizados en el periodo C para recibir 40 mg de adalimumab en semanas alternas o placebo durante otras 19 semanas. Considerando todos los grupos de tratamiento, la puntuación PASI media inicial fue de 18,9 y la valoración global del médico al inicio (PGA – Physician´s Global Assesment) abarcó desde “moderado” (53 % de los pacientes incluidos) a “grave” (41 %) o “muy grave” (6 %)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El ensayo clínico Psoriasis II (CHAMPION) comparó la eficacia y seguridad de adalimumab frente a metotrexato y placebo en 271 pacientes. Los pacientes recibieron placebo, una dosis inicial de metotrexato de 7,5 mg que se fue incrementando hasta la semana 12, con un máximo de 25 mg, o una dosis inicial de 80 mg de adalimumab seguida de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) durante 16 semanas. No se dispone de datos comparativos de adalimumab y metotrexato pasadas las 16 semanas de tratamiento. A los pacientes en tratamiento con metotrexato que consiguieron una respuesta superior o igual al PASI 50 a la semana 8 y/o 12 no se les realizaron incrementos adicionales de dosis. A lo largo de todos los grupos de tratamiento, la puntuación media PASI inicial era 19,7 y la puntuación PGA inicial comprendía desde “media” (&lt; 1 %) a “moderada” (48 %), a “grave” (46 %) o a “muy grave” (6 %).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que participaron en todos los estudios de psoriasis Fase 2 y Fase 3 fueron candidatos para ser incluidos en un estudio de extensión abierto, en el que recibieron adalimumab durante al menos 108 semanas adicionales.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los ensayos de psoriasis I y II, la variable primaria de eficacia fue la proporción de pacientes que consiguieron respuesta PASI 75 respecto al valor inicial en l</span><span style="font-family:Times New Roman; font-size:11pt">a semana 16 (ver las tablas 16 y 17).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 16</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">ensayo Ps I (REVEAL)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">resultados de eficacia a las 16 semanas</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr style="height:84.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:160.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:96pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">398</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">n (%)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:90.9pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg de</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en semanas</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">alternas</span></strong></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">814</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">n (%)</span></strong></p></td></tr><tr style="height:14pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:160.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">≥</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">PASI</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">75</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(6,5)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:90.9pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">578</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(70,9)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:160.55pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">PASI</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">100</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(0,8)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:90.9pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">163</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(20,0)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td></tr><tr style="height:25.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:160.55pt"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">PGA: aclaramiento total/mínimo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(4,3)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:90.9pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">506</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(62,2)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td></tr><tr style="height:38.45pt"><td colspan="3" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:347.45pt"><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">porcentaje de pacientes que consiguieron respuesta PASI</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">75</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">calculada como ratio ajustado por centro</span></p><p style="margin:0pt; text-indent:-28.35pt; page-break-inside:avoid; page-break-after:avoid; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001,</span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs</span></em><span style="font-family:Times New Roman; font-size:11pt">. placebo</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:160.55pt; border:none">
                                        </td>
                                        <td style="width:96pt; border:none">
                                        </td>
                                        <td style="width:90.9pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 17</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Ensayo Ps II (CHAMPION)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">resultados de eficacia a las 16 semanas</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:50.8pt" ><tr style="height:69.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.95pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:83.4pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N =</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">53</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">n (%)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:76.25pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Metotrexato N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">110</span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">n (%)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:110.7pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg de</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en semanas alternas</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">108</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">n (%)</span></strong></p></td></tr><tr style="height:13.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.95pt"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">≥</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">PASI</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">75</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:83.4pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(18,9)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:76.25pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">39</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(35,5)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.7pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">86</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(79,6)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a, b</span></p></td></tr><tr style="height:13.2pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.95pt"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">PASI</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">100</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:83.4pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(1,9)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:76.25pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(7,3)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.7pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(16,7)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c, d</span></p></td></tr><tr style="height:38.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.95pt"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">PGA:</span></strong></p><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">Aclaramiento total/mínimo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:83.4pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(11,3)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:76.25pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">33</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(30,0)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.7pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">79</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(73,1)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a, b</span></p></td></tr><tr style="height:51.1pt"><td colspan="4" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:352.3pt"><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs.</span></em><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs</span></em><span style="font-family:Times New Roman; font-size:11pt">. metotrexato</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,01</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs</span></em><span style="font-family:Times New Roman; font-size:11pt">. plac</span><span style="font-family:Times New Roman; font-size:11pt">ebo</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,05</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs</span></em><span style="font-family:Times New Roman; font-size:11pt">. metotrexato</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:81.95pt; border:none">
                                        </td>
                                        <td style="width:83.4pt; border:none">
                                        </td>
                                        <td style="width:76.25pt; border:none">
                                        </td>
                                        <td style="width:110.7pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de psoriasis I, el 28 %de pacientes respondedores PASI 75 re-aleatorizados a placebo en la semana 33 experimentaron una “pérdida de respuesta adecuada” (puntuación PASI entre las semanas 33 y 52 resultante en &lt; PASI 50 respecto al valor inicial, con un incremento mínimo de 6 puntos relativa a la semana 33), comparado con el 5 % que continuaron con adalimumab (p &lt; 0,001). De los pacientes que dejaron de responder adecuadamente después de la re-aleatorización a placebo e incluidos en la extensión abierta del ensayo, el 38 % (25/66) y el 55 % (36/66) recuperaron la respuesta PASI 75 después de 12 y 24 semanas de tratamiento, respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Un total de 233 respondedores PASI 75 en las semanas 16 y 33 recibieron tratamiento continuo con adalimumab durante 52 semanas en el Estudio de Psoriasis I, y continuaron con adalimumab en el estudio de extensión abierto. Las tasas de respuesta PASI 75 y PGA “sin lesiones” o “mínimas lesiones” en estos pacientes fue de 74,7 % y 59,0 %, respectivamente, después de 108 semanas adicionales de tratamiento abierto (un total de 160 semanas). En un análisis en el cual todos los pacientes que salieron del estudio por efectos adversos o falta de eficacia, o quienes aumentaron la dosis, fueron considerados no respondedores, los índices de respuesta PASI 75 y PGA “sin lesiones” o “mínimas lesiones” después de 108 semanas adicionales de tratamiento abierto (total de 160 semanas) fue de 69,6 % y 55,7 %, respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Un total de 347 respondedores estables participaron en una evaluación de retirada y re-tratamiento en un estudio de extensión abierto. Durante el periodo de retirada, los síntomas de psoriasis reaparecieron con un tiempo medio de recaída (descenso a PGA “moderado” o peor) de aproximadamente 5 meses. Ninguno de estos pacientes experimentó un rebote durante el periodo de retirada. Un total del 76,5 % (218/285) de los pacientes que entraron en el periodo de retratamiento tuvieron una respuesta PGA de “sin lesiones” o “mínimas lesiones” después de 16 semanas de retratamiento, independientemente de si recayeron o no durante la retirada (69,1 % [123/178] y 88,8 % [95/107] para los pacientes que recayeron y no recayeron durante la retirada respectivamente). El perfil de seguridad observado durante el retratamiento fue similar al de antes de la retirada.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El DLQI (Dermatology Life Quality Index – índice de calidad de vida en dermatología) demostró mejoras significativas en la semana 16 respecto al nivel inicial comparado con placebo (Ensayos I y II) y metotrexato (Ensayo II). En el Ensayo I las mejoras en la puntuación del resumen de los componentes físico y mental del SF-36 también fueron significativas comparadas con placebo.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En una extensión abierta del ensayo, en aquellos pacientes que habían incrementado la dosis de 40 mg en semanas alternas a 40 mg semanales debido a una respuesta PASI inferior al 50 %, 92 de 349 pacientes (26,4 %) y 132 de 349 pacientes (37,8 %) consiguieron respuesta PASI 75 en las semanas 12 y 24, respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El ensayo de psoriasis III (REACH) comparó la eficacia y seguridad de adalimumab versus placebo en 72 pacientes con psoriasis crónica en placas de moderada a grave y psoriasis de mano y/o pie. Los pacientes recibieron una dosis inicial de 80 mg de adalimumab seguida de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) o placebo durante 16 semanas. En la semana 16, una proporción estadísticamente significativa mayor de pacientes que recibieron adalimumab, obtubieron una PGA de “sin lesiones” a “casi sin lesiones” para manos y/o pies comparada con los pacientes que recibieron placebo (30,6% versus 4,3 %, respectivamente [P = 0,014]).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el Ensayo Psoriasis IV se comparó la eficacia y seguridad de adalimumab frente a placebo en 217 pacientes adultos con psoriasis ungueal de moderada a grave. Los pacientes recibieron una dosis inicial de 80 mg de adalimumab seguido de 40 mg en semanas alternas (comenzando una semana después de la dosis inicial) o placebo durante 26 semanas seguido de un periodo de tratamiento abierto de adalimumab durante 26 semanas más. La valoración de la afectación ungueal de la psoriasis incluyó el Índice de Gravedad de la Psoriasis Ungueal modificado (mNAPSI), la Evaluación Global del Médico de la Psoriasis Ungueal (PGA-F) y el Índice de Gravedad de la Psoriasis Ungueal (NAPSI) (ver tabla 18). Adalimumab demostró un beneficio para el paciente en el tratami</span><span style="font-family:Times New Roman; font-size:11pt">ento de la psoriasis ungueal con diferentes grados de afectación cutánea (BSA ≥ 10% (60 % de los pacientes) y BSA &lt; 10 % y ≥ 5 % (40 % de los pacientes)).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 18</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">ensayo Ps IV resultados de eficacia a las semanas 16, 26 y 52</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:490.6pt" ><tr style="height:25.8pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:135.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">variable</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:122.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">placebo</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">control</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">26</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">placebo</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">control</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span><br /><span style="font-family:Times New Roman; font-size:11pt">abierto</span></p></td></tr><tr style="height:72.35pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:54pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">108</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:68.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">109</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">108</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:72.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">109</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:135.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">≥ mNAPSI</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">75</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:54pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:68.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">26,0</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3,4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:72.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">46,6</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">65,0</span></p></td></tr><tr style="height:38.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:135.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">PGA</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">F sin lesiones/mínimas lesiones y</span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">grados de mejoría (%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:54pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">2,9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:68.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">29,7</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">6,9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:72.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">48,9</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">61,3</span></p></td></tr><tr style="height:25.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:135.9pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">cambio porcentual en la puntuación NAPSI (%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:54pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">-7,8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:68.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">-44,2</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:49.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">-11,5</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:72.3pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">-56,2</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:110.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">-72,2</span></p></td></tr><tr style="height:13.2pt"><td colspan="6" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:490.6pt"><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001,</span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">vs.</span></em><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:124.9pt; border:none">
                                        </td>
                                        <td style="width:52.4pt; border:none">
                                        </td>
                                        <td style="width:68.6pt; border:none">
                                        </td>
                                        <td style="width:48.95pt; border:none">
                                        </td>
                                        <td style="width:95.75pt; border:none">
                                        </td>
                                        <td style="width:100pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes tratados con adalimum</span><span style="font-family:Times New Roman; font-size:11pt">ab mostraron mejoría estadísticamente significativa en la semana 26 en comparacion con placebo en el DLQI.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la seguridad y la eficacia de adalimumab en estudios aleatorizados, doble ciego, controlados con placebo y en un estudio de extensión abierto en pacientes adultos con hidradenitis supurativa (HS) de moderada a grave que eran intolerantes, tenían contraindicación o respuesta inadecuada a tratamiento con antibióticos sistémicos durante al menos tres meses. Los pacientes en HS-I y HS-II estaban en un estadío de la enfermedad Hurley II o Hurley III con al menos tres abscesos o nódulos inflamatorios.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio HS-I (PIONEER I) se evaluó a 307 pacientes en dos periodos de tratamiento. En el periodo A, los pacientes recibieron placebo o adalimumab a una dosis inicial de 160 mg, en la semana 0, 80 mg en la semana 2, y 40 mg semanales comenzando en la semana 4 hasta la semana 11. No se permitió el uso concomitante de antibiótico durante el estudio. Después de 12 semanas de tratamiento, los pacientes que habían recibido adalimumab en el periodo A fueron re-aleatorizados en el periodo B a 1 de 3 grupos de tratamiento (adalimumab 40 mg semanal, adalimumab 40 mg en semanas alternas o placebo de la semana 12 a la semana 35). Los pacientes aleatorizados a placebo en el periodo A fueron asignados para recibir adalimumab 40 mg semanal en el periodo B.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio HS-II (PIONEER II) se evaluó a 326 pacientes en dos periodos de tratamiento. En el periodo A, los pacientes recibieron placebo o adalimumab a una dosis inicial de 160 mg, en la semana 0, 80 mg en la semana 2, y 40 mg semanales comenzando en la semana 4 hasta la semana 11. Un 19,3 %de los pacientes tenían tratamiento inicial continuado con antibióticos orales durante el estudio. Después de 12 semanas de tratamiento, los pacientes que habían recibido adalimumab en el periodo A fueron re-aleatorizados en el periodo B a 1 de 3 grupos de tratamiento (adalimumab 40 mg semanal, adalimumab 40 mg en semanas alternas o placebo de la semana 12 a la semana 35). Los pacientes aleatorizados al grupo placebo en el periodo A fueron asignados para recibir placebo en el periodo B.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que participaron en los estudios HS-I y HS-II fueron reclutados en un estudio de extensión abierto en el que se administraba adalimumab 40 mg semanal. La exposición media en toda la población tratada con adalimumab fue de 762 días. Durante los tres estudios los pacientes utilizaron líquido antiséptico tópico a diario.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Respuesta Clínica</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la reducción de las lesiones inflamatorias y la prevención del empeoramiento de abscesos y fistulas drenantes utilizando la Respuesta Clínica de Hidradenitis Supurativa (HiSCR, reducción del recuento total de abscesos y nódulos inlamatorios de al menos un 50 % sin incremento en el recuento de abscesos ni incremento en el recuento de fístulas drenantes con respecto al inicio). La reducción del dolor cutáneo asociado a la HS se evaluó utilizando una Escala de Evaluación Numérica en los pacientes que entraron al estudio con una puntuación basal al inicio de 3 o más en una escala de 11 puntos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Una proporción significativamente mayor de pacientes tratados con adalimumab versus placebo alcanzó el HiSCR en la semana 12. Una proporción significativamente mayor de pacientes en el Estudio HS-II experimentó una disminución clínicamente relevante en el dolor cutáneo asociado a HS (ver tabla 19), en la semana 12. El riesgo de brote de la enfermedad se redujo significativamente en los pacientes tratados con adalimumab durante las 12 semanas iniciales de tratamiento.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 19</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">resultados de eficacia a la semana 12, estudios HS-I y II</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:1pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.4%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">estudio HS I</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">estudio HS II</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.88%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.54%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanal</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.4%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">respuesta clínica de la hidradenitis supurativa (HiSCR)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">154</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(26,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.88%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">153</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">64</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(41,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) *</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">163</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(27,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.54%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">163</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">96</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(58,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) ***</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:16.4%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% reducción en el dolor cutáneo</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:18.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">109</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">27</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(24,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.88%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">122</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">34</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(27,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.84%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">111</span><span style="font-family:Times New Roman; font-size:11pt"> </span><br /><span style="font-family:Times New Roman; font-size:11pt">23</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(20,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:22.54%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">105</span></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(45,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%) ***</span></p></td></tr><tr style="height:1pt"><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:11pt">*</span><span style="font-family:Times New Roman; font-size:11pt">             </span><em><span style="font-family:Times New Roman; font-size:11pt;">p</span></em><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,05,</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:11pt">***</span><span style="font-family:Times New Roman; font-size:11pt">             </span><em><span style="font-family:Times New Roman; font-size:11pt;">p</span></em><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001,</span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">versus</span></em><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">de todos los pacientes aleatorizados.</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">de todos los pacientes con una evaluación inicial de dolor cutáneo asociado a HS</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3, según una Escala de Evaluación Numérica de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">–</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sin dolor cutáneo,</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">tanto dolor cutáneo como puedas imaginar.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:74.2pt; border:none">
                                        </td>
                                        <td style="width:83.05pt; border:none">
                                        </td>
                                        <td style="width:103.6pt; border:none">
                                        </td>
                                        <td style="width:89.8pt; border:none">
                                        </td>
                                        <td style="width:102.05pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">El tratamiento con adalimumab 40 mg semanal redujo significativamente el riesgo de</span><span style="font-family:Times New Roman; font-size:11pt">empeoramiento de abscesos y fistulas drenantes. En las 12 primeras semanas de tratamiento en los Estudios HS-I y HS-II, de manera aproximada, dos veces la proporción de pacientes en el grupo de placebo comparado con aquellos en el grupo de adalimumab experimentaron un empeoramiento de abscesos (23,0 % vs. 11,4 %, respectivamente) y fístulas drenantes (30,0% vs. 13,9 %, respectivamente).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 12 se demostraron mejorías superiores desde el inicio comparado con placebo en la calidad de vida relacionada con la salud especifica para piel, medida por el Índice de Calidad de Vida en Dermatología (DLQI, Estudios HS-I y HS-II); la satisfacción global del paciente con el tratamiento farmacológico medida por el Cuestionario de Satisfacción con el Tratamiento - medicación (TSQM, Estudios HS-I y HS-II), y la salud física medida por la puntuación del componentefísico del SF-36 (Estudio HS-I).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En la semana 12, en los pacientes con al menos una respuesta parcial a adalimumab 40 mg semanal, la tasa HiSCR en la semana 36 fue superior entre aquellos pacientes que continuaron en tratamiento semanal con adalimumab que en aquellos pacientes en los que se redujo la frecuencia de la dosis a semanas alternas o en los que se retiró el tratamiento (ver tabla 20).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 20</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">proporción de pacientesa que alcanzaron respuesta HiSCRb en las semanas 24 y 36</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">después de la reasignación de tratamiento desde adalimumab semanal en la semana 12</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr style="height:75.25pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">(retirada de tratamiento)</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">73</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanas alternas N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">70</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.75pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanales</span></strong></p><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">70</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.8pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(32,9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(51,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.75pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(57,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.8pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">36</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">22</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(30,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:99pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">28</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(40,0</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.75pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">39</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(55,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%)</span></p></td></tr><tr style="height:1pt"><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:362.6pt"><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">pacientes con al menos una respuesta parcial a</span><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanal después de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento.</span></p><p style="margin:0pt; text-indent:-28.35pt; widows:0; orphans:0; padding-left:28.35pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b.</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">pacientes que cumplieron el criterio especificado en protocolo para pérdida de respuesta o no mejoría y que requirieron abandonar los estudios y ser contabilizados como no</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">respondedores.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:71.8pt; border:none">
                                        </td>
                                        <td style="width:99pt; border:none">
                                        </td>
                                        <td style="width:101.3pt; border:none">
                                        </td>
                                        <td style="width:101.3pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En aquellos pacientes que tuvieron al menos una respuesta parcial en la semana 12, y que recibieron tratamiento semanal continuo con adalimumab, el índice HiSCR en la semana 48 fue del 68,3 % y del 65,1 % en la semana 96. No se identificaron nuevos hallazgos de seguridad durante el tratamiento a largo plazo con adalimumab 40 mg semanal durante 96 semanas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En aquellos pacientes en los que el tratamiento con adalimumab fue retirado en la semana 12 en los Estudios HS-I y HS-II, el índice HiSCR alcanzó niveles similares a los observados antes de la retirada 12 semanas después de la reintroducció</span><span style="font-family:Times New Roman; font-size:11pt">n de adalimumab 40 mg semanal (56,0 %).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se valoró la seguridad y la eficacia de adalimumab en más de 1.500 pacientes con enfermedad de Crohn moderada a grave (Índice de Actividad de la Enfermedad de Crohn (CDAI) ≥ 220 y ≤ 450) en ensayos aleatorizados doble-ciego controlados con placebo. Se permitieron tratamientos con dosis estables de aminosalicilatos, corticoesteroides y/o agentes inmunomoduladores, y el 80 % de los pacientes continuaron recibiendo como mínimo uno de estos medicamen</span><span style="font-family:Times New Roman; font-size:11pt">tos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la inducción de la remisión clínica (definida como CDAI &lt; 150) en dos ensayos, ensayo de enfermedad de Crohn I (CLASSIC I) y ensayo de enfermedad de Crohn II (GAIN). En el ensayo de enfermedad de Crohn I, 299 pacientes que no habían recibido tratamiento previo con antagonistas del TNF, fueron aleatorizados a uno de los siguientes 4 grupos de tratamiento: placebo en las semanas 0 y 2, 160 mg de adalimumab en la semana 0 y 80 mg en la semana 2, 80 mg en la semana 0 y 40 mg en la semana 2, o bien 40 mg en la semana 0 y 20 mg en la semana 2. En el ensayo de enfermedad de Crohn II, 325 pacientes que habían dejado de responder o eran intolerantes a infliximab fueron aleatorizados para recibir 160 mg de adalimumab en la semana 0 y 80 mg en la semana 2 o bien placebo en las Semanas 0 y 2. Los pacientes no-respondedores primarios fueron excluidos de los ensayos y, por tanto, no fueron evaluados.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de enfermedad de Crohn III (CHARM) se evaluó el mantenimiento de la remisión clínica. En el en</span><span style="font-family:Times New Roman; font-size:11pt">sayo de enfermedad de Crohn III, 854 pacientes recibieron en el periodo abierto 80 mg en la semana 0 y 40 mg en la semana 2. En la semana 4 los pacientes fueron aleatorizados a 40 mg en semanas alternas, 40 mg semanales o placebo, con una duración total del ensayo de 56 semanas. Los pacientes que respondieron clínicamente (disminución en CDAI ≥ 70) en la semana 4 fueron estratificados y analizados por separado de aquellos que no habían respondido en la semana 4. La reducción de la dosis de corticoesteroides</span><span style="font-family:Times New Roman; font-size:11pt">se permitió después de la semana 8.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las tasas de inducción de la remisión y respuesta de los ensayos de enfermedad de Crohn I y II se presentan en la tabla 21.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 21</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">inducción de remisión clínica y la respuesta</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:100%" ><tr style="height:58.3pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.06%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">ensayo de enfermedad de Crohn I: pacientes sin tratamiento previo con infliximab</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">ensayo de enfermedad de Crohn II: pacientes con tratamiento previo con infliximab.</span></strong></p></td></tr><tr style="height:66.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.06%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">74</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">80/40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">75</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.26%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab 160/80</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">76</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">166</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">160/80</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">159</span></strong></p></td></tr><tr style="height:12.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.06%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.5%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.76%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.26%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.34%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:12.55pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.06%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.26%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:25.95pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.06%"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">respuesta clínica (CR</span><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:12.5%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.76%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">37</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:15.26%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">49</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%**</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:14.34%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:19.08%"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">38</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%**</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:103.75pt; border:none">
                                        </td>
                                        <td style="width:55.95pt; border:none">
                                        </td>
                                        <td style="width:72.85pt; border:none">
                                        </td>
                                        <td style="width:70.1pt; border:none">
                                        </td>
                                        <td style="width:64.25pt; border:none">
                                        </td>
                                        <td style="width:85.8pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Todos los p-valores se refieren a la comparación del par de valores proporcionales para adalimumab</span><em><span style="font-family:Times New Roman; font-size:11pt;">versus</span></em><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">*</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p &lt; 0,001</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">**</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p &lt; 0,01</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron incidencias similares de remisión para los regímenes de inducción 160/80 mg y 80/40 mg en la semana 8, siendo los efectos adversos más frecuentes en el grupo 160/80 mg.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el ensayo de enfermedad de Crohn III, en la semana 4, el 58 % (499/854) de los pacientes presentaban respuesta clínica, y fueron evaluados en el análisis primario. En aquellos pacientes que presentaban respuesta clínica en la semana 4, el 48 % habían recibido previamente tratamiento con otro anti-TNF. Las tasas de mantenimiento de la remisión y la respuesta se presentan en la tabla 22. Los resultados de remisión clínica permanecieron relativamente constantes, independientemente de si había un tratamiento previo con antagonistas del TNF o no.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las hospitalizaciones y cirugías relacionadas con la enfermedad se redujeron de forma estadísticamente significativa con adalimumab comparado con placebo en la semana 56.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 22</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">mantenimiento de la remisión clínica y la respuesta</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt" ><thead><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en semanas alternas</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">semanales</span></strong></p></td></tr></thead><tbody><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">26</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">170</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">172</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">157</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">47</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">respuesta clínica (CR-100)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">27</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt 0pt 0pt 16.8pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">pacientes con remisión libre de esteroides durante &gt;=90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">días</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (2/66)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (11/58)**</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (11/74)**</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">56</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">170</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">172</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">157</span></strong></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">41</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">respuesta clínica (CR-100)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">41</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">48</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:187.45pt"><p style="margin:0pt 0pt 0pt 16.8pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">pacientes con remisión libre de esteroides</span><span style="font-family:Times New Roman; font-size:11pt">durante</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">días</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:87.55pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (3/66)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:96.4pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">29</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (17/58)*</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.95pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">% (15/74)**</span></p></td></tr></tbody></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">*</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p &lt; 0,001 comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">**</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p &lt; 0,02 comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">de aquellos que recibían corticoesteroides al inicio del ensayo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Entre los pacientes que no respondieron en la semana 4, el 43 % de los pacientes en tratamiento de mantenimiento con adalimumab respondió hasta la Semana 12, comparado con el 30% de los pacientes con placebo. Estos resultados sugieren que algunos pacientes que no habían respondido en la Semana 4 se benefician del tratamiento continuado de mantenimiento hasta la Semana 12. El tratamiento continuado pasada la Semana 12 no dio lugar a una tasa de respuesta significativamente superior (ver sección 4.2).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se realizó un seguimiento durante 3 años en tratamiento abierto con adalimumab en 117/276 pacientes del ensayo I de enfermedad de Crohn y 272/777 pacientes de los ensayos II u III de enfermedad de Crohn. De estos, 88 y 189 pacientes respectivamente continuaron en remisión clínica. Se mantuvo la respuesta clínica (CR-100) en 102 y 233 pacientes respectivamente.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Calidad de vida</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En los ensayos de enfermedad de Crohn I y II, se consiguió una mejora estadísticamente significativa de la puntuación total en el Cuestionario de la Enfermedad Inflamatoria Intestinal (IBDQ) específico de la patología, realizado en la semana 4 en pacientes aleatorizados al tratamiento con adalimumab 80/40 mg y 160/80 mg comparado con placebo. Estos resultados se pudieron reproducir en las semanas 26 y 56 en los grupos de tratamiento con adalimumab comparado con placebo durante el ensayo de enfermedad de Crohn III.</span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:60pt" ><tr style="height:13.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.65pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr></table><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La seguridad y eficacia de múltiples dosis de adalimumab se evaluó en pacientes adultos con colitis ulcerosa activa de moderada a grave (puntuación Mayo 6 a 12 con subpuntuación endoscópica de 2 a 3) en ensayos aleatorizados controlados con placebo y doble ciego.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio UC-I, se aleatorizó a 390 pacientes sin tratamiento previo con el antagonista de TNF que recibieron bien placebo en las semanas 0 y 2; bien 160 mg de adalimumab en la semana 0 seguidos de 80 mg en la semana 2; o bien 80 mg de adalimumab en la semana 0 seguidos de 40 mg en la semana 2. Después de la semana 2, los pacientes en ambos grupos de adal</span><span style="font-family:Times New Roman; font-size:11pt">imumab recibieron 40 mg cada dos semanas. Se evaluó la remisión clínica (definida como puntuación Mayo ≤ 2 con ninguna subpuntuación &gt; 1) en la semana 8.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio UC-II, se administró a 248 pacientes 160 mg de adalimumab en la semana 0, 80 mg en la s</span><span style="font-family:Times New Roman; font-size:11pt">emana 2 y después 40 mg cada dos semanas; y se administró placebo a 246. Se evaluaron los resultados clínicos de la inducción de la remisión en la semana 8 y el mantenimiento de la remisión en la semana 52.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes inducidos con 160/80 mg de adalimumab alcanzaron remisión clínica en la semana 8 en mayores porcentajes de forma estadísticamente significativa frente a placebo en el estudio UC-I (18% vs. 9 % respectivametne, p = 0,031) y en el estudio UC-II (17 % vs. 9 % respectivametne, p = 0,019). En el estudio UC-II, entre aquellos tratados con adalimumab que estaban en remisión en la semana 8, 21/41 (51 %) estaban en remisión en la semana 52.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los resultados del estudio poblacional UC-II se muestran en la tabla 23.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 23</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta, remisión y curación de la mucosa en el ensayo UC-II</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">(porcentaje de pacientes)</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt" ><tr style="height:25.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">placebo</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">semanas alternas</span></strong></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 0.4pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">246</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">248</span></strong></p></td></tr><tr style="height:13.15pt"><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">respuesta clínica</span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:13.15pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">remisión clínica</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">9</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:13.15pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">curación de la mucosa</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:25.8pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">remisión libre de estero</span><span style="font-family:Times New Roman; font-size:11pt">ides ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">días</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">140)</span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">13</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">(N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">150)</span></strong></p></td></tr><tr style="height:13.2pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">semanas</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">y</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:13.15pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">respuesta mantenida</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%**</span></p></td></tr><tr style="height:13.15pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">remisión mantenida</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr><tr style="height:13.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:247.1pt"><p style="margin:0pt 0pt 0pt 5.9pt; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">curación mantenida de la mucosa</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:81.1pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">11</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:125.8pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">%*</span></p></td></tr></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La remisión clínica es una puntuación Mayo ≤ 2 con ninguna subpuntuación &gt; 1;</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La respuesta clínica se reduce en una puntuación Mayo respecto al inicio ≥ 3 puntos y ≥ 30 %, más una reducción de la subpuntación del sangrado rectal [RBS] ≥ 1 o una RBS absoluta de 0 o 1.</span></p><p style="margin:0pt; text-indent:-28.35pt; text-align:justify; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt">*   p &lt; 0,05 se refiere a la comparación del par de valores proporcionale</span><span style="font-family:Times New Roman; font-size:11pt">s para adalimumabversus placebo</span></p><p style="margin:0pt; text-indent:-28.35pt; text-align:justify; padding-left:28.35pt" ><span style="font-family:Times New Roman; font-size:11pt">**      p &lt; 0,001 se refiere a la comparación del par de valores proporcionales para adalimumab versus placebo</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a             </span><span style="font-family:Times New Roman; font-size:11pt">en aquellos que recibían corticoesteroides en estado basal.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">De aquellos pacientes que respondieron en la semana 8, el 47 % estaban en respuesta, el 29 % estaban en remisión, el 41 % presentaban curación d</span><span style="font-family:Times New Roman; font-size:11pt">e la mucosa y el 20 % estuvieron en remisión libre de esteroides por ≥ 90 días en la semana 52.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Aproximadamente en el 40 % de los pacientes del estudio UC-II habían fracasado tratamientos previos anti-TNF con infliximab. La eficacia de adalimumab se reduj</span><span style="font-family:Times New Roman; font-size:11pt">o en estos pacientes en comparación con los pacientes naïve (sin tratamiento previo) para anti-TNF. Entre los pacientes en los que habían fracasado tratamientos previos anti-TNF en la semana 52 estaban en remisión un 3 % con placebo y un 10 % con adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes de los estudios UCI y UC-II tenían la opción de formar parte en una extensión del estudio abierto a largo plazo (UC-III). Después de 3 años de tratamiento con adalimumab, el 75% (301/402) continuaban estando en remisión clínica por puntuación Mayo parcial.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tasas de hospitalización</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Durante las 52 semanas de los estudios UC-I y UC-II, se observaron tasas menores de hospitalizaciones por cualquier causa y de hospitalizaciones relacionadas con la UC en pacientes del grupo de tratamiento con adalimumab comparado con los pacientes del grupo placebo. El número de hospitalizaciones por cualquier causa en el grupo de tratamiento con adalimumab fue de 0,18 por paciente-año versus 0,26 por paciente-año en el grupo placebo y las cifras correspondientes para las hospitalizaciones relacionadas con la UC fue de 0,12 por paciente año versus 0,22 por paciente-año.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Calidad de vida</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio UC-II, el tratamiento con adalimumab consiguió una mejoría en la puntuación del</span><em><span style="font-family:Times New Roman; font-size:11pt;">Cuestionario de la Enfermedad Inflamatoria Intestinal</span></em><span style="font-family:Times New Roman; font-size:11pt">(IBDQ).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;">Uveítis</span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la seguridad y la eficacia de adalimumab en pacientes adultos con uveítis no infecciosa intermedia y posterior, y panuveítis, excluyendo pacientes con uveítis anterior aislada, en dos estudios aleatorizados, doble ciego, controlados con placebo (UV I y II). Los pacientes recibieron placebo o adalimumab a una dosis inicial de 80 mg seguido de 40 mg en semanas alternas comenzando una semana después de la dosis inicial. Se permitieron dosis estables concomitantes con un inmunosupresor no biológico.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio UV I se evaluaron 217 pacientes con uveítis activa a pesar del tratamiento con corticoesteroides (prednisona oral a una dosis de entre 10 y 60 mg/día). Al comienzo del estudio todos los pacientes recibieron una dosis estandarizada de 60 mg/día de prednisona durante 2 semanas seguido de una pauta de reducción obligatoria, con una discontinuación completa de corticoesteroides en la semana 15.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el estudio UV II se evaluaron 226 pacientes con uveítis inactiva que requerían tratamiento crónico basal con corticoesteroides (de 10 a 35 mg/día de prednisona oral) para controlar su enfermedad. Posteriormente, los pacientes se sometieron a una pauta de reducción obligatoria con una discontinuación completa de corticoesteroides en la semana 19.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La variable primaria de eficacia en ambos estudios fue “tiempo hasta fallo a tratamiento”. Se definió el fallo a tratamiento mediante un resultado multi-componente basado en lesiones vasculares inflamatorias coriorretinianas y/o retinianas, grado de celularidad en la cámara anterior (CA), grado de turbidez vítrea (VH por sus siglas en inglés) y mejor agudeza visual corregida (BCVA por sus siglas en inglés).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que completaron los estudios UV I y UV II fueron elegibles para inscribirse en un estudio de extensión no controlado a largo plazo con una duración planificada originalmente de 78 semanas. Se permitió a los pacientes continuar con la medicación del estudio después de la Semana 78 hasta que tuvieran acceso a adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Respuesta clínica</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los resultados de ambos estudios demostraron una reducción estadísticamente significativa del riesgo de fallo a tratamiento en pacientes tratados con adalimumab versus aquellos pacientes que recibieron placebo (ver tabla 24). Ambos estudios demostraron un efecto temprano y sostenido de adalimumab en la tasa de fallo a tratamiento versus placebo (ver Figura 2).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 24</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;">tiempo hasta fallo a tratamiento en los estudios UV I y UV II</span></strong></p><p style="margin:0pt; text-align:center" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt" ><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:98.9pt"><h2 style="margin:10pt 0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">análisis</span></strong></h2><h2 style="margin:10pt 0pt 10pt 27.5pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tratamiento</span></strong></h2></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44pt"><p style="margin:0pt 0pt 0pt 2.75pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:55pt"><p style="margin:0pt 0pt 0pt 14pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">fallo</span></strong></p><p style="margin:0pt 0pt 0pt 14pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">N (%)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:103.2pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">tiempo medio</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">hasta fallo</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">(meses)</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:39.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">HR</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:5pt">a</span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.9pt"><p style="margin:0pt 0pt 0pt 8pt; text-align:center; widows:0; orphans:0"><strong><span style="font-family:Times New Roman; font-size:11pt;">CI</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">95</span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span><strong><span style="font-family:Times New Roman; font-size:11pt;">% para HR</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:5pt">a</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.7pt"><p style="margin:0pt; text-indent:-10.9pt; text-align:center; widows:0; orphans:0; padding-left:10.9pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">valor</span></strong><strong><em><span style="font-family:Times New Roman; font-size:11pt;">p</span></em></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></strong></p></td></tr><tr style="height:1pt"><td colspan="8" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:464.5pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tiempo hasta fallo a tratamiento hasta o después de la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">6</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en el estudio UV I</span></strong></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">análisis primario (ITT)</span></p></td></tr><tr style="height:1pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:98.9pt"><p style="margin:0pt 0pt 0pt 28.35pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">107</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:55pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">84</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(78,5)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:103.2pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">3,0</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:39.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td><td colspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:98.9pt"><p style="margin:0pt 0pt 0pt 28.35pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">110</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:55pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(54,5)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:103.2pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">5,6</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:39.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,50</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">–</span><span style="font-family:Times New Roman; font-size:11pt">0,70</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,001</span></p></td></tr><tr style="height:1pt"><td colspan="8" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:464.5pt"><h2 style="margin:10pt 0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">tiempo hasta fallo a tratamiento hasta o después de la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">2</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en el estudio UV II</span></strong></h2><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">análisis primario (ITT)</span></p></td></tr><tr style="height:1pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:98.9pt"><p style="margin:0pt 0pt 0pt 28.35pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">placebo</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">111</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:55pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">61</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(55,0)</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:103.2pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">8,3</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:39.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td><td colspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">‑</span><span style="font-family:Times New Roman; font-size:11pt">‑</span></p></td></tr><tr style="height:1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:98.9pt"><p style="margin:0pt 0pt 0pt 28.35pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">adalimumab</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:44pt"><p style="margin:0pt; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">115</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:55pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">45</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(39,1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:103.2pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">NE</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:39.8pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,57</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:71.5pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,39</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">–</span><span style="font-family:Times New Roman; font-size:11pt">0,84</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.1pt"><p style="margin:0pt; text-align:center; widows:0; orphans:0"><span style="font-family:Times New Roman; font-size:11pt">0,004</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:98.4pt; border:none">
                                        </td>
                                        <td style="width:42.25pt; border:none">
                                        </td>
                                        <td style="width:54.6pt; border:none">
                                        </td>
                                        <td style="width:97.2pt; border:none">
                                        </td>
                                        <td style="width:38.85pt; border:none">
                                        </td>
                                        <td style="width:70.1pt; border:none">
                                        </td>
                                        <td style="width:0.4pt; border:none">
                                        </td>
                                        <td style="width:50.9pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Nota: El fallo a tratamiento hasta o después de la semana 6 (estudio UV I), o hasta o después de la semana 2 (estudio UV II), se contabilizó como evento. Las retiradas por razones diferentes al fallo a tratamiento fueron monitorizadas hasta el momento de la retirada.</span></p><ol style="margin:0pt; padding-left:0pt" ><li style="margin:0pt 0pt 0pt 9.88pt; text-indent:0pt; text-align:justify; padding-left:18.47pt; font-family:Times New Roman; font-size:7.33pt; vertical-align:super"><span style="font-family:Times New Roman; font-size:11pt">HR de adalimumab vs placebo de regresión proporcional de riesgos con el tratamiento como factor.</span></li><li style="margin:0pt 0pt 0pt 10.5pt; text-indent:0pt; text-align:justify; padding-left:17.85pt; font-family:Times New Roman; font-size:7.33pt; vertical-align:super"><span style="font-family:Times New Roman; font-size:11pt">Valor p bilateral del test Log Rank.</span></li><li style="margin:0pt 0pt 0pt 9.88pt; text-indent:0pt; text-align:justify; padding-left:18.47pt; font-family:Times New Roman; font-size:7.33pt; vertical-align:super"><span style="font-family:Times New Roman; font-size:11pt">NE = no estimable. Menos de la mitad de que un sujeto en riesgo tuviera un evento.</span></li></ol><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Figura 2. curvas de Kaplan-Meier que resume el tiempo hasta fallo a tratamiento en o después de la semana 6 (estudio UV I) o de la semana 2 (estudio UV II)</span></strong></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><img src="data:image/jpg;base64,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" width="567" height="252" alt="" /></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><img src="data:image/jpg;base64,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" width="568" height="244" alt="" /></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Nota: P# = Placebo (Número de Eventos/Número en Riesgo); A# = Adalimumab (Número de Eventos/Número en Riesgo).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En el Estudio UV I se observaron diferencias estadísticamente significativas para cada componente del fallo a tratamiento en favor de adalimumab versus placebo. En el Estudio UV II, sólo se observaron diferencias estadísticamente significativas para la agudeza visual, pero los otros componentes fueron numéricamente favorables a adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">De los 424 sujetos incluidos en la extensión no controlada a largo plazo de los estudios UV I y UV II, 60 de los sujetos se consideraron no elegibles (p. ej., por desviaciones o por complicaciones secundarias a retinopatía diabética, d</span><span style="font-family:Times New Roman; font-size:11pt">ebido a una cirugía de cataratas o a una vitrectomía) y fueron excluidos del análisis primario de eficacia. De los 3641 pacientes restantes, 269 pacientes evaluables (74%) alcanzaron las 78 semanas de tratamiento abierto con adalimumab. Basándose en el enfoque de los datos observados, 216 (80,3 %) presentaron inactividad (sin lesiones inflamatorias activas, grado de celularidad en la CA ≤ 0,5+, grado VH ≤ 0,5+) con una dosis concomitante de esteroides ≤ 7,5 mg al día, y 178 (66,2 %) presentaron inactividad</span><span style="font-family:Times New Roman; font-size:11pt">sin esteroides. La BCVA se mejoró o se mantuvo (&lt; 5 letras de deteriodo) en el 88,6 % de los ojos en la semana 78. Los datos más allá de la Semana 78 fueron generalmente consistentes con estos resultados, pero la cantidad de sujetos reclutados disminuyó después de este tiempo. Generalmente entre los pacientes que interrumpieron el estudio, el 18 % fue debido a acontecimientos adversos, y el 8 % fue debido a una respuesta insuficiente al tratamiento de adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Calidad de Vida</span></span></em></p><p style="margin:0pt; text-align:justify" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se midieron los resultados notificados por los pacientes respecto a la funcionalidad relacionada con la visión usando el cuestionario NEI VFQ-25. Adalimumab fue numéricamente favorable para la mayoría de las sub-puntuaciones con diferencias medias estadísticamente significativas para visión general, dolor ocular, visión cercana, salud mental, y puntuación total en el estudio UV I, y para visión general y salud mental en el estudio UV II. En los efectos relacionados con la visión, no hubo resultados numéricamente favorables a adalimumab para visión de color en el estudio UV I y para visión de color, visión periférica y visión cercana en el estudio UV II.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Inmunogenicidad</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Durante el tratamiento con adalimumab se pueden producir anticuerpos anti-adalimumab.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La formación de anticuerpos anti-adalimumab se asocia con un incremento en el aclaramiento y una reducción de la eficacia de adalimumab. No existe una correlación aparente entre la presencia de anticuerpos anti-adalimumab y la incidencia de los efectos adversos.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Población pediátrica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0" ><em><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil (AIJ)</span></em></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil poliarticular (AIJp)</span></span></em></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se han evaluado la seguridad y la eficacia de adalimumab en dos ensayos (pJIA</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">I y II) en niños con artritis idiopática juvenil poliarticular activa o de curso poliarticular, que tenían una variedad de tipos de AIJ (más frecuentemente factor reumatoide negativo o poliartritis positiva y oligoartritis extendida).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">pJIA I</span></p><p style="margin:0pt 0pt 6pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 2.65pt 0pt 0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se ha evaluado la seguridad y eficacia de adalimumab en un estudio multicéntrico, aleatorizado, doble ciego, de grupo paralelo en 171</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">niños (de 4 a 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años) con AIJ poliarticular. En la fase inicial abierta los pacientes fueron estratificados en dos grupos, tratados con metotrexato (MTX) o no tratados con metotrexato (no-MTX). Los pacientes del estrato no-MTX fueron tanto pacientes naïve como pacientes a los que se les había retirado el MTX al menos dos semanas antes de la administración del fármaco. Los pacientes permanecieron en dosis estables de AINEs o prednisona (</span><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg /kg/día o 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/día máximo). En la fase inicial abierta todos los pacientes recibieron 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">hasta un máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de adalimumab en semanas alternas durante 16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. La distribución de pacientes por edad y dosis mínima, media y máxima recibida durante la fase inicial abierta se presenta en la Tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">25.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 2.65pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 25</span></strong></p><p style="margin:0pt 2.65pt 6pt 5.5pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">distribución de pacientes por edad y dosis de adalimumab recibida en la fase inicial abierta</span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0.1pt" ><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Grupo de edad</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Número inicial de pacientes n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Dosis mínima, media y máxima</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">4 a 7 años</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">31 (18,1)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">10, 20 y 25 mg</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">8 a 12 años</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">71 (41,5)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">20, 25 y 40 mg</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">13 a 17 años</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">69 (40,4)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">25, 40 y 40 mg</span></p></td></tr></table><p style="margin:0pt 2.65pt 0pt 0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 2.65pt 0pt 0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que demostraron respuesta ACR pediátrico-30 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">16 fueron candidatos para ser aleatorizados en una fase doble ciego, y recibir durante 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas adicionales o hasta el exacerbación de la enfermedad adalimumab 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">hasta un máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, o placebo en semanas alternas. Los criterios de exacerbación de la enfermedad se definieron como un empeoramiento</span><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30% desde el nivel basal en</span><span style="font-family:Symbol; font-size:11pt">?</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3 de 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">criterios ACR-pediátri</span><span style="font-family:Times New Roman; font-size:11pt">cos básicos, ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 articulaciones activas y mejora &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30% en no más de 1 de los 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">criterios. Después de 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas de tratamiento o en la exacerbación de la enfermedad, los pacientes fueron candidatos para ser reclutados en la fase de extensión abierta.</span></p><p style="margin:0pt 2.55pt 0pt 5.4pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">26</span></strong></p><p style="margin:0pt 2.55pt 6pt 5.5pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">respuesta ACR-pediátrico 30 en el ensayo de AIJ</span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0.1pt" ><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Estrato</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MTX</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No MTX</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Fase</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Inicial abierta tras 16 semanas</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 14.15pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Respuesta ACR-pediátrico 30 (n/N)</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:176pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">94,1% (80/85)</span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:161.95pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">74,4% (64/86)</span></p></td></tr><tr><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:458.85pt"><p style="margin:0pt 2.55pt 0pt 0pt; text-align:center; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Resultados de eficacia</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">32 semanas doble ciego</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab/ MTX</span></p><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(N = 38)</span></p><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Placebo/MTX</span></p><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(N = 37)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:82.5pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab</span></p><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(N = 30)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:79.45pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Placebo</span></p><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">(N = 28)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 14.15pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Exacerbación de la enfermedad después de 32 semanas</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">(n/N)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">36,8% (14/38)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">64,9% (24/37)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:82.5pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">43,3% (13/30)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:79.45pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">71,4% (20/28)</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.9pt"><p style="margin:0pt 2.55pt 0pt 14.15pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mediana del tiempo de exacerbación de la enfermedad</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&gt;32 semanas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:88pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">20 semanas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:82.5pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">&gt;32 semanas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:79.45pt"><p style="margin:0pt 2.55pt 0pt 0pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">14 semanas</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:117.05pt; border:none">
                                        </td>
                                        <td style="width:86.35pt; border:none">
                                        </td>
                                        <td style="width:86.55pt; border:none">
                                        </td>
                                        <td style="width:81.15pt; border:none">
                                        </td>
                                        <td style="width:76.1pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt 2.55pt 0pt 5.5pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">             </span><span style="font-family:Times New Roman; font-size:11pt">Respuestas ACR-pediátrico 30/50/70 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">48 significativamente mayores que aquellos pacientes tratados con placebo.</span></p><p style="margin:0pt 2.55pt 0pt 5.5pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p = 0,015</span></p><p style="margin:0pt 2.55pt 0pt 5.5pt; page-break-after:avoid; line-height:115%; widows:0; orphans:0; font-size:11pt" ><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p = 0,031</span></p><p style="margin:0pt 2.65pt 6pt 5.5pt; line-height:115%; widows:0; orphans:0; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt">Entre aquellos pacientes respondedores a la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">16 (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">144), las respuestas ACR-pediátrico 30/50/70/90 se mantuvieron durante seis años en la fase de extensión abierta en pacientes que recibieron adalimumab a lo largo del ensayo. Un total de 19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sujetos, de los cuales 11 pertenecían inicialmente al grupo de edad de 4 a 12 y 8 al grupo de 13 a 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años, fueron tratados durante 6 años o más.</span></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt">La respuesta global fue generalmente mejor y, menos pacientes desarrollaron anticuerpos cuando fueron tratados con adalimumab y MTX en comparación con adalimumab sólo. Teniendo en cuenta estos resultados, se recomienda el uso de Hyrimoz en combinación con MTX y para uso en monoterapia en pacientes para los que el uso de MTX no es apropiado (ver sección</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.2).</span></p><p style="margin:0pt; widows:0; orphans:0" ><span style="font-family:Times New Roman; font-size:11pt; display:none"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">pJIA II</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la seguridad y la eficacia de adalimumab en un estudio abierto, multicéntrico en 32</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">niños (entre 2 y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad o de 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años o más y un peso &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg) con AIJ poliarticular activa de moderada a grave. Los pacientes recibieron 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">de área de superficie corporal de adalimumab hasta un máximo de 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas como una dosis única vía inyección subcutánea durante al menos 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. Durante el estudio la mayoría de los sujetos se trataron con metotrexato concomitante, con unas pocas notificaciones de tratamientos con corticoesteroides o AINEs.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En las semanas</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12 y 24, la respuesta PedACR30 fue del 93,5% y del 90,0%, respectivamente, usando la aproximación de observación de datos. Las proporciones de sujetos con PedACR50/70/90 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12 y en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24 fue del 90,3%/61,3%/38,7% y del 83,3%/73,3%/36,7%, respectivamente. De aquellos pacientes que respondieron (ACR 30 pediátrico) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">24 (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">27 de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes), la respuesta ACR 30 pediátrica se mantuvo hasta un máximo de 60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas en la fase de extensión abierta en los pacientes que recibieron adalimumab a lo largo de este periodo de tiempo. En total, 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">sujetos fueron tratados durante 60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas o más.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis asociada a entesitis</span></span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó la seguridad y la eficacia de adalimumab en un estudio multicéntrico, aleatorizado, doble-ciego en 46</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos (de 6 a 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años) con artritis asociada a entesitis moderada. Los pacientes se aleatorizaron para recibir 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">de área de superficie corporal (ASC) de adalimumab hasta un máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg o placebo en semanas alternas durante 12</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas. Tras el periodo doble ciego se continuó con un periodo abierto (PA) durante el que los pacientes recibieron 24</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/m</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:11pt">de ASC de adalimumab hasta un máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas por vía subcutánea durante 192</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas adicionales. La variable primaria del ensayo fue el porcentaje de cambio respecto al inicial hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12 en el número de articulaciones activas con artritis (inflamación no atribuida a la deformación o articulaciones con pérdida de movilidad más dolor y/o sensibilidad), que se alcanzó con descenso medio porcentual del -62,6% (mediana del cambio porcentual del -88,9%) en pacientes del grupo de adalimumab comparado con el -11,6% (mediana del cambio porcentual del -50%) en pacientes del grupo de placebo. Durante el PA se mantuvo la mejora en el número de articulaciones activas con artritis hasta la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">156 para los 26 de 31</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes (84%) del grupo de adalimumab que permanecieron en el estudio. A pesar de que no sea estadísticamente significativo, la mayoría de los pacientes mostraron mejoras clínicas en variables secundarias como el número de zonas de entesitis, el recuento de articulaciones dolorosas (RAD), el recuento de articulaciones inflamadas (RAI), la repuesta ACR 50 pediátrica y la respuesta ACR 70 pediátrica.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis pediátrica en placas</span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La eficacia de adalimumab se evaluó en un ensayo aleatorizado, doble ciego y controlado de 114</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos desde los 4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con psoriasis crónica en placas grave (definida por una PGA</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 o una BSA &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20% o &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10% con lesiones muy gruesas o con una respuesta PASI ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20 o ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10 con afectación clínica relevante en cara, genitales o manos/pies) con un control inadecuado con tratamiento tópico y helioterapia o fototerapia.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se administró a los pacientes adalimumab</span><span style="font-family:Times New Roman; font-size:11pt">0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (hasta 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) o 0,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/</span><span style="font-family:Times New Roman; font-size:11pt">kg (hasta 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg)</span><span style="font-family:Times New Roman; font-size:11pt">en semanas alternas,</span><span style="font-family:Times New Roman; font-size:11pt">o metotrexato 0,1-0,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg semanalmente (hasta 25</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg). En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">16, el número de pacientes aleatorizados al tratamiento con adalimumab 0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg con respuesta de eficacia positiva (por ejemplo, PASI 75) fue mayor que el de los pacientes aleatorizados al tratamiento 0,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg en semanas alternas o aquellos con MTX.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:89.16%" ><tr><td colspan="3" style="padding:0.75pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 27</span></strong><br /><strong><span style="font-family:Times New Roman; font-size:11pt;">resultados de eficacia de psoriasis pediátrica en placas a las 16</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">MTX</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><br /><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">37</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg en semanas alternas</span><br /><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">38</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"></span><span style="font-family:Times New Roman; font-size:11pt">PASI 75</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">12 (32,4%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">22 (57,9%)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"></span><span style="font-family:Times New Roman; font-size:11pt">PGA: sin lesiones/mínimas lesiones</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">15 (40,5%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">23 (60,5%)</span></p></td></tr><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">             </span><span style="font-family:Times New Roman; font-size:11pt">MTX = metotrexato</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,027, adalimumab 0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg versus MTX</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">             </span><span style="font-family:Times New Roman; font-size:11pt">p</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,083, adalimumab 0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg versus MTX</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:189.6pt; border:none">
                                        </td>
                                        <td style="width:55.7pt; border:none">
                                        </td>
                                        <td style="width:150.05pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">A los pacientes que alcanzaron una respuesta PASI 7</span><span style="font-family:Times New Roman; font-size:11pt">5 y PGA de sin lesiones o mínimas lesiones se les retiró el tratamiento durante un máximo de 36</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas y fueron monitorizados para evaluar la pérdida del control de la enfermedad (es decir, empeoramiento de PGA en al menos 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">grados). Tras este periodo de tiempo se reinició el tratamiento con adalimumab 0,8</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg en semanas alternas durante 16</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas observándose un índice de respuesta muy similar al obtenido previamente en el ensayo doble ciego: respuesta PASI 75 de 78,9% (15 de 19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes) y PGA de sin lesiones o mínimas lesiones de 52,6% (10 de 19</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Durante la fase abierta del estudio, las respuestas PASI 75 y PGA</span><span style="font-family:Times New Roman; font-size:11pt">de sin lesiones o mínimas lesiones</span><span style="font-family:Times New Roman; font-size:11pt">se mantuvieron</span><span style="font-family:Times New Roman; font-size:11pt">durante al menos 52</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas adicionales sin nuevos hallazgos relevantes de seguridad.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 0pt 10pt; page-break-after:avoid" ><em><span style="font-family:Times New Roman; font-size:11pt; text-decoration:none">Hidradenitis supurativa en adolescentes</span></em></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">No hay ensayos clínicos con adalimumab en pacientes adolescentes con HS. La eficacia de adalimumab para el tratamiento de pacientes adolescentes con HS se predice en base a la eficacia demostrada y la relación exposición/respuesta en pacientes adultos con HS y la probabilidad de que el curso de la enfermedad, la fisiopatología y los efectos del fármaco sean sustancialmente similares a los de adultos con los mismos niveles de exposición. La seguridad de la dosis recomendada de adalimumab en la población adolescente con HS está basada en el perfil de seguridad del conjunto de indicaciones de adalimumab en pacientes adultos y pediátricos a dosis similares o más frecuentes (ver sección 5.2).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 0pt 10pt" ><em><span style="font-family:Times New Roman; font-size:11pt; text-decoration:none">Enfermedad de Crohn</span></em><em><span style="font-family:Times New Roman; font-size:11pt; text-decoration:none">pediátrica</span></em></p><p style="margin:0pt 0pt 10pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluó adalimumab mediante un ensayo clínico multicéntrico, aleatorizado, doble ciego diseñado para evaluar la eficacia y seguridad del tratamiento de inducción y mantenimiento con dosis dependientes del peso corporal (&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg) en 192</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos con edades comprendidas entre 6 y 17 (inclusive) años, con enfermedad de Crohn de moderada a grave definida como con una puntuación en el índice de actividad de la enfermedad de Crohn pediátrica (PCDAI) &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30. En los sujetos tenían</span><span style="font-family:Times New Roman; font-size:11pt">que haber fracasado la terapia convencional (incluyendo un corticoesteroide y/o un inmunomodulador) para EC. Además previamente los sujetos podían haber perdido respuesta o sido intolerantes a infliximab.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Todos los sujetos recibieron un tratamiento de inducción abierto con dosis dependientes del peso corporal al inicio: 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 para pacientes ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg, y 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg y 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, respectivamente, para pacientes con peso &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">En la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4, los sujetos fueron aleatorizados 1:</span><span style="font-family:Times New Roman; font-size:11pt">1 según su peso corporal en ese momento a los regímenes de mantenimiento a dosis bajas o a dosis estándar que se muestran en la tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">28.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr style="height:13.15pt"><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#ffffff; border-left-style:solid; border-left-width:1pt; border-right-color:#ffffff; border-right-style:solid; border-right-width:1pt; border-top-color:#ffffff; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">28</span></strong></p><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">Régimen de mantenimiento</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Peso del paciente</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis bajas</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis estándar</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanas alternas</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanas alternas</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:90.85pt; border:none">
                                        </td>
                                        <td style="width:115.6pt; border:none">
                                        </td>
                                        <td style="width:115.6pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Resultados de eficacia</span></span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La variable primaria del estudio fue la remisión clínica en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">26, definida como una puntuación en el PCDAI ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Las tasas de remisión clínica y de respuesta clínica (</span><span style="font-family:Times New Roman; font-size:11pt">definidas como una reducción en la puntuación del PCDAI de al menos 15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">puntos desde el inicio) se presentan en la tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">29. Las tasas de interrupción de corticoesteroides o inmunomoduladores se presentan en la tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:333.65pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 29</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Estudio de EC pediátrica</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">PCDAI Remisión y respuesta clínica</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis estándar</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">40/20</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanas alternas</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">93</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis bajas</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">20/10</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanas alternas</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">95</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Valor p</span></strong><span style="font-family:Times New Roman; font-size:11pt">*</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Semana 26</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">   Remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">38,7%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">28,4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,075</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">   Respuesta clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">59,1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">48,4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,073</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Semana 52</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">   Remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">33,3%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">23,2%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,100</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:116.05pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">   Respuesta clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.7pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">41,9%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:79.55pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">28,4%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57.35pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,038</span></p></td></tr><tr><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:333.65pt"><p style="margin:0pt 25.1pt 0pt 0pt; text-indent:-14.2pt; page-break-inside:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">*</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">valor p para la comparación Dosis estándar</span><em><span style="font-family:Times New Roman; font-size:11pt;">versus</span></em><span style="font-family:Times New Roman; font-size:11pt">Dosis baja.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:116.05pt; border:none">
                                        </td>
                                        <td style="width:80.7pt; border:none">
                                        </td>
                                        <td style="width:79.55pt; border:none">
                                        </td>
                                        <td style="width:57.35pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto" ><tr><td colspan="4" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:422pt"><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla 30</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Estudio de EC pediátrica</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Interrupción de corticoesteroides o inmunomoduladores y remisión de fistulas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:201.25pt"><p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis estándar</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">40/2</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanas alternas</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Dosis bajas</span></strong></p><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">20/10</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg semanas alternas</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Valor p</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Interrupción</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">de corticoesteroides</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">33</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">38</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">26</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">84,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">65,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,066</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">69,7%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">60,5%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,420</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Interrupción</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">de inmunomoduladores</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">60</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">57</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:bottom; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Semana 52</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">30,0%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">29,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,983</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Remisión de fistulas</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">15</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">N</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">=</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">21</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Semana 26</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">46,7%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">38,1%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,608</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:201.25pt"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Semana 52,</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:82.8pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40,0%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:80.95pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">23,8%</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:57pt"><p style="margin:0pt 0pt 0pt 0.75pt; text-align:center; page-break-inside:avoid; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">0,303</span></p></td></tr><tr style="height:8.85pt"><td colspan="4" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:422pt"><p style="margin:0pt 19.65pt 0pt 0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">valor p para la comparación Dosis estándar</span><em><span style="font-family:Times New Roman; font-size:11pt;">versus</span></em><span style="font-family:Times New Roman; font-size:11pt">Dosis bajas.</span></p><p style="margin:0pt 19.65pt 0pt 0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">             </span><span style="font-family:Times New Roman; font-size:11pt">el tratamiento con inmunosupresores solo se puede interrumpir en o después de la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">26 a criterio del investigador si el sujeto cumple los criterios de respuesta clínica.</span></p><p style="margin:0pt 19.65pt 0pt 0pt; text-indent:-14.2pt; page-break-inside:avoid; page-break-after:avoid; line-height:115%; padding-left:14.2pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:Times New Roman; font-size:11pt">             </span><span style="font-family:Times New Roman; font-size:11pt">definido como cierre de todas las fistulas que fueron drenando desde el inicio hasta al menos dos visitas consecutivas post-basal</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:201.25pt; border:none">
                                        </td>
                                        <td style="width:82.8pt; border:none">
                                        </td>
                                        <td style="width:80.95pt; border:none">
                                        </td>
                                        <td style="width:57pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En ambos grupos de tratamiento se observaron aumentos estadísticamente significativos (mejoras) desde el inicio hasta las semanas 26 y 52 en el índice de masa corporal y la velocidad de crecimiento.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt 0pt 10pt" ><span style="font-family:Times New Roman; font-size:11pt; text-decoration:none">En ambos grupos de tratamiento se observaron también mejoras estadística y clínicamente significativas desde el inicio para parámetros de calidad de vida (incluyendo IMPACT III).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Cien pacientes (n</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">100) del estudio de enfermedad de Crohn pediátrica continuaron en una extensión abierta del estudio a largo plazo. Tras 5</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de tratamiento con adalimumab, el 74% de los 50</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes que siguieron en el estudio (37/50) continuaron en remisión clínica, y el 92% de los pacientes (46/50) continuaron en respuesta clínica según PCDAI.</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa pediátrica</span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se evaluaron la seguridad y la eficacia de adalimumab en un ensayo clínico multicéntrico, aleatorizado y doble ciego con 93</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos de entre 5 y 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años con colitis ulcerosa de moderada a grave (puntuación Mayo 6 a 12 con subpuntuación endoscópica de 2 a 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">puntos, confirmada por lectura endoscópica central) que presentaban respuesta inadecuada o intolerancia a los tratamientos convencionales. Aproximadamente el 16% de los pacientes del estudio había fracasado con un tratamiento anti-TNF anterior. Los pacientes que recibían corticoesteroides durante la inscripción pudieron</span><span style="font-family:Times New Roman; font-size:11pt">reducir progresivamente su tratamiento con corticoesteroides después de la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">En el periodo de inducción del estudio, se aleatorizó a</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">77</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">pacientes en una proporción de 3:2 para que recibieran tratamiento en régimen doble ciego con adalimumab con una dosis de inducción de 2,4</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">0 y la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">1, y de 1,2</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">2; o una dosis de inducción de 2,4</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">0, placebo en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">1, y 1,2</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">2. Ambos grupos recibieron 0,6</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">4 y la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">6. Tras una enmienda al diseño del estudio, los 16</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">pacientes restantes inscritos en el periodo de inducció</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">n recibieron tratamiento sin enmascaramiento con adalimumab con una dosis de inducción de 2,4</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">0 y en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">1 y de 1,2</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">2.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">En la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8, se aleatorizó de forma igualitaria a 62</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">pacientes que mostraron respuesta clínica según la puntuación Mayo parcial (PMS;</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">definida como un descenso de PMS de ≥</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">2</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">puntos y ≥</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">30% desde el inicio)</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">para recibir en régimen doble ciego tratamiento de mantenimiento con adalimumab a una dosis de 0,6</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) cada semana, o a una dosis de mantenimiento de 0,6</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg) en semanas alternas. Previo a una enmienda al diseño del estudio, se aleatorizaron 12</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">pacientes adicionales que mostraron respuesta clínica según la PMS para recibir placebo, aunque no se les incluyó en el análisis de confirmación de eficacia.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La exacerbación de la enfermedad se definió como un aumento de la PMS de al menos 3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">puntos (para pacientes con una PMS de 0 a 2 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8), de al menos 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">puntos (para pacientes con una PMS de 3 a 4 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8) o de al menos 1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">punto (para pacientes con una PMS de 5 a 6 en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se aleatorizó a los pacientes que cumplían los criterios de exacerbación de la enfermedad en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">12 o después de esta para recibir una dosis de reinducción de 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) o una dosis de 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) y siguieron recibiendo su régimen de dosis de mantenimiento respectivo posteriormente.</span></p><p style="margin:12pt 0pt; line-height:125%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Resultados de eficacia</span></em></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Las variables coprimarias del estudio fu</span><span style="font-family:Times New Roman; font-size:11pt">eron la remisión clínica según la PMS (definida como PMS ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 y ninguna subpuntuación individual &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8, y la remisión clínica según la puntuación Mayo completa (FMS, Full Mayo Score) (definida como una puntuación Mayo de ≤</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2 y ninguna subpuntuación individual &gt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52 en pacientes que alcanzaron una respuesta clínica según la PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Las tasas de remisión clínica según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8 de los pacientes en cada uno de los grupos de inducción en régimen doble ciego de a</span><span style="font-family:Times New Roman; font-size:11pt">dalimumab se presentan en la tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31.</span></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:125%; font-size:11pt" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">31: Remisión clínica según PMS a las 8</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:46.05pt; width:84.92%" ><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:24.76%"><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><a name="_Hlk51699630"><span style="font-family:Times New Roman; font-size:11pt"> </span></a></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.28%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">160</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0/placebo</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.96%"><p style="margin:0pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">, c</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">160</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0 y</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1</span></strong></p><p style="margin:0pt; text-align:center; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">47</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:24.76%"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión clínica</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top; width:37.28%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">13/30 (43,3%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:middle; width:37.96%"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">28/47 (59,6%)</span></p></td></tr><tr style="height:19.8pt"><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; padding:0.75pt; vertical-align:top"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0, placebo en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">(máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">Sin incluir la dosis de inducción abierta de adalimumab de 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y de 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1: Ambos grupos de inducción recibieron 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2: Se consideró que los pacientes a los que les faltaban valores en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8 no habían cumplido el criterio de evaluación</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:93.2pt; border:none">
                                        </td>
                                        <td style="width:140.4pt; border:none">
                                        </td>
                                        <td style="width:142.95pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">En la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">52, se evaluaron la remisión clínica según la FMS en los pacientes que respond</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">ieron en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8, la respuesta clínica según la FMS (definida como un descenso en la puntuación Mayo de ≥</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">3</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">puntos y ≥</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">30% desde el inicio) en los pacientes que respondieron en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8, la curación mucosa (definida como subpuntuación endoscópica Mayo de ≤</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">1) en los pacientes que respondieron en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8, la remisión clínica según la FMS en los pacientes que presentaron remisión en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8 y la proporción de sujetos que presentó remisión sin corticoesteroides según la FMS en los pacientes que</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">respondieron en la semana</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">8, de los pacientes que recibieron dosis de mantenimiento de adalimumab doble ciego máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg en semanas alternas (0,6</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg) y máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg cada semana (0,6</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">mg/kg) (tabla</span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff"> </span><span style="font-family:Times New Roman; font-size:11pt; background-color:#ffffff">32).</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt" ><a name="_Hlk51693203"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">32: Resultados de eficacia a las 52</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">semanas</span></strong></a></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:378.4pt" ><tr style="height:45.6pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:top; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">en semanas alternas</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">cada semana</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31</span></p></td></tr><tr style="height:28.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión clínica en respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">9/31 (29,0%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">14/31 (45,2%)</span></p></td></tr><tr style="height:27.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Respuesta clínica en respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">19/31 (61,3%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">21/31 (67,7%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Curación mucosa en respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">12/31 (38,7%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">16/31 (51,6%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión clínica en pacientes en remisión según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">9/21 (42,9%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">10/22 (45,5%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.75pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:126.3pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión sin corticoesteroides en respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:120.45pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">4/13 (30,8%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.75pt; vertical-align:middle; width:131.65pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">5/16 (31,3%)</span><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr><td colspan="3" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; vertical-align:top; width:378.4pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en semanas alternas</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) cada semana</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">En pacientes con tratamiento concomitante de corticoesteroides en el inicio</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Nota: Los pacientes sin valores en semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52 o aleatorizados para recibir tratamiento de reinducción o de mantenimiento fueron considerados no respondedores para las variables de la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:126.3pt; border:none">
                                        </td>
                                        <td style="width:120.45pt; border:none">
                                        </td>
                                        <td style="width:131.65pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Las variables exploratorias de eficacia adicionales fueron la respuesta clínica según el índice de actividad de la colitis ulcerosa pediátrica (Paediatric Ulcerative Colitis Activity Index, PUCAI)</span><span style="font-family:Times New Roman; font-size:11pt">(definido como un descenso de PUCAI de ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">puntos desde el inicio) y la remisión clínica según PUCAI (definida como PUCAI &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">10) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8 y en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52 (tabla</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">33).</span></p><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:413.1pt" ><tr style="height:3pt"><td colspan="3" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:413.1pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Tabla</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">33: Resultados de los criterios de valoración exploratorios según PUCAI</span></strong></p></td></tr><tr style="height:13.25pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:266.4pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">S</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">emana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">8</span></strong></p></td></tr><tr style="height:52.1pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de 160</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0/placebo en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b,c</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de 160</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">0 y la semana</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">1</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">47</span></p></td></tr><tr style="height:16.15pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión clínica según PUCAI</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">10/30 (33,3%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">22/47 (46,8%)</span></p></td></tr><tr style="height:11.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Respuesta clínica según PUCAI</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">15/30 (50,0%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">32/47 (68,1%)</span></p></td></tr><tr style="height:11.9pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:266.4pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Semana 52</span></strong></p></td></tr><tr style="height:11.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de 40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg en semanas alternas</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Adalimumab</span></strong><strong><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">e</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Máximo de 40</span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong><strong><span style="font-family:Times New Roman; font-size:11pt;">mg cada semana</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">N</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">=</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">31</span></p></td></tr><tr style="height:11.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Remisión clínica según PUCAI para respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">14/31 (45,2%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">18/31 (58,1%)</span></p></td></tr><tr style="height:11.9pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:146.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Respuesta clínica según PUCAI para respondedores según PMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.9pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">18/31 (58,1%)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:121.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">16/31 (51,6%)</span></p></td></tr><tr style="height:26.65pt"><td colspan="3" style="border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:413.1pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">a</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0, placebo en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">b</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">c</span><span style="font-family:Times New Roman; font-size:11pt">Sin incluir la dosis de inducción en régimen abierto de adalimumab de 2,4</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1 y de 1,2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">d</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en semanas alternas</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:7.33pt; vertical-align:super">e</span><span style="font-family:Times New Roman; font-size:11pt">Adalimumab 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) cada semana</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">1: Ambos grupos de inducción recibieron 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">4 y la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">6</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">2: Se consideró que los pacientes sin valores en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8 no habían cumplido los criterios de evaluación</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3:</span><span style="font-family:Times New Roman; font-size:11pt">Los pacientes sin valores en semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52 o aleatorizados para recibir tratamiento de reinducción o de mantenimiento fueron considerados no respondedores para las variables de la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:146.7pt; border:none">
                                        </td>
                                        <td style="width:144.9pt; border:none">
                                        </td>
                                        <td style="width:121.5pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">De los pacientes tratados con adalimumab que recibieron tratamiento de reinducción durante el periodo de mantenimiento, 2/6 (33%) consiguieron una respuesta clínica según FMS en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52.</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Calidad de vida</span></span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron mejoras clínicamente significativas desde el inicio en las puntuaciones IMPACT III y del deterioro de la actividad y la productividad laboral (WPAI, Work Productivity and Activity Impairment) de los grupos tratados con adalimumab.</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Se observaron aumentos clínicamente significativos (mejoras) desde el inicio en la velocidad de crecimiento en los grupos tratados con adalimumab, y aumentos clínicamente significativos (mejoras) desde el inicio en el índice de masa corporal en sujetos con dosis alta de mantenimiento de un máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg) cada semana.</span></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em></p><p style="margin:0pt" ><em><span style="font-family:Times New Roman; font-size:11pt;">Uveítis pediátrica</span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La seguridad y la eficacia de adalimumab se evaluaron en un ensayo controlado, aleatorizado, doble ciego con 90</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">pacientes pediátricos de edades entre 2 y &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años con uveítis anterior no infecciosa asociada a AI</span><span style="font-family:Times New Roman; font-size:11pt">J activa, los cuales fueron resistentes a al menos 12 semanas de tratamiento con metotrexato. Los pacientes recibieron placebo, 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de adalimumab (si &lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg) o 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de adalimumab (si ≥</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg) en semanas alternas en combinación con su dosis basal de metotrexato.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">La variable primaria fue el “tiempo hasta el fallo del tratamiento”. Los criterios determinantes del fallo del tratamiento fueron un empeoramiento o una no mejora mantenida de la inflamación ocular; una mejora parcial con desarrollo de comorbilidades oculares mantenidas o un empeoramiento de las comorbilidades, impidiendo el uso de medicamentos concomitantes y una suspensión del tratamiento por un largo periodo de tiempo.</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><em><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Respuesta clínica</span></span></em></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab retrasó de forma significativa el tiempo hasta fallo del tratamiento, en comparación con el placebo (ver figura</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3, P</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">&lt;</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">0,0001 de la prueba de rango logarítmico). La mediana del tiempo hasta fallo del tratamiento fue de 24,1</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">semanas para los pacientes tratados con placebo, mientras que la mediana del tiempo hasta fallo del tratamiento no se pudo estimar para los pacientes tratados con adalimumab porque menos de la mitad de ellos experimentaron fallo del tratamiento. Adalimumab disminuyó significativamente el riesgo de fallo del tratamiento en un 75% respecto a placebo, tal y como muestra el cociente de riesgo (HR = 0,25 [IC 95%: 0,12- 0,49]).</span></p><p style="margin:0pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:center; page-break-after:avoid" ><strong><span style="font-family:Times New Roman; font-size:11pt;">Figura 3: Curva de Kaplan-Meier que resume el tiempo hasta fallo del tratamiento en el estudio de uveítis pediátrica</span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:464.4pt" ><tr style="height:190.3pt"><td style="height:190.3pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:23.4pt; writing-mode:tb-rl"><p style="margin:0pt 5.65pt; text-align:center; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">PROBABILIDAD EN EL FALLO DEL TRATAMIENTO</span></strong></p></td><td colspan="5" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:441pt"><p style="margin:0pt; page-break-after:avoid"><img src="data:image/jpg;base64,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" width="583" height="480" alt="Uveitis" /></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="5" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:441pt"><p style="margin:0pt; text-align:center"><strong><span style="font-family:Times New Roman; font-size:11pt;">TIEMPO (SEMANAS)</span></strong></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:175.5pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tratamiento</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:58.5pt"><p style="margin:0pt; text-align:center"><img src="data:image/jpg;base64,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" width="50" height="14" alt="Humira PED UV KM Curve 11" /></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:67.5pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Placebo</span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:45pt"><p style="margin:0pt; page-break-after:avoid"><img src="data:image/jpg;base64,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" width="47" height="10" alt="Humira PED UV KM Curve 11" /></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:94.5pt"><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab</span></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:23.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td colspan="5" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:441pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Nota: P = Placebo (Número en riesgo);</span><strong><span style="font-family:Times New Roman; font-size:11pt;">A = Adalimumab</span></strong><span style="font-family:Times New Roman; font-size:11pt">(Número en riesgo).</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:23.4pt; border:none">
                                        </td>
                                        <td style="width:175.5pt; border:none">
                                        </td>
                                        <td style="width:58.5pt; border:none">
                                        </td>
                                        <td style="width:67.5pt; border:none">
                                        </td>
                                        <td style="width:45pt; border:none">
                                        </td>
                                        <td style="width:94.5pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">).</span></p></div></text></section><section id="459137c3-2a34-41e8-a440-50c9b8596007"><title value="5.2. Propiedades farmacocinéticas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029827" /><display value="Propiedades farmacocinéticas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Absorción y distribución</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La absorción y distribución de adalimumab tras la administración subcutánea de una dosis única de 40 mg, fue lenta, alcanzándose las concentraciones plasmáticas máximas a los 5 días después de la administración. La media de biodisponibilidad absoluta de adalimumab fue del 64 %, estimada a partir de tres ensayos con una dosis subcutánea única de 40 mg. Tras la administración intravenosa de dosis únicas en un rango de 0,25 a 10 mg/kg, las concentraciones fueron proporcionales a la dosis. Tras la administración de dosis de 0,5 mg/kg (~40 mg), el aclaramiento osciló en el rango de 11 a 15 ml/hora, el volumen de distribución (Vss) entre 5 y 6 litros, y la semivida media de eliminación terminal fue aproximadamente dos semanas. Las concentraciones de adalimumab en el líquido sinovial, determinadas en varios pacientes con artritis reumatoide, oscilaron entre el 31 y el 96 % de las plasmáticas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración subcutánea de 40 mg de adalimumab en semanas alternas en pacientes adultos con artritis reumatoide (AR), la media de las concentraciones en el punto mínimo en el estado estacionario fue aproximadamente 5 microgramos/ml (sin tratamiento concomitante con metotrexato) y 8 a 9 microgramos/ml (con metotrexato concomitante). Los niveles plasmáticos de adalimumab en el estado estacionario aumentaron más o menos proporcionalmente con la dosis tras la administración subcutánea de 20, 40 y 80 mg en semanas alternas y cada semana.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración subcutánea en semanas alternas de 24</span><span style="font-family:Times New Roman; font-size:11pt">mg/m2 (máximo de 40 mg) en pacientes con artritis idiopática juvenil poliarticular (AIJ), que tenían entre 4 y 17 años, la concentración plasmática media de adalimumab en estado estacionario (valores medidos de la semana 20 a la 48) fue 5,6 ± 5,6 μg/ml (102 % CV) con adalimumab sin metotrexaro concomitante y 10,9 ± 5,2 μg/ml (47,7 % CV) con metotrexato concomitante.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes con AIJ poliarticular que tenían de 2 a &lt; 4 años de edad o con 4 años de edad y un peso inferior a 15 kg dosificados con 24 mg/m2 de adalimumab, la concentración plasmática media de adalimumab en estado estacionario fue 6,0 ± 6,1 μg/ml (101 % CV) para adalimumab sin metotrexato concomitante y 7,9 ± 5,6 μg/ml (71,2 % CV) con metotrexato concomitante.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración de 24 mg/</span><span style="font-family:Times New Roman; font-size:11pt">m2 (máximo de 40 mg) por vía subcutánea en semanas alternas en pacientes de 4 a 17 años con artritis asociada entesitis, la concentración media de adalimumab en estado estacionario (valores medidos en la semana 24) fue de 8,8 ±6,6 μg/ml para adalimumab sin metotrexaro concomitante y 11,8 ± 4,3 μg/ml con metotrexato concomitante.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes adultos con psoriasis, la media de la concentración en el punto mínimo en el estado estacionario fue de 5 microgramos/ml durante el tratamiento en monoterapia con adal</span><span style="font-family:Times New Roman; font-size:11pt">imumab 40 mg en semanas alternas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración subcutánea de 0,8 mg/kg (máximo de 40 mg) en semanas alternas a pacientes pediátricos con psoriasis en placas crónica, la media (± DS) de las concentraciones de adalimumab en el punto mínimo del estado estacionario fue 7,4 ± 5,8 μg/ml (79 % CV).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración subcutánea de 40 mg de adalimumab cada dos semanas en pacientes adultos con espondiloartritis axial no radiográfica, la concentración media (±SD) en el estado estacionario en la semana 68 fue de 8,0 ± 4,6 μg/ml.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes adultos con hidradenitis supurativa, con una dosis de 160 mg de adalimumab en la semana 0 seguido de 80 mg en la semana 2 se alcazaron concentraciones séricas mínimas de adalimumab de aproximadamente 7 a 8 μg/ml en la semana 2 y la semana 4. La concentración media en el estado estacionario en la semana 12 hasta la semana 36 fue aproximadamente de 8 a 10 μg/ml durante el tratamiento con adalimumab 40 mg semanal.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La exposición de adalimumab en pacientes adolescentes</span><span style="font-family:Times New Roman; font-size:11pt">con HS se predijo usando modelos de farmacocinética poblacional y simulación basado en la farmacocinética del conjunto de indicaciones en otros pacientes pediátricos (psoriasis pediátrica, artritis idiopática juvenil, enfermedad de Crohn pediátrica, y artritis asociada a entesitis). La pauta posológica recomendada para HS en adolescentes es 40 mg en semanas alternas. Debido a que la exposición a adalilumab se puede ver afectada por el tamaño corporal, los adolescentes con mayor peso corporal y una respuesta inadecuada se pueden beneficiar de la dosis recomendada en adultos de 40 mg semanales.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes con enfermedad de Crohn, con la dosis de carga de 80 mg de adalimumab en la semana 0, seguida de 40 mg de adalimumab en la semana 2, se alcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 5,5 microgramos/ml durante el periodo de inducción. Con la dosis de carga de 160 mg de adalimumab en la semana 0, seguida de 80 mg de adalimumab en la semana 2, se alcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 12 microgramos/ml durante el periodo de inducción. Se observaron niveles medios en el punto mínimo en el estado estacionario de aproximadamente 7 microgramos/ml en pacientes con enfermedad de Crohn que recibieron una dosis de mantenimiento de 40 mg de adalimumab en semanas alternas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes pediátricos con enfermedad de Crohn de moderada a grave, la dosis de inducción con adalimumab fue de 160/80 mg u 80/40 mg en las semanas 0 y 2, respectivamente, dep</span><span style="font-family:Times New Roman; font-size:11pt">endiendo de un corte de 40 kg de peso corporal. En la semana 4, los pacientes fueron aleatorizados 1:1 en grupos de tratamiento de mantenimiento según su peso corporal a la Dosis Estándar (40/20 mg en semanas alternas) o Dosis Baja (20/10 mg en semanas alternas). La media (± DS) de la concentración sérica valle de adalimumab alcanzada en la semana 4 fue 15,7±6,6 μg/ml para pacientes ≥ 40 kg (160/80 mg) y 10,6±6,1 μg/ml para pacientes &lt; 40 kg (80/40 mg).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Para aquellos pacientes que permanecieron en el tratamiento aleatorizado, la media (± DS) de la concentración valle de adalimumab en la semana 52 fue de 9,5±5,6 μg/ml para el grupo de la Dosis Estándar y 3,5±2,2 μg/ml para el grupo de Dosis Bajas. Se mantuvo la media de las concentraciones valle en los sujet</span><span style="font-family:Times New Roman; font-size:11pt">os que continuaron el tratamiento con adalimumab en semanas alternas durante 52 semanas. Para aquellos pacientes en los que se produjo una escalada de dosis del régimen de semanas alternas a semanalmente, la media (± DS) de las concentraciones séricas de adalimumab en la semana 52 fueron 15,3±11,4 μg/ml (40/20 mg semanalmente) y 6,7±3,5 (20/10 mg semanalmente).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes con colitis ulcerosa, con la dosis de carga de 160 mg de adalimumab en la semana 0, seguida de 80 mg de adalimumab en la semana 2 se a</span><span style="font-family:Times New Roman; font-size:11pt">lcanzaron concentraciones plasmáticas mínimas de adalimumab de aproximadamente 12 microgramos/ml durante el periodo de inducción. Se observaron niveles medios en el punto mínimo en el estado estacionario de 8 microgramos/ml en pacientes con colitis ulcerosa que recibieron una dosis de mantenimiento de 40 mg de adalimumab en semanas alternas.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Tras la administración subcutánea de una dosis basada en el peso corporal de 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) en semanas alternas en pacientes pediátricos con colitis ulcer</span><span style="font-family:Times New Roman; font-size:11pt">osa, la concentración sérica media de adalimumab en el punto mínimo del estado estacionario fue de 5,01</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">±</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">3,28</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μg/ml en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52. Para pacientes que recibieron 0,6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg/kg (máximo de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) cada semana, la concentración sérica media (± DE) de adalimumab en el punto mínimo del estado estacionario fue de 15,7</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">±</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">5,60</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">μg/ml en la semana</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">52.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">En pacientes adultos con uveítis, una dosis de carga de 80 mg de adalimumab en la semana 0 seguida de 40 mg de adalimumab en semanas alternas comenzando en la semana 1, permitió alcanzar concentraciones medias en el estado estacionario de aproximadamente 8 a 10 μg/ml.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La exposición a adalimumab en pacientes pediátricos con uveítis se predijo utilizando el modelo farmacocinético de población y la simulación basada en la farmacocinética de indicación cruzada en otros pacientes pediátricos (psoriasis pediátrica, artritis idiopática juvenil, enfermedad de Crohn pediátrica y artritis asociada a entesitis). No se dispone de datos de exposición clínica sobre el uso de una dosis de carga en niños menores de 6 años. Las exposiciones predichas indican que, en ausencia de metotrexato, una dosis de carga puede llevar a un aumento inicial de la exposición sistémica.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La modelización y simulación de la farmacocinética/farmacodinámica y la farmacocinética de la población predijo una exposición a adalimumab y eficacia similar en pacientes tratados con 80 mg cada dos semanas comparado con 40 mg semanal (incluyendo pacientes adultos con AR, HS, CU, EC o Ps, pacientes con HS adolescente, y pacientes pediátricos ≥ 40 kg con EC).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Relación exposición-respuesta en la población pediátrica</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Basándose en los datos de ensayos clínicos en pacientes con JIA (pJIA y ERA) se estableció una relación exposición-respuesta entre las concentraciones plasmáticas y la respuesta PedACR50. La concentración plasmática aparente de adalimumab que produce la mitad del máximo de probabilidad de respuesta PedACR50 (EC50) fue 3 μg/ml (IC 95 %: 1-6 μg/ml).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se establecieron las relaciones exposición-respuesta entre la concentración de adalimumab y la eficacia en pacientes pediátricos con psoriasis en placas crónica grave para el PASI 75 y la PGA de sin lesiones o mínimas lesiones, respectivamente. El PASI 75 y la PGA de sin lesiones o mínimas lesiones aumentó con el aumento de las concentraciones de adalimumab, ambas con un EC50 aparente similar de aproximadamente 4,5 μg/ml (IC 95 % 0,4-47,6 y 1,9-10,5, respectivamente).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Eliminación</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los análisis farmacocinéticos poblacionales con datos de aproximadamente 1.300 pacientes con AR revelaron una tendencia a una correlación directa entre el incremento aparente del aclaramiento de adalimumab y el peso corporal. Después de un ajuste según las diferencias de peso corporal, se observó que el efecto del sexo y la edad sobre el aclaramiento de adalimumab era mínimo. Los niveles plasmáticos de adalimumab libre (no unido a anticuerpos anti-adalimumab, AAA) se observó que eran inferiores en pacientes con AAA cuantificables.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia renal o hepática</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Adalimumab no se ha estudiado en pacientes con insuficiencia hepática o renal.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="d942d277-fe42-47e1-af8a-0b03eaba58eb"><title value="5.3. Datos preclínicos sobre seguridad" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029834" /><display value="Datos preclínicos sobre seguridad" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Los datos de los estudios preclínicos no muestran riesgos especiales para los seres humanos según los estudios convencionales de toxicidad a dosis única, a dosis repetidas y genotoxicidad.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Se ha llevado a cabo un estudio de toxicidad en el desarrollo embrio-fetal/perinatal en monos cinomolgos con dosis de 0,30 y 100 mg/kg (9-17 monos/grupo) que no ha revelado evidencia de daños fetales debidos a adalimumab. No se llevaron a cabo ni estudios de carcinogénesis ni de evaluación estándar de la fertilidad y de la toxicidad postnatal con adalimumab debido a la falta de modelos apropiados para estudiar un anticuerpo con reactividad cruzada limitada al TNF del roedor y al desarrollo de anticuerpos neutralizantes en roedores.</span></p></div></text></section></section><section id="5cc17884-aa27-4dbc-9730-ed5079663fea"><title value="6. Datos farmacéuticos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029836" /><display value="Datos farmacéuticos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="b768b473-88e6-47ae-aae0-4a3de66afeeb"><title value="6.1. Lista de excipientes" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029837" /><display value="Lista de excipientes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ácido adípico</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ácido cítrico monohidrato</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Cloruro de sodio</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Manitol (E 421)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Polisorbato 80 (E 433)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Ácido clorhídrico (para el ajuste del pH) (E 507)</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Hidróxido de sodio (para el ajuste del pH) (E 524)</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Agua para preparaciones inyectables</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="bd5d7a60-a8a3-4f8d-a763-16d1a8bd4b4b"><title value="6.2. Incompatibilidades" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029838" /><display value="Incompatibilidades" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">En ausencia de estudios de compatibilidad, este medicamento no debe mezclarse con otros.</span></p></div></text></section><section id="f02397e3-1a6d-43ae-b6c7-158594c94c94"><title value="6.3. Periodo de validez" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029839" /><display value="Periodo de validez" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">30 meses </span></p></div></text></section><section id="13913971-b887-4f43-8024-6f9060fdc36b"><title value="6.4. Precauciones especiales de conservación" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029840" /><display value="Precauciones especiales de conservación" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Conservar en nevera (2 °C-8 °C). No congelar. Conservar la jeringa precargada/pluma precargada en el embalaje exterior para protegerla de la luz.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">La jeringa precargada/pluma precargada de Hyrimoz se puede almacenar a una temperatura maxima de 25 ºC durante un periodo de hasta 21 días. La jeringa precargada/pluma precargada se tiene que proteger de la luz y desechar si no se usa dentro de este periodo de 21 días.</span></p></div></text></section><section id="bbc2ac3b-5595-4492-ad77-c9a931ed6530"><title value="6.5. Naturaleza y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029841" /><display value="Naturaleza y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">20</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">mg solución inyectable en jeringa precargada</span></span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Solución de 0,4 ml se suministra en una jeringa de vidrio de tipo</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">I transparente, de un solo uso, con un tapón de caucho (goma de bromobutilo) y una aguja de acero inoxidable del calibre 29 con protector automático de la aguja con alas de sujeción, capuchón de la aguja de caucho (elastómero termoplástico) y émbolo de plástico.</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Envase de 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">jeringas precargadas en un blíster</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en jeringa precargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Solución de 0,8 ml en una jeringa de vidrio de tipo I transparente, de un solo uso, con un tapón de caucho (goma de bromobutilo) y una aguja de acero inoxidable del calibre 29 con protector automático de la aguja con alas de sujeción, capuchón de la aguja de caucho (elastómero termoplástico) y émbolo de plástico.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Envases de 1 y 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">jeringas precargadas en un blíster</span></p><p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid" ><span style="font-family:Times New Roman; font-size:11pt">Envase múltiple con 6 (3</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">envases de 2)</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">jeringas precargadas en un blíster</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en pluma precargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Solución de 0,8 ml en una jeringa precargada de un solo uso acoplada a una pluma de forma triangular con ventana transparente y etiqueta. La jeringa del interior de la pluma es de vidrio de tipo I con aguja de acero inoxidable del calibre 29, capuchón de aguja interior de caucho (elastómero termoplástico) y tapón de caucho (goma de bromobutilo).</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Envases de 1 y 2 plumas precargadas</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Envase múltiple con 6 (3 envases de 2) plumas precargadas</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p></div></text></section><section id="6d9f863b-387a-4d93-a2d7-8be43eeb0953"><title value="6.6. Precauciones especiales de eliminación y otras manipulaciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029842" /><display value="Precauciones especiales de eliminación y otras manipulaciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él se realizará de acuerdo con la normativa local.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Las instrucciones de uso completas figuran en el prospecto, sección 7, “Instrucciones de uso”.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section><section id="f1c61dd5-2a04-44ea-a253-7549c4000c76"><title value="7. Titular de la autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029844" /><display value="Titular de la autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Sandoz GmbH</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">Biochemiestr. 10</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">6250 Kundl</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Austria</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="542bff45-ea79-47a6-836d-916e743bdf61"><title value="8. Número(s) de autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029845" /><display value="Número(s) de autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; widows:0; orphans:0" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">20</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;"> </span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">mg solución inyectable en jeringa precagargada</span></span></p><p style="margin:0pt 19.7pt 0pt 0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/007</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en jeringa precagargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/001</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/002</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/003</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en pluma precargada</span></span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/004</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/005</span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">EU/1/18/1286/006</span></p></div></text></section><section id="386d3377-ef02-43ab-b77a-7e1f73615c13"><title value="9. Fecha de la primera autorización/ renovación de la autorización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029846" /><display value="Fecha de la primera autorización/ renovación de la autorización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt">Fecha de la primera autorización: 26/julio/2018</span></p></div></text></section><section id="fc85fe72-c48d-4364-abc2-2a5f61b42117"><title value="10. Fecha de la revisión del texto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029847" /><display value="Fecha de la revisión del texto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos</span><a href="http://www.ema.europa.eu/"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">http://www.ema.europa.eu/</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt" ><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section></section></Composition></resource></entry></Bundle></resource></entry><entry><fullUrl value="471e9e0d-3266-44c9-bfc0-3698a11a2301" /><resource><Bundle><id value="471e9e0d-3266-44c9-bfc0-3698a11a2301" /><identifier><system value="http://ema.europa.eu/fhir/epiDocument" /><value value="471e9e0d-3266-44c9-bfc0-3698a11a2301" /></identifier><type value="document" /><timestamp value="2024-12-03T18:15:21.690675+01:00" /><entry><fullUrl value="471e9e0d-3266-44c9-bfc0-3698a11a2301" /><resource><Composition><language value="es" /><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml">electronic Product Information (ePI) document</div></text><status value="final" /><type><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="100000155538" /><display value="Prospecto" /></coding></type><subject><reference value="subjectReference" /></subject><date value="2024-12-03" /><author><reference value="systemUser" /></author><title value="Prospecto" /><section><title value="Prospecto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/100000155531" /><code value="200000029894" /><display value="Prospecto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Prospecto: Información para el paciente</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz 40 mg solución inyectable en pluma precargada</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adalimumab</span></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">40 mg/0,8 ml</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="24" height="22" alt="" /><span style="font-family:Times New Roman; font-size:11pt">Este medicamento está sujeto a seguimiento adicional, lo que agilizará la detección de nueva información sobre su seguridad. Puede contribuir comunicando los efectos adversos que pudiera usted tener. La parte final de la sección 4 incluye información sobre cómo comunicar estos efectos adversos.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lea todo el prospecto detenidamente antes de empezar a usar este medicamento, porque contiene información importante para usted.</span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conserve este prospecto, ya que puede tener que volver a leerlo.</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Su médico le dará una tarjeta de información para el paciente, que contiene información de seguridad importante que necesita conocer antes y durante el tratamiento con Hyrimoz. Conserve esta tarjeta de información para el paciente durante su tratamiento y durante los 4 meses siguientes a su última inyección (o la de su hijo) de Hyrimoz.</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene alguna duda, consulte a su médico o farmacéutico.</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento se le ha recetado solamente a usted, y no debe dárselo a otras personas aunque tengan los mismos síntomas que usted, ya que puede perjudicarles.</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta efectos adversos, consulte a su médico o farmacéutico, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Contenido del prospecto</span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Qué es Hyrimoz y para qué se utiliza</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Qué necesita saber antes de empezar a usar Hyrimoz</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cómo usar Hyrimoz</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Posibles efectos adversos</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservación de Hyrimoz</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Contenido del envase e información adicional</span></li><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Instrucciones de uso</span></li></ol></div></text><section id="2b2a8a8b-a6d7-4b07-bb31-ed509ccb02e9"><title value="1. Qué es Hyrimoz y para qué se utiliza" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029895" /><display value="Qué es &quot;X&quot; y para qué se utiliza" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz contiene el principio activo adalimumab, un medicamento que actúa sobre el sistema inmunitario (de defensa) de su organismo.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está indicado en el tratamiento de las enfermedades inflamatorias que se describen a continuación:</span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">artritis reumatoide,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">artritis idiopática juvenil poliarticular,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">artritis asociada a entesitis,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">espondilitis anquilosante</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">artritis psoriásica,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">psoriasis,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hidradenitis supurativa,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">enfermedad d</span><span style="font-family:Times New Roman; font-size:11pt">e Crohn,</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">colitis ulcerosa y</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">uveítis no infecciosa.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El principio activo de Hyrimoz, adalimumab, es un anticuerpo monoclonal. Los anticuerpos monoclonales son proteínas que atacan a una diana específica del organismo.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La diana de adalimumab es otra proteína llamada factor de necrosis tumoral (TNFα), que se encuentra en concentraciones elevadas en las enfermedades inflamatorias anteriormente descritas. Mediante la unión al TNFα, Hyrimoz bloquea su acción y disminuye la inflamación en dichas enfermedades.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Ar</span></span><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">tritis reumatoide</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La artritis reumatoide es una enfermedad inflamatoria de las articulaciones.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la artritis reumatoide en adultos. Si usted padece artritis reumatoide activa moderada a grave, puede que se le administren antes otros medicamentos modificadores de la enfermedad tales como metotrexato. En caso de que dichos medicamentos no funcionen lo suficientemente bien, se le administrará Hyrimoz para tratar su artritis reumatoide.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz también puede usarse en el tratamiento de la artritis reumatoide grave, activa y progresiva sin tratamiento previo con metotrexato.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz puede reducir el daño de los cartílagos y huesos de las articulaciones producido por la enfermedad y mejorar el rendimiento físico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Habitualmente, Hyrimoz se usa junto con metotrexato. Si su médico considera que el metotrexato no es apropiado, Hyrimoz puede administrarse solo.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil poliarticular y artritis asociada a entesitis</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La artritis idiopática juvenil poliarticular y la artritis asociada a entesitis son enfermedades inflamatorias de las articulaciones que normalmente aparecen por primera vez en la infancia.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la artritis idiopática juvenil poliarticular en niños y adolescentes de edades comprendidas entre los 2 y los 17 años y la artritis asociada a entesitis en niños entre 6 y 17 años. Los pacientes pueden haber recibido primero otros fármacos modificadores de la enfermedad, como metotrexato. Si esos medicamentos no funcionan lo suficientemente bien, los pacientes recibirán Hyrimoz para tratar su artritis idiopática poliarticular o artritis asociada a entesitis.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Espondilitis anquilosante y espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La espondilitis anquilosante y la espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante son enfermedades inflamatorias que afectan a la columna vertebral.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza en adultos para tratar dichas enfermedades. Si tiene espondilitis anquilosante o espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante, será tratado primero con otros medicamentos y si esos medicamentos no funcionan lo suficientemente bien, recibirá Hyrimoz para reducir los signos y síntomas de su enfermedad.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis en placas en adultos y niños</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La psoriasis en placas es una enfermedad inflamatoria de la piel que causa áreas enrojecidas, escamosas, con costras y cubiertas por escamas plateadas. La psoriasis en placas también puede afectar las uñas, provocando que se deterioren, se engrosen y se levanten del lecho de la uña, lo cual puede ser doloroso. Se cree que la psoriasis está causada por un defecto en el sistema inmune del cuerpo que lleva a un incremento en la producción de células de la piel.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la psoriasis en placas de moderada a grave en adultos. Hyrimoz también se utiliza para tratar la psoriasis en placas grave en niños y adolescentes de entre 4 y 17 años de edad que no hayan respondido o no sean buenos candidatos para recibir medicamentos que se aplican sobre la piel o tratamiento con luz UV.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Artritis psoriásica</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La artritis psoriásica es una enfermedad inflamatoria de las articulaciones asociada con la psoriasis.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la artritis psoriásica en adultos. Hyrimoz puede reducir el daño articular que produce la enfermedad en el cartílago y en el hueso y mejorar el rendimiento físico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa en adultos y adolescentes</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La hidradenitis supurativa (a veces denominada acné inverso) es una enfermedad inflamatoria de la piel de larga duración y a menudo dolorosa. Los síntomas pueden incluir nódulos sensibles (bultos) y abscesos (forúnculos) que pueden secretar pus.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Normalmente afecta a áreas específicas de la piel, como debajo del pecho, de las axilas, zona interior de los muslos, ingle y nalgas. También puede haber cicatrices en las áreas afectadas.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la hidradenitis supurativa en adultos y adolescentes a partir de 12 años. Hyrimoz puede reducir el número de nódulos y abscesos, y el dolor que normalmente va asociado a esta enfermedad. Puede haber recibido otros medicamentos previamente. Si esos medicamentos no funcionan lo suficientemente bien, recibirá Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn en adultos y niños</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La enfermedad de Crohn es una enfermedad inflamatoria del tubo digestivo.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la enfermedad de Crohn en adultos y niños de edades comprendidas entre los 6 y los 17 años. Si padece enfermedad de Crohn será tratado primero con otros medicamentos. Si no responde suficientemente a estos medicamentos, recibirá Hyrimoz para reducir los signos y síntomas de la enfermedad de Crohn.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa en adultos y niños</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La colitis ulcerosa es una enfermedad inflamatoria del intestino grueso.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar la colitis ulcerosa de moderada a grave en adultos y niños de edades comprendidas entre los 6 y los 17 años de edad. Si usted sufre colitis ulcerosa puede que primero le receten otros medicamentos. Si esos medicamentos no funcionan lo suficientemente bien, le recetarán Hyrimoz para reducir los signos y los síntomas de su enfermedad.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Uveítis no infecciosa en adultos y niños</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La uveítis no infecciosa es una enfermedad inflamatoria que afecta a ciertas partes del ojo. La inflamación produce una disminución de la visión y/o la presencia de moscas volantes en el ojo (puntos negros o líneas delgadas que se mueven a lo largo del campo de visión). Hyrimoz actúa reduciendo esta inflamación.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se utiliza para tratar</span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">adultos con uveítis no infecciosa con inflamación que afecta a la parte posterior del ojo,</span></li></ul></div><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">niños desde los 2 años de edad con uveítis crónica no infecciosa con inflamación que afecta a la parte frontal del ojo.</span></p></div></text></section><section id="b5fd663c-420b-4284-8b07-a1586585b8f3"><title value="2. Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; Qué necesita saber antes de empezar a usar Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029896" /><display value="Qué necesita saber antes de empezar a &lt;tomar&gt;&lt;usar&gt; &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="abb8bfaf-8189-44c9-aee4-15c5bd90b231"><title value="No use Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029897" /><display value="No use Hyrimoz" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si es alérgico a adalimumab o a alguno de los demás componentes de este medicamento (incluidos en la sección 6).</span></li></ul><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; padding-left:21.3pt"><span style="font-family:Times New Roman; font-size:12pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si padece una infección grave, incluyendo tuberculosis, sepsis (intoxicación de la sangre) u otras infecciones oportunistas (infecciones poco habituales asociadas al debilitamiento del sistema inmunitario). En caso de tener síntomas de cualquier infección, por ejemplo: fiebre, heridas, cansancio, problemas dentales, es importante que informe a su médico (ver “Advertencias y precauciones”).</span></li></ul><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; padding-left:21.3pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si padece insuficiencia cardiaca moderada o grave. Es importante que le diga a su médico si ha tenido o tiene algún problema cardiaco serio (ver “Advertencias y precauciones”).</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="f629c6bd-5a0e-4803-b5f6-881f84bcd52a"><title value="Advertencias y precauciones" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029898" /><display value="Advertencias y precauciones" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Consulte a su médico o farmacéutico antes de empezar a usar Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Reacción alérgica</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene una reacción alérgica con síntomas como opresión en el pecho, dificultad para respirar, mareo, hinchazón o sarpullido, interrumpa la administración de Hyrimoz y póngase en contacto con su médico inmediatamente ya que, en casos raros, estas reacciones pueden poner en peligro la vida.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Infección</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si padece cualquier infección, incluyendo las crónicas o las localizadas (por ejemplo, una úlcera en la pierna), consulte a su médico antes de comenzar el tratamiento con Hyrimoz. Si no está seguro, póngase en contacto con su médico.</span></li></ul></div><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Con el tratamiento con Hyrimoz podría contraer infecciones con más facilidad. Este riesgo puede ser mayor si disminuye la actividad de sus pulmones. Estas infecciones pueden ser graves e incluyen tuberculosis, infecciones causadas por virus, hongos, parásitos o bacterias u otros organismos infecciosos poco habituales y sepsis (intoxicación de la sangre).</span></li></ul></div><p style="margin:0pt 0pt 0pt 36pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En casos raros, estas infecciones pueden poner en peligro su vida. Es importante que en el caso de que tenga síntomas como fiebre, heridas, cansancio o problemas dentales, se lo diga a su médico. Su médico le puede recomendar parar temporalmente el tratamiento con Hyrimoz.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Tuberculosis (TB)</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Dado que se han descrito casos de tuberculosis en pacientes en tratamiento con adalimumab, su médico le examinará en busca de signos o síntomas de tuberculosis antes de comenzar su tratamiento con Hyrimoz. Esto incluirá la realización de una evaluación médica minuciosa, incluyendo sus antecedentes médicos y pruebas de diagnóstico (por ejemplo, radiografía de tórax y la prueba de la tuberculina). La realización y resultados de estas pruebas se debe anotar en su tarjeta de información para el paciente. Es muy importante que informe a su médico en caso de haber padecido tuberculosis o haber estado en contacto con un paciente de tuberculosis. Se puede desarrollar tuberculosis durante el tratamiento incluso si usted ha recibido tratamiento preventivo para la tuberculosis. Si apareciesen síntomas de tuberculosis (tos persistente, pérdida de peso, malestar general, febrícula) o de cualquier otra infección durante o una vez finalizado el tratamiento, póngase en contacto inmediatamente con su médico.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Viajes/infección recurrente</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico si ha residido o viajado por regiones en las que infecciones fúngicas como histoplasmosis, coccidiomicosis o blastomicosis son frecuentes.</span></li></ul></div><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico si tiene antecedentes de infecciones recurrentes u otras patologías o factores que aumenten el riesgo de infecciones.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Virus de la hepatitis B</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico si es usted portador del virus de la hepatitis B (VHB), si tiene infección activa por el VHB o si piensa que podría correr riesgo de contraer el VHB. Su médico le debe realizar un análisis para el VHB. Adalimumab puede reactivar el VHB en personas portadoras de este virus. En casos raros, especialmente si está tomando otros medicamentos que suprimen el sistema inmune, la reactivación de la infección por el VHB puede poner en peligro su vida.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Edad superior a 65 años</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene más de 65 años puede ser más susceptible de padecer infecciones mientras está en tratamiento con Hyrimoz. Tanto usted como su médico deben prestar atención especial a la aparición de signos de infección mientras esté siendo tratado con Hyrimoz. Es importante informar a su médico si tiene síntomas de infecciones, como fiebre, heridas, sensación de cansancio o problemas dentales.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Procedimientos dentales o cirugía</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si le van a realizar una intervención quirúrgica o dental, informe a su médico de que está usando Hyrimoz. Su médico le puede recomendar que suspenda temporalmente el tratamiento con Hyrimoz.</span></li></ul></div><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad desmielinizante</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si padece o desarrolla una enfermedad desmielinizante (una enfermedad que afecta a la capa aislante que rodea los nervios, como la esclerosis múltiple), su médico decidirá si debe ser tratado o continuar en tratamiento con Hyrimoz. Informe inmediatamente a su médico si tiene síntomas tales como cambios en la visión, debilidad en brazos o piernas o entumecimiento u hormigueo en cualquier parte del cuerpo.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Vacunas</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Ciertas vacunas contienen formas vivas pero debilitadas de bacterias o virus, que provocan enfermedades y no se deben administrar durante el tratamiento con Hyrimoz por si causan infecciones. Consulte con su médico antes de la administración de cualquier tipo de vacuna. Se recomienda, si es posible, que los niños reciban todas las vacunas programadas para su edad antes de iniciar el tratamiento con Hyrimoz. Si recibe Hyrimoz mientras está embarazada, su hijo puede tener un riesgo mayor de sufrir infecciones durante aproximadamente los 5 meses siguientes a la última dosis que haya recibido de Hyrimoz durante su embarazo. Es importante que informe al médico de su hijo y a otros profesionales sanitarios sobre su uso de Hyrimoz durante el embarazo, para que ellos puedan decidir si su hijo debe recibir alguna vacuna.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Insuficiencia cardiaca</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante que informe a su médico si ha padecido o padece problemas serios de corazón. Si padece insuficiencia cardiaca leve y está en tratamiento con Hyrimoz, su médico debe hacerle un seguimiento continuo de su insuficiencia cardiaca. En caso de que aparezcan nuevos síntomas de insuficiencia cardíaca o empeoren los actuales (por ejemplo: dificultad al respirar, o hinchazón de los pies), debe ponerse en contacto con su médico inmediatamente.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Fiebre, cardenales, sangrado o aspecto pálido</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En algunos pacientes, el organismo puede ser incapaz de producir un número suficiente del tipo de células sanguíneas que combaten las infecciones (glóbulos blancos) o de las que contribuyen a parar las hemorragias (plaquetas). Si tiene fiebre persistente, cardenales o sangra muy fácilmente o está muy pálido, consulte enseguida a su médico. Su médico puede decidir la interr</span><span style="font-family:Times New Roman; font-size:11pt">upción del tratamiento.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Cáncer</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En muy raras ocasiones se han dado casos de ciertos tipos de cáncer en niños y adultos tratados con adalimumab u otros agentes que bloquean el TNFα. Las personas con artritis reumatoide de grados más graves y que padezcan la enfermedad desde hace mucho tiempo pueden tener un riesgo mayor que la media de desarrollar un linfoma y leucemia (cáncer que afecta a las células de la sangre y a la médula ósea). Si está en tratamiento con Hyrimoz el riesgo de padecer linfoma, leucemia</span><span style="font-family:Times New Roman; font-size:11pt">y otros tipos de cáncer puede incrementarse. Se ha observado, en raras ocasiones, un tipo de linfoma específico y grave en pacientes en tratamiento con adalimumab. Algunos de estos pacientes recibían tratamiento también con los medicamentos azatioprina o mercaptopurina. Informe a su médico si está tomando azatioprina o mercaptopurina con Hyrimoz.</span></li></ul></div><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Además se han observado casos de cáncer de piel (tipo no melanoma) en pacientes que usan adalimumab. Avise a su médico si durante o después del tratamiento apare</span><span style="font-family:Times New Roman; font-size:11pt">cen nuevas zonas de piel dañada o si las marcas o zonas con daños existentes cambian de apariencia.</span></li></ul></div><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se han producido casos de cánceres, diferentes del linfoma, en pacientes con una determinada enfermedad pulmonar, denominada enfermedad pulmonar obstructiva crónica (EPOC), tratados con otro agente bloqueante del TNFα. Si tiene EPOC, o fuma mucho, debe consultar a su médico si el tratamiento con un bloqueante del TNFα es adecuado en su caso.</span></li></ul></div><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Enfermedades autoinmunes</span></span></p><p style="margin:0pt; text-indent:-21.3pt; text-align:justify; line-height:115%; padding-left:21.3pt; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En raras ocasiones el tratamiento con Hy</span><span style="font-family:Times New Roman; font-size:11pt">rimoz podría dar lugar a un síndrome tipo lupus. Contacte con su médico si tiene síntomas como erupción persistente sin explicación, fiebre, dolor articular o cansancio.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="d604e68b-f75d-46c5-9b7a-5a8fe19b434f"><title value="Niños y adolescentes" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029899" /><display value="Niños y adolescentes" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No administre Hyrimoz a niños menores de 2 años con artritis idiopática juvenil poliarticular.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No administre Hyrimoz a niños menores de 4 años con psoriasis pediátrica en placas o colitis ulcerosa pediátrica.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No administre Hyrimoz a niños menores de 6 años con enfermedad de Crohn pediátrica.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No utilice la pluma precargada de 40 mg si están recomendadas dosis diferentes a 40 mg.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="c6158c0f-ca3a-4abc-bcca-55e983bab62e"><title value="Otros medicamentos y Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029900" /><display value="Otros medicamentos y Hyrimoz" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Informe a su médico o farmacéutico si está tomando, ha tomado recientemente o pudiera tener que tomar cualquier otro medicamento.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se puede tomar junto con metotrexato o con ciertos medicamentos antirreumáticos modificadores de la enfermedad (sulfasalazina, hidroxicloroquina, leflunomida y preparaciones inyectables a base de sales de oro), corticoesteroides o medicamentos para el dolor, incluidos los antiinflamatorios no esteroideos (AINEs).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No debe utilizar Hyrimoz junto con medicamentos cuyos principios activos sean anakinra o abatacept debido a un incremento del riesgo de infección grave. No se recomienda combinar adalimumab y otros antagonistas del TNF con anakinra o abatacept, debido al posible aumento del riesgo de infecciones, incluidas las infecciones graves y otras posibles interacciones farmacológicas. Si tiene alguna duda, consulte a su médico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="e93ef887-890d-41a6-943a-d90ecb8139f7"><title value="Embarazo y lactancia" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029902" /><display value="Embarazo y lactancia" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Debe considerar el uso de métodos anticonceptivos adecuados para evitar quedarse embarazada y continuar con su uso durante al menos 5 meses después del último tratamiento con Hyrimoz.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si está embarazada, cree que podría estar embarazada o tiene intención de tener un bebé, pida consejo a su médico sobre el uso de este medicamento.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz debe usarse durante el embarazo solo si es necesario.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Según un</span><span style="font-family:Times New Roman; font-size:11pt">estudio en embarazo, no hubo un mayor riesgo de defectos congénitos cuando la madre había recibido tratamiento con adalimumab durante el embarazo comparado con las madres con la misma enfermedad que no recibieron tratamiento con adalimumab.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz puede usarse durante la lactancia.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si utiliza Hyrimoz mientras está embarazada, su hijo puede tener un riesgo más alto de contraer una infección.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es importante que informe al médico pediatra y a otros profesionales sanitarios sobre el uso de Hyrimoz durante el embarazo antes de que el bebé reciba ninguna vacuna (para más información sobre vacunas ver la sección “Advertencias y precauciones”).</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="112efd35-401f-47f6-a303-a4cf279df0e5"><title value="Conducción y uso de máquinas" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029903" /><display value="Conducción y uso de máquinas" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La influencia de Hyrimoz sobre la capacidad para conducir, montar en bicicleta o utilizar máquinas es pequeña. Se puede producir sensación de que la habitación da vueltas (vértigo) y alteraciones de la visión después de utilizar Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hyrimoz contiene sodio</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Este medicamento contiene menos de 1 mmol (23 mg) de sodio por dosis de 0,8 ml; esto es, esencialmente “exento de sodio”.</span></p></div></text></section></section><section id="6d7e7872-d28f-403a-8158-c5ade14e428e"><title value="3. Cómo usar Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029905" /><display value="Cómo &quot;&lt;tomar&gt;&lt;usar&gt; X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Siga exactamente las instrucciones de administración de este medicamento indicadas por su médico. En caso de duda, consulte de nuevo a su médico.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está disponible como pluma de 40 mg y como jeringas precargadas de 20 mg y 40 mg para que los pacientes se administren una dosis de 20 mg o 40 mg completa.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Artritis reumatoide, artritis psoriásica, espondilitis anquilosante o espondiloartritis axial sin evidencia radiográfica de espondilitis anquilosante</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.5pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.5pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas como dosis única</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">En el caso de la artritis reumatoide el tratamiento con metotrexato se mantiene durante el uso de Hyrimoz. Si su médico determina que el metotrexato es inapropiado, Hyrimoz puede administrarse solo.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Si usted padece artritis reumatoide y no recibe metotrexato durante su tratamiento con Hyrimoz, su médico puede decidir darle 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg de Hyrimoz cada semana u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:120.5pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                        <td style="width:163pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Artritis idiopática juvenil poliarticular</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Niños, adolescentes y adultos desde 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Niños, adolescentes desde 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de entre 10</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg y menos de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:155.95pt; border:none">
                                        </td>
                                        <td style="width:163pt; border:none">
                                        </td>
                                        <td style="width:113.4pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Artritis asociada a entesitis</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Niños, adolescentes y adultos desde 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 6</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de entre15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg y menos de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:155.95pt; border:none">
                                        </td>
                                        <td style="width:163pt; border:none">
                                        </td>
                                        <td style="width:113.4pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día), seguida de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando una semana después de la primera dosis.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Debe continuar inyectándose Hyrimoz durante tanto tiempo como le haya indicado su médico. Si esa dosis no funciona lo suficientemente bien, su médico puede incrementar la dosis a 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Psoriasis en placas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 4 hasta 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, seguida de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una semana después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:155.95pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 4 hasta 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de entre 15</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg y menos de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, seguida de 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg una semana después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.4pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No procede</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:155.95pt; border:none">
                                        </td>
                                        <td style="width:163pt; border:none">
                                        </td>
                                        <td style="width:113.4pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hidradenitis supurativa</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día durante dos días consecutivos), seguida de una dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en el mismo día) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Después de dos semanas más, continuar con una dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales</span><span style="font-family:Times New Roman; font-size:11pt">u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas, según se lo haya recetado su médico.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se recomienda que utilice a diario un líquido antiséptico en las zonas afectadas.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adolescentes desde 12 hasta 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como 2 inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día), seguida de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando una semana después.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si esa dosis no funciona lo suficientemente bien, su médico puede aumentar la dosis a 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Se recomienda que utilice a diario un líquido antiséptico en las zonas afectadas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como 2 inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día), seguida de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si se requiere una respuesta más rápida, su médico puede recetarle una primera dosis de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día durante dos días consecutivos), seguida de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si esa dosis no funciona lo suficientemente bien, su médico puede incrementar la dosis a 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Enfermedad de Crohn pediátrica</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 6 hasta 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como 2 inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día), seguida de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si se requiere una respuesta más rápida, su médico puede recetarle una primera dosis de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día durante dos días consecutivos) seguida de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si esa dosis no funciona lo suficientemente bien, el médico de su hijo puede incrementar la dosis a 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 6 hasta 17</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso menor de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg seguida de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si se requiere una respuesta más rápida, su médico puede recetarle una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) seguida de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si esa dosis no funciona lo suficientemente bien, el médico de su hijo puede incrementar la frecuencia de la dosis a</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día durante dos días consecutivos) seguidos de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si esa dosis no funciona lo suficientemente bien, su médico puede incrementar la dosis a</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg semanales u 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:430.6pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Colitis ulcerosa pediátrica</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:151.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Niños y adolescentes desde 6</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">años de edad con un peso de 40</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">kg o más</span></em></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:151.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 160</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como cuatro inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día o dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día durante dos días consecutivos) inicialmente, seguidos de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg por día).</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que cumplan 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad mientras estén en tratamiento con 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas, deberán continuar con la dosis prescrita.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Niños y adolescentes desde 6</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">años de edad con un peso inferior a 40</span></em><em><span style="font-family:Times New Roman; font-size:11pt;"> </span></em><em><span style="font-family:Times New Roman; font-size:11pt;">kg</span></em></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:151.2pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en un día) inicialmente, seguidos de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como una inyección de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg) dos semanas después.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A partir de entonces, la dosis habitual es de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:144.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los pacientes que cumplan 18</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad mientras estén en tratamiento con 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas, deberán continuar con la dosis prescrita</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:151.2pt; border:none">
                                        </td>
                                        <td style="width:144.7pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:432.35pt"><tr><td colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.35pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Uveítis no infecciosa</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Edad y peso corporal</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué cantidad y con qué frecuencia se debe tomar?</span></strong></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Notas</span></strong></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Adultos</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una primera dosis de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg (como dos inyecciones de 40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg), seguida de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas comenzando una semana después de la primera dosis.</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En la uveítis no infecciosa, se puede continuar el tratamiento con corticoesteroides u otros medicamentos que afectan el sistema inmune durante el uso de Hyrimoz. Hyrimoz también se puede administrar solo.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Debe continuar inyectándose Hyrimoz durante el tiempo que le haya indicado su médico.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg o más</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas junto con metotrexato</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Su médico también puede prescribir una primera dosis de 80</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, que puede ser administrada una semana antes de empezar con la dosis habitual.</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:134.7pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Niños y adolescentes desde 2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">años de edad con un peso menor de 30</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">kg</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.8pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">20</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg en semanas alternas junto con metotrexato</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:148.85pt"><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Su médico también puede prescribir una primera dosis de</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">40</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">mg, que puede ser administrada una semana antes de empezar con la dosis habitual.</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt">
                                        <td style="width:134.7pt; border:none">
                                        </td>
                                        <td style="width:148.8pt; border:none">
                                        </td>
                                        <td style="width:148.85pt; border:none">
                                        </td>
                                </tr><![endif]--></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Forma y vía de administración</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se inyecta bajo la piel (vía subcutánea).</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Las instrucciones detalladas sobre cómo inyectar Hyrimoz figuran en la sección 7,</span><strong><span style="font-family:Times New Roman; font-size:11pt;">“Instrucciones de uso”.</span></strong></p></div></text><section id="354e104d-d1a5-45c4-9fe8-928b882624d6"><title value="Si usa más Hyrimoz del que debe" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029907" /><display value="Si usa más Hyrimoz del que debe" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si accidentalmente se inyecta Hyrimoz con más frecuencia de la que debe, llame a su médico o farmacéutico y explíqueles que ha tomado más de lo necesario. Siempre lleve la caja del medicamento consigo, incluso si está vacía.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="ef8a476b-8f5f-47a6-be0a-08ac5b2637fd"><title value="Si olvidó usar Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029908" /><display value="Si olvidó usar Hyrimoz" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si olvida administrarse una inyección, debe inyectarse la siguiente dosis de Hyrimoz tan pronto como lo recuerde. Después se administrará la siguiente dosis como habitualmente, como si no se hubiese olvidado una dosis.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="fc796ae5-eb48-4b9c-b90c-d53ecfbf6e7f"><title value="Si interrumpe el tratamiento con Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029909" /><display value="Si interrumpe el tratamiento con Hyrimoz" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La decisión de dejar de usar Hyrimoz debe ser discutida con su médico. Sus síntomas pueden volver tras parar el tratamiento.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si tiene cualquier otra duda sobre el uso de este medicamento, pregunte a su médico o farmacéutico.</span></p></div></text></section></section><section id="f167e390-6e03-43a7-898a-a7ed649a42e5"><title value="4. Posibles efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029910" /><display value="Posibles efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran. La mayoría de los efectos adversos son leves a moderados. Sin embargo, algunos pueden ser graves y requerir tratamiento. Los efectos adversos pueden aparecer hasta 4 meses o más después de la última inyección de Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Busque atención médica urgentemente</span></strong><span style="font-family:Times New Roman; font-size:11pt">si nota cualquiera de los siguientes signos de reacción alérgica o insuficiencia cardiaca:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">erupción grave, urticaria;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hinchazón de la cara, manos, pies;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultad para respirar, tragar;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">respiración difícil al hacer ejercicio o al estar tumbado o hinchazón de pies.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Póngase en contacto con su médico tan pronto como sea posible</span></strong><span style="font-family:Times New Roman; font-size:11pt">si nota alguno de los siguientes efectos</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">signos y síntomas de infección tales como fiebre, ganas de vomitar, heridas, problemas dentales, sensación de quemazón al orinar, sensación de debilidad, cansancio o tos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">síntomas de problemas nerviosos, como hormigueo, entumecimiento, visión doble, debilidad en brazos o piernas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">signos de un cáncer de piel, como una protuberancia o una herida abierta que no se cura;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">signos y síntomas de alteraciones en la sangre como fiebre persistente, cardenales, hemorragias y palidez.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los siguientes efectos adversos se han observado con adalimumab:</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Muy frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar a más de 1 de cada 10 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacciones en el lugar de inyección (incluyendo dolor, hinchazón, enrojecimiento o picor);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones del tracto respiratorio inferior (incluyendo resfriado, moqueo, sinusitis, neumonía);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de cabeza;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor abdominal (de vientre);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">náuseas y vómitos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sarpullido;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor en los músculos.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 10 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones graves (incluyendo envenenamiento sanguíneo y gripe);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones intestinales (incluyendo gastroenteritis);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones de la piel (incluyendo celulitis y herpes);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infección de oído;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones de la boca (incluyendo infección dental y dolor frío);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones en el sistema reproductor;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infección del tracto urinario;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones por hongos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infección en las articulaciones;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">tumores benignos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cáncer de piel;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacciones alérgicas (incluyendo alergia estacional);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">deshidratación;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cambios de humor (incluyendo depresión);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ansiedad;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">somnolencia y dificultad para dormir;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alteraciones sensoriales como hormigueo, escozor o entumecimiento;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">migraña;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">síntomas de compresión de la raíz nerviosa (incluyendo dolor en las parte baja de la espalda y la pierna);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alteraciones visuales;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación del ojo;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación del párpado e hinchazón del ojo;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">vértigo (sensación de que la habitación da vueltas);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sensación de pulso acelerado;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alta presión sanguínea;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rubor;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hematomas (hinchazón sólida con sangre coagulada);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">tos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">asma;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultad para respirar;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sangrado gastrointestinal;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dispepsia (indigestión, hinchazón y ardor);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reflujo ácido;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">síndrome del ojo seco (incluyendo sequedad en ojos y boca);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">picores;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sarpullido con picor;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">moratones;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación de la piel (como eczema);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">rotura de uñas de las manos y los pies;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de la transpiración;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">pérdida de pelo;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">psoriasis de nueva aparición o empeoramiento de la psoriasis existente;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">espasmos musculares;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sangre en orina;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas renales;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dolor de pecho;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">edema (acumulación de líquido en el cuerpo que puede causar la hinchazón del tejido afectado);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">fiebre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">disminución de plaquetas en sangre, lo que incrementa el riesgo de sangrado o moratones;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas de cicatrización.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Poco frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 100 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones inusuales (que incluyen tuberculosis) y otras infecciones que ocurren cuando la resistencia a la enfermedad disminuye;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones neurológicas (incluyendo meningitis viral);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones del ojo;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">infecciones bacterianas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">diverticulitis (inflamación e infección del intestino grueso);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cáncer, que incluye cáncer que afecta al sistema linfático (linfoma) y melanoma (un tipo de cáncer de piel);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alteraciones inmunológicas que pueden afectar a los pulmones, piel y ganglios linfáticos (la presentación más frecuente es en forma de una enfermedad llamada sarcoidosis);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">vasculitis (inflamación de los vasos sanguíneos);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">temblor;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">neuropatía (lesión de nervio);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">derrame cerebral;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">visión doble;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">pérdida de oído, zumbidos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sensación de pulso irregular como brincos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">problemas del corazón que pueden causar dificultad para respirar o hinchazón de tobillos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">ataque al corazón;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">saco en la pared de una arteria mayor, inflamación y coagulación en una vena, bloqueo de un vaso sanguíneo;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">enfermedades pulmonares que pueden causar dificultad para respirar (incluyendo inflamación);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">embolia pulmonar (bloqueo de una arteria del pulmón);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">derrame pleural (almacenamiento anormal de fluido en el espacio pleural);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación del páncreas que causa un dolor grave en el abdomen y la espalda;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">dificultad para tragar;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">edema (hinchazón) facial;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamación de la vesícula; piedras en la vesícula;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">grasa en el hígado (acumulación de grasa en las células del hígado);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">sudores nocturnos;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">cicatrices;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">crisis muscular anormal;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">lupus eritematoso sistémico (un trastorno inmunitario que incluye inflamación de la piel, corazón, pulmones, articulaciones y otros órganos);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">interrupciones del sueño;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">impotencia;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">inflamaciones.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Raros</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 1.000 personas)</span></p><p style="margin:0pt 0pt 0pt 21.3pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">leucemia (cáncer que afecta a la sangre y la médula ósea);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacción alérgica grave con shock;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">esclerosis múltiple;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alteraciones nerviosas (como inflamación del nervio óptico del ojo y síndrome de Guillain-Barré, una enfermedad que puede provocar debilidad muscular, sensaciones anormales, hormigueo en los brazos y la parte superior del cuerpo);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">parada cardiaca;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">fibrosis pulmonar (cicatriz en el pulmón);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">perforación intestinal (agujero en la pared del intestino);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hepatitis (inflamación del hígado);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reactivación del virus de la infección de la hepatitis B;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">hepatitis autoinmune (inflamación del hígado causada por el propio sistema inmunológico del cuerpo);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">vasculitis cutánea (inflamación de los vasos sanguíneos en la piel);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">síndrome de Stevens-Johnson (una enfermedad potencialmente mortal con síntomas tipo gripal y erupción con ampollas);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">edema (hinchazón) facial asociado con reacciones alérgicas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">eritema multiforme (erupción inflamatoria en la piel);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">síndrome similar al lupus;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">angioedema (hinchazón localizada de la piel);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">reacción liquenoide en la piel (sarpullido rojizo-morado con picor).</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Frecuencia no conocida</span></strong><span style="font-family:Times New Roman; font-size:11pt">(no puede estimarse a partir de los datos disponibles)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">linfoma hepatoesplénico de células T (cáncer sanguíneo raro que a menudo es mortal);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">carcinoma de células de Merkel (un tipo de cáncer de piel);</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sarcoma de Kaposi, un cáncer poco común relacionado con la infección por el virus del herpes humano</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">8. El sarcoma de Kaposi suele manifestarse con mayor frecuencia como lesiones cutáneas de color púrpura;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">fallo hepático;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">empeoramiento de una enfermedad llamada dermatomiositis (visto como erupción cutánea acompañada de debilidad muscular).</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de peso (para la mayoría de pacientes, el aumento de peso fue reducido</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Algunos efectos adversos observados en los ensayos clínicos con adalimumab no tienen síntomas y sólo pueden ser identificados mediante un análisis de sangre. Estos incluyen:</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Muy frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar a más de 1 de cada 10 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo recuento sanguíneo de células blancas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo recuento sanguíneo de células rojas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de lípidos en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">enzimas hepáticas altas.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 10 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">alto recuento sanguíneo de células blancas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo recuento sanguíneo de plaquetas;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">aumento de ácido úrico en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">valores anormales de sodio en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo nivel de calcio en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo nivel de fosfato en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">azúcar en sangre alto;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">valores altos de lactato deshidrogenasa en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">presencia de autoanticuerpos en sangre;</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">bajo nivel de potasio en sangre.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Poco frecuentes</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 100 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">valores de bilirrubina altos (análisis de sangre de la función hepática).</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Raros</span></strong><span style="font-family:Times New Roman; font-size:11pt">(pueden afectar hasta 1 de cada 1.000 personas)</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">recuentos bajos en sangre para células blancas, células rojas y plaquetas.</span></li></ul></div></text><section id="e3882316-ba26-4f6b-a89e-c0073ab0d338"><title value="Comunicación de efectos adversos" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029912" /><display value="Comunicación de efectos adversos" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si experimenta cualquier tipo de efecto adverso, consulte a su médico o farmacéutico, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="0a3a3a7e-113c-4051-b454-8234747b13ae"><title value="También puede comunicarlos directamente a través del sistema nacional de notificación incluido en elApéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento." /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="XXXXXXXXXXXX" /><display value="También puede comunicarlos directamente a través del sistema nacional de notificación incluido en elApéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento." /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text></section></section><section id="568b7791-c4ea-40a5-8ff9-411ad40c4453"><title value="5. Conservación de Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029913" /><display value="Conservación de &quot;X&quot;" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantener este medicamento fuera de la vista y del alcance de los niños.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No utilice este medicamento después de la fecha de caducidad que aparece en la etiqueta/blíster/caja después de “CAD” o “EXP”. La fecha de caducidad es el último día del mes que se indica.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservar en nevera (entre 2 °C y 8 °C). No congelar.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conservar la pluma precargada en el embalaje exterior para protegerla de la luz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt;">Almacenamiento alternativo:</span></span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cuando sea necesario (por ejemplo, cuando esté de viaje), puede almacenar Hyrimoz a temperatura ambiente (hasta 25 ºC) durante un periodo máximo de 21 días (asegúrese de protegerlo de la luz). Una vez que se ha sacado de la nevera para almacenarla a temperatura ambiente, la pluma precargada</span><strong><span style="font-family:Times New Roman; font-size:11pt;">se debe usar en los siguientes 21 días o desecharse</span></strong><span style="font-family:Times New Roman; font-size:11pt">, incluso si se vuelve a meter más tarde en la nevera. Debe anotar la fecha en la que retiró la pluma precargada de la nevera y la fecha después de la cual debe desecharla.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.</span></p></div></text></section><section id="905ed01b-34b5-4acd-bbb7-853c6a7882ce"><title value="6. Contenido del envase e información adicional" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029914" /><display value="Contenido del envase e información adicional" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p> </p></div></text><section id="0d57a21e-c64f-4e3b-a7bb-af6a4d206e82"><title value="Composición de Hyrimoz" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029915" /><display value="Composición de Hyrimoz" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El principio activo es adalimumab. Cada pluma  precargada contiene 40 mg de adalimumab en 0,8 ml de solución.</span></li><li style="margin:0pt 0pt 0pt 8.66pt; text-indent:0pt; text-align:justify; padding-left:12.64pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los demás componentes son: ácido adípico, ácido cítrico monohidrato, cloruro de sodio, manitol</span><span style="font-family:Times New Roman; font-size:11pt">(E</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">421)</span><span style="font-family:Times New Roman; font-size:11pt">, polisorbato 80</span><span style="font-family:Times New Roman; font-size:11pt">(E</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">433)</span><span style="font-family:Times New Roman; font-size:11pt">, ácido clorhídrico</span><span style="font-family:Times New Roman; font-size:11pt">(E</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">507)</span><span style="font-family:Times New Roman; font-size:11pt">, hidróxido de sodio</span><span style="font-family:Times New Roman; font-size:11pt">(E</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">524)</span><span style="font-family:Times New Roman; font-size:11pt">y agua para preparaciones inyectables.</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="fd1e10d0-885a-4146-aa4b-85383b6cea03"><title value="Aspecto del producto y contenido del envase" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029916" /><display value="Aspecto del producto y contenido del envase" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz 40 mg solución inyectable (inyección) en pluma precargada se suministra como 0,8 ml de solución de transparente a ligeramente opalescente, incolora a ligeramente amarillenta.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz se suministra en una jeringa precargada de un solo uso acoplada a una pluma de forma triangular con visor transparente y etiqueta. La jeringa del interior de la pluma es de vidrio de tipo I con aguja de acero inoxidable del calibre 29 y capuchón de la aguja interior de caucho (elastómero termoplástico), con 0,8 ml de solución.</span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cajas con 1 y 2 plumas precargadas de Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cajas de envases múltiples con 6 (3 envases de 2) plumas precargadas de Hyrimoz.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Puede que solamente estén comercializados algunos tamaños de envases.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Hyrimoz está disponible en jeringa precargada y en pluma precargada.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="c18d2ad5-5e66-4d07-8846-d024afa6577d"><title value="Titular de la autorización de comercialización" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029917" /><display value="Titular de la autorización de comercialización" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz GmbH</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biochemiestr. 10</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">6250 Kundl</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Austria</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Responsable de la fabricación</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz GmbH Schaftenau</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biochemiestr. 10</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">6336 Langkampfen</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Austria</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Novartis Pharmaceutical Manufacturing GmbH</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Biochemiestrasse 10</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">6336 Langkampfen</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Austria</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Pueden solicitar más información respecto a este medicamento d</span><span style="font-family:Times New Roman; font-size:11pt">irigiéndose al representante local del titular de la autorización de comercialización:</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:444.1pt"><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">België/Belgique/Belgien</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz nv/sa</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tél/Tel:</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">+32 2 722 97 97</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Lietuva</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Pharmaceuticals d.d filialas</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +370 5 2636 037</span></p></td></tr><tr style="height:51.7pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">????????</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">?????? ???????? ???</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">???</span><span style="font-family:Times New Roman; font-size:11pt">.: +359</span><span style="font-family:Times New Roman; font-size:11pt">2</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">970 4</span><span style="font-family:Times New Roman; font-size:11pt">7</span><span style="font-family:Times New Roman; font-size:11pt">47</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Luxembourg/Luxemburg</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz nv/saTél/Tel.: +32 2 722 97 97</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ceská republika</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz s.r.o.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +420 225 775 111</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Magyarország</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Hungária Kft.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: +36 1 430 2890</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Danmark/Norge/Ísland/Sverige</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz A/S</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tlf: +45 63 95 10 00</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Malta</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">San</span><span style="font-family:Times New Roman; font-size:11pt">doz Pharmaceuticals d.d.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +356 21222872</span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Deutschland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Hexal AG</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Tel: +49 8024 908 0</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Nederland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz B.V.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +31 36 52 41 600</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Eesti</span></strong></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Sandoz d.d. Eesti filiaal</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Tel: +372 665 2400</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Österreich</span></strong></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Sandoz GmbH</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Tel: +43 5338 2000</span></p></td></tr><tr style="height:49.65pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ελλ?δα</span></strong></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Novartis (Hellas) A.E</span><span style="font-family:Times New Roman; font-size:11pt">.B.E.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ: +30 210 281 17 12</span></p><p style="margin:0pt; page-break-after:avoid; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Polska</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Polska Sp. z o.o.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel.: +48 22 209 70 00</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">España</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Farmacéutica, S.A.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +34 900 456 856</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Portugal</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Farmacêutica Lda.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +351 21</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">196 40 00</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">France</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz SAS</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tél:</span><span style="font-family:Times New Roman; font-size:11pt">+33 1 49 64 48 00</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">România</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sando</span><span style="font-family:Times New Roman; font-size:11pt">z SRL</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +40 21 407 51 60</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:2pt 0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Hrvatska</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz d.o.o.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +385 1 23 53 111</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenija</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Lek farmacevtska družba d.d.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt; font-weight:normal">Tel: +386 1 580 21 11</span></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Ireland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Rowex Ltd.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: + 353 27 50077</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;">Slovenská republika</span></strong></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Sandoz d.d. - organizacná zložka</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt">Tel: +421 2 48 200</span><span style="font-family:Times New Roman; font-size:11pt"> </span><span style="font-family:Times New Roman; font-size:11pt">600</span></p><p style="margin:0pt; page-break-after:avoid"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr><tr style="height:51.15pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Italia</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz S.p.A.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +39 02 96541</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Suomi/Finland</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz A/S</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Puh/Tel: +</span><span style="font-family:Times New Roman; font-size:11pt">358 10 6133 400</span></p><p style="margin:0pt; page-break-after:avoid"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:50.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Κ?προς</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Pharmaceuticals d.d.</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Τηλ: +357 22 69 0690</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">United Kingdom (Northern Ireland)</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz Limited</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +44</span><span style="font-family:Times New Roman; font-size:11pt">1276 69 8020</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td></tr><tr style="height:75.5pt"><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:221.25pt"><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Latvija</span></strong></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Sandoz d.d. Parstavnieciba Latvija</span></p><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt">Tel: +371 67 892 006</span></p><p style="margin:0pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:222.85pt"><p style="margin:0pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p></div></text></section><section id="ddc2e303-15bc-4deb-bde2-84aac8b4e374"><title value="Fecha de la última revisión de este prospecto" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029919" /><display value="Fecha de la última revisión de este prospecto" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></div></text></section><section id="5856bb57-ae85-4240-9814-3cb046a67aeb"><title value="Otras fuentes de información" /><code><coding><system value="http://spor.ema.europa.eu/v1/lists/200000029659" /><code value="200000029920" /><display value="Otras fuentes de información" /></coding></code><text><status value="generated" /><div xmlns="http://www.w3.org/1999/xhtml"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos:</span><a href="http://www.ema.europa.eu"><span style="text-decoration: underline;"><span style="font-family:Times New Roman; font-size:11pt; color:#0000ff">http://www.ema.europa.eu</span></span></a><span style="font-family:Times New Roman; font-size:11pt">.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">7. Instrucciones de uso</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Para ayudar a evitar posibles infecciones y garantizar un uso correcto del medicamento, es importante que siga estas instrucciones.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Asegúrese de leer, comprender y seguir estas instrucciones de uso antes de inyectar Hyrimoz. Su profesional sanitario le debe enseñar a preparar e inyectar de forma correcta Hyrimoz con la pluma precargada antes de usarlo por primera vez. Si tiene alguna pregunta, consulte con su profesional sanitario.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Su pluma precargada de un solo uso de Hyrimoz</span></strong></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="376" height="149" alt="" /></p><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Figura A: piezas de la pluma de Hyrimoz</span></em></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">En la</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura A</span></em><span style="font-family:Times New Roman; font-size:11pt">se muestra la pluma una vez retirado el capuchón.</span><strong><span style="font-family:Times New Roman; font-size:11pt;">No</span></strong><span style="font-family:Times New Roman; font-size:11pt">retire el capuchón hasta que esté listo para administrar la inyección.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Es importante que:</span></strong></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No abra</span></strong><span style="font-family:Times New Roman; font-size:11pt">la caja exterior hasta que esté listo para usar la pluma.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No use</span></strong><span style="font-family:Times New Roman; font-size:11pt">la pluma si el precinto de la caja exterior o el precinto de seguridad de la pluma están rotos.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">No deje nunca</span></strong><span style="font-family:Times New Roman; font-size:11pt">la pluma sin vigilancia en lugares en los que otras personas podrían manipularla.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Si se le cae la pluma,</span><strong><span style="font-family:Times New Roman; font-size:11pt;">no la utilice</span></strong><span style="font-family:Times New Roman; font-size:11pt">si presenta daños o si se ha caído sin el capuchón de la aguja puesto.</span></li></ul></div><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Para que la inyección resulte más cómoda, inyecte Hyrimoz 15–30 minutos después de sacarlo de la nevera.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Deseche la jeringa usada de forma inmediata después de usarla.</span><strong><span style="font-family:Times New Roman; font-size:11pt;">No reutilice la pluma.</span></strong><span style="font-family:Times New Roman; font-size:11pt">Ver “</span><strong><span style="font-family:Times New Roman; font-size:11pt;">4. Eliminación de plumas usadas”</span></strong><span style="font-family:Times New Roman; font-size:11pt">al final de estas instrucciones de uso.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Conservación de la pluma</span></strong></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Conserve la pluma en la caja en una nevera, entre 2 ºC y 8 ºC.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Cuando sea necesario (por ejemplo, cuando esté de viaje), puede almacenar Hyrimoz a temperatura ambiente (hasta 25 ºC) durante un periodo máximo de 21 días (asegúrese de protegerlo de la luz). Una vez que se ha sacado de la nevera para almacenarla a temperatura ambiente, la pluma precargada</span><strong><span style="font-family:Times New Roman; font-size:11pt;">se debe usar en los siguientes 21 días o desecharse</span></strong><span style="font-family:Times New Roman; font-size:11pt">, incluso si se vuelve a meter más tarde en la nevera. Debe anotar la fecha en la que retiró la pluma precargada de la nevera y la fecha después de la cual debe desecharla.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mantenga la pluma en el embalaje original hasta que esté listo para usarla a fin de protegerla de la luz.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No someta a la pluma a calor o frío extremos.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No congelar la pluma.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Mantenga Hyrimoz y todos los medicamentos fuera del alcance de los niños.</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">¿Qué se necesita para la inyección?</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Coloque los siguientes artículos sobre una superficie limpia y plana.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La caja incluye:</span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Plumas/s precargada/s de Hyrimoz (ver Figura A). Cada pluma contiene 40 mg/0,8 ml de Hyrimoz.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La caja no incluye (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura B</span></em><span style="font-family:Times New Roman; font-size:11pt">):</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Toallita humedecida en alcohol</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Algodón o gasa</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Contenedor para desechar objetos punzantes</span></li></ul><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 21.3pt; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="279" height="118" alt="" /></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Figura B: artículos que no se incluyen en la caja</span></em></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Ver</span><strong><span style="font-family:Times New Roman; font-size:11pt;">“8. Eliminación de plumas usadas”</span></strong><span style="font-family:Times New Roman; font-size:11pt">al final de estas instrucciones de uso.</span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Antes de la inyección</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Preparación de la pluma</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Para que la inyección resulte más cómoda, saque la pluma de la nevera entre 15 y 30 minutos antes de inyectar Hyrimoz a fin de que alcance la temperatura ambiente.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mire a través del visor. La solución debe ser incolora a ligeramente amarillenta, así como transparente a ligeramente opalescente.</span><strong><span style="font-family:Times New Roman; font-size:11pt;">No la use</span></strong><span style="font-family:Times New Roman; font-size:11pt">si observa partículas o cambios de color. Si le preocupa el aspecto de la solución, consulte a su farmacéutico.</span></li></ul></div><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 21.3pt; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="222" height="131" alt="" /></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">Figura C: comprobaciones de seguridad</span></em></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; line-height:115%; font-size:11pt"><em><span style="font-family:Times New Roman; font-size:11pt;">antes de la inyección</span></em></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt"> </span></p><div style="margin: 0pt; margin-left: 4em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Mire la fecha de caducidad (CAD) en la pluma. No utilice la pluma una vez superada la fecha de caducidad.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No la utilice si el precinto de seguridad se ha roto.</span></li></ul></div><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si la jeringa no supera alguna de las comprobaciones anteriores, contacte con su farmacéutico.</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Elección de la zona de inyección:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">La zona de inyección recomendada es la parte delantera de los muslos. También se puede administrar en la parte inferior del abdomen, excepto en un área de 5 cm alrededor del ombligo (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura D</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Elija una zona diferente cada vez que se autoadministre una inyección.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No se inyecte nunca en zonas donde la piel esté dolorida, contusionada, enrojecida, descamada o endurecida. Evite las zonas con cicatrices o marcas extensas. Si padece psoriasis, NO se debe inyectar directamente en zonas con placas de psoriasis.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="221" height="189" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Limpieza de la zona de inyección:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.52pt; text-indent:0pt; text-align:justify; padding-left:10.78pt; font-family:serif; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">L</span><span style="font-family:Times New Roman; font-size:12pt">á</span><span style="font-family:Times New Roman; font-size:12pt">vese bien las manos con agua y jab</span><span style="font-family:Times New Roman; font-size:12pt">ó</span><span style="font-family:Times New Roman; font-size:12pt">n.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; padding-left:11.19pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:12pt">Limpie la zona de inyección con una toallita con alcohol realizando movimientos circulares. Espere</span><span style="font-family:Times New Roman; font-size:11pt">a que se seque antes de administrar la inyección (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura E</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li><li style="margin:0pt 0pt 0pt 10.52pt; text-indent:0pt; text-align:justify; padding-left:10.73pt; font-family:serif; font-size:12pt"><span style="font-family:Times New Roman; font-size:12pt">No toque la zona limpia antes de la inyección.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="171" height="206" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Extracción del capuchón de la pluma:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.2pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">No retire</span><span style="font-family:Times New Roman; font-size:12pt">el capuchón</span><span style="font-family:Times New Roman; font-size:11pt">hasta que esté listo para utilizar la pluma.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Extraiga</span><span style="font-family:Times New Roman; font-size:12pt">el capuchón</span><span style="font-family:Times New Roman; font-size:11pt">girándolo en la dirección de las flechas (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura F</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Una vez extraído, tire</span><span style="font-family:Times New Roman; font-size:12pt">el capuchón</span><span style="font-family:Times New Roman; font-size:11pt">.</span><strong><span style="font-family:Times New Roman; font-size:11pt;">No intente volver a colocarla</span></strong><span style="font-family:Times New Roman; font-size:11pt">.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Utilice la pluma en los 5 minutos siguientes a la extracción del capuchón.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es posible que vea unas cuantas gotas de líquido saliendo de la aguja. Es normal.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:179pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="162" height="132" alt="8951 0017w Full IFU Layout_single page" /></p><p style="margin:0pt; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Figura F: extraiga el capuchón</span></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Sujeción de la pluma:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Sujete la pluma formando un ángulo de 90 grados con respecto a la zona limpia de inyección (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura G</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td rowspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="171" height="198" alt="" /></p></td></tr><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><p style="margin:0pt; text-align:center; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="223" height="125" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Inyección</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:1pt; border-left-color:#000000; border-left-style:solid; border-left-width:1pt; border-right-color:#000000; border-right-style:solid; border-right-width:1pt; border-top-color:#000000; border-top-style:solid; border-top-width:1pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:432.2pt"><p style="margin:0pt; text-align:justify"><strong><span style="font-family:Times New Roman; font-size:11pt;">Antes de la inyección, lea lo siguiente:</span></strong></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt">Durante la inyección, oirá</span><strong><span style="font-family:Times New Roman; font-size:11pt;">2 fuertes clics</span></strong><span style="font-family:Times New Roman; font-size:11pt">:</span></p><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 11.6pt; text-indent:0pt; text-align:justify; padding-left:9.7pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El</span><strong><span style="font-family:Times New Roman; font-size:11pt;">primer clic</span></strong><span style="font-family:Times New Roman; font-size:11pt">indica que la inyección ha</span><strong><span style="font-family:Times New Roman; font-size:11pt;">comenzado</span></strong><span style="font-family:Times New Roman; font-size:11pt">.</span></li><li style="margin:0pt 0pt 0pt 11.6pt; text-indent:0pt; text-align:justify; padding-left:9.7pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Varios segundos más tarde, un</span><strong><span style="font-family:Times New Roman; font-size:11pt;">segundo clic</span></strong><span style="font-family:Times New Roman; font-size:11pt">indicará que la inyección</span><strong><span style="font-family:Times New Roman; font-size:11pt;">casi</span></strong><span style="font-family:Times New Roman; font-size:11pt">ha finalizado.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:Times New Roman; font-size:11pt"> </span></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Debe seguir sujetando la pluma con firmeza contra la piel hasta que vea que un</span><strong><span style="font-family:Times New Roman; font-size:11pt;">indicador verde</span></strong><span style="font-family:Times New Roman; font-size:11pt">ocupa todo el visor y se deja de mover.</span></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Comienzo de la inyección:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Presione la pluma con firmeza contra la piel para comenzar la inyección (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura H</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El</span><strong><span style="font-family:Times New Roman; font-size:11pt;">primer clic</span></strong><span style="font-family:Times New Roman; font-size:11pt">indica que la inyección ha comenzado.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Siga sujetando</span></strong><span style="font-family:Times New Roman; font-size:11pt">la pluma con firmeza contra la piel.</span></li><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">El</span><strong><span style="font-family:Times New Roman; font-size:11pt;">indicador verde</span></strong><span style="font-family:Times New Roman; font-size:11pt">muestra el avance de la inyección.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="206" height="184" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Finalización de la inyección:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.36pt; text-indent:0pt; text-align:justify; padding-left:7.94pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Espere hasta oír el</span><strong><span style="font-family:Times New Roman; font-size:11pt;">segundo clic</span></strong><span style="font-family:Times New Roman; font-size:11pt">, que indica que la inyección</span><strong><span style="font-family:Times New Roman; font-size:11pt;">casi</span></strong><span style="font-family:Times New Roman; font-size:11pt">ha terminado.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.36pt; text-indent:0pt; text-align:justify; padding-left:7.94pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Compruebe que el</span><strong><span style="font-family:Times New Roman; font-size:11pt;">indicador verde</span></strong><span style="font-family:Times New Roman; font-size:11pt">ha ocupado todo el visor y ha dejado de moverse (ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura I</span></em><span style="font-family:Times New Roman; font-size:11pt">).</span></li><li style="margin:0pt 0pt 0pt 13.36pt; text-indent:0pt; text-align:justify; padding-left:7.94pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">A continuación, puede extraer la pluma.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="183" height="182" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Después de la inyección</span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Compruebe que el indicador verde ocupa todo el visor</span></strong><span style="font-family:Times New Roman; font-size:11pt">(ver</span><em><span style="font-family:Times New Roman; font-size:11pt;">Figura J</span></em><span style="font-family:Times New Roman; font-size:11pt">)</span><strong><span style="font-family:Times New Roman; font-size:11pt;">:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Esto significa que el medicamento se ha administrado. Contacte con su médico si no se ve el indicador verde.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Es posible que haya una pequeña cantidad de sangre en la zona de inyección. Puede presionar un algodón o gasa contra dicha zona durante 10 segundos. No frote la zona de inyección. Si es necesario, puede cubrirla con un pequeño apósito adhesivo.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCACnAM4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6n1y51NvEmj6TYah9hS6jnkkkWJXY7AmB83H8Rqb+x9e/6Guf/wABIv8ACoNU/wCSg+Hf+ve7/lHXS0AYP9j69/0Nc/8A4Cxf4Uf2Pr3/AENc/wD4Cxf4VvUUAYP9j69/0Nc//gLF/hR/Y+vf9DXP/wCAsX+Fb1FAGD/Y+vf9DXP/AOAsX+FH9j69/wBDXP8A+AsX+Fb1FAGD/Y+vf9DXP/4Cxf4Uf2Pr3/Q1z/8AgLF/hW9RQBg/2Pr3/Q1z/wDgLF/hR/Y+vf8AQ1z/APgLF/hW9Wdfa7o2mzCHUNUtbWQjISWUKxHrigCl/Y+vf9DXP/4Cxf4Uf2Pr3/Q1z/8AgLF/hWtZ31lqFuLixuormE8b4nDD9KsUAYP9j69/0Nc//gLF/hR/Y+vf9DXP/wCAsX+Fb1FAGD/Y+vf9DXP/AOAsX+FH9j69/wBDXP8A+AsX+Fb1FAGD/Y+vf9DXP/4Cxf4VXt21iw8V2en3WsNf29zbyyFXhRCpUrjBUf7Rrpq5+9/5HzSP+vS4/mlAHQUUUUAFFFFABRRRQBzWqf8AJQPDv/Xvd/yjrpa5rVP+Sg+Hf+ve7/lHXS0AFFFFABRRRQAUUUUAFFFZPiLU5NJ0OW6t4/NuWZYYE/vSOwVf1NAEuuX0mnaBfX0IBkghZ1B6ZA4rP8NaKthY/aLhzPeXX7yeaQAvIx7k/oB0A4rPPg21vrJl8Qahe3l5cKVZxdSRhSR0VVYKB+FaGi3l3Z37eHtWlEs8UYe2uMY+0xDjkf3l6H8D3oAj1nRbO1FxrVhctpN8Fy0sOAsx7B1PDc8Dv6GsDToPEUFpFrkevz3LX8SXDCVPMtlYrygQfNGvTBHvnNd1qFlb6lp09jdLvhnQowrzvwtqWpeFLvUNB1/DafbznybhMnyUblWb0RjnnopyOmKAGR63dardz3WvaheaBJDIYrb7M7G1Qj+JpMbXJ9GAx068113h/wAQPeyNpuoeUNQiXcHhbMdzH2kQ/wAx2Ptg1vL9nngDLslicZGMFWBrgtf8BFtct/EHhtYdLu7L98vkZQTOM5RkGFIYcEnmgD0KiqWlajDqulwX0B+WVeV7qw4Kn3ByPwq7QAVz97/yPmkf9elx/NK6Cufvf+R80j/r0uP5pQB0FFFFABRRRQAUUUUAc1qn/JQfDv8A173f8o66Wua1T/koHh3/AK97v+UddLQAUUUUAFFFFABRRRQAjsqIzuwVVGST0AriNWuNY8U2DnQ1trWxgkSaG8vA3790YMNijGFyMbj17A11Wr2pvtFvbMSeWZ4XjDntkYrM8M6lY65odrNCyeZafuJoFYERSr8rDj0I49sGgCxourW+sIXeFra/txsntpPvRE/zB7EdRU2saPDq1qisxguYG8y3uE+/C/qP5EdwSKg1jRXu549S06f7JqkC7Y5R92Rf7jj+JT+Y6iq0PiJrjSJy9ubXU7ZlintpOfLYkAN7pzkHuKAKkOu3bXUNlq3+h3VsxF0E+5IpGFlU/wBwn/vknnpWdazJP4+ItXeazis3WUy/MSCylRzyR97GfftVzxhpVteeGV+3XEi6hHlre5icxSI33jypB24HzD0rIh1C3tbbTtG8OWCrqWpKspU5YQgrlpZWPJx2zyTgUDILy30PTfGGn2a3N3ZafPvFxb29zJHBG7EGMsAcKGIIxxkmvTEnt22xxzIxxwAwJxWD/wAIlZf8I9NpYkZpp5FnlunG55JVYMGPryo46ADFbcNlaW7b4bWGNyOWRApP5UCMSxRdL8Z3tknyQalGLyNe3mr8smPqNh+uTXR1znixWt7G21yHibS5lnP+1EflkX/vkk/UCuiByoPrQAtc/e/8j5pH/XpcfzSugrn73/kfNI/69Lj+aUAdBRRRQAUUUUAFFFFAHN6p/wAlB8O/9e95/KOukrmtU/5KD4d/697v+UddLQAUUUUAFFFFABRRRQBzOqW/9teJl0W7kYadDbi5lgU4FwxYgKx/ujGcd8jNS3nhe0WRb3Q9uk38a4WS3QKkg/uyIOGH6jsah8Ts2jyQ+KoZNos18q6jxnzYGYZx/tKcMPXkd6zNE8dXVxbvPrmkSWlt5rot1ENyqAcDzE+9GSMHnI55IoA6HRda+3h7O9h+x6pb8T2zH/x9T/Eh6g/ng1h+IbZNcjkn0kT2moxK0dvfiPMTnvG4z8yHpyMdwaXXEt9Wuo721uz5scYbT7i1wxMhPI3DqOmVPGM+lcra+MpluJfDc2nz3l3DKyrbWS70uGB5Ak4CxhjznkYI5AoAy7jVNZ1WytrCW5huLyRDHJbRbiYlVsOJSfuruGMDJc4GcGvSfDuiw6Reom0tdSW3mTyvyzuTzz6cAAdAABVHTPDCaHp731ysb6pqOoRXN7Ii4XJkGEH+yvAH0zXUYx4g+tt/7NQBfooooAyPE8fneEdWj9bWT/0E1oWcnm2FvL/fjVvzFLdwi5sZ7duksbIfxGKzPC05uPCemsxy6wiNvZl+U/qDQBs1z97/AMj5pH/XpcfzSugrn73/AJHzSP8Ar0uP5pQB0FFFFABRRRQAUUUUAc1qn/JQPDv/AF73f8o66Wua1T/koHh3/r3u/wCUddLQAUUUUAFFFFABUN1dW9jaSXV3MsMMY3M7HgCku7u2sbOW7vJkhgiUs7ucBRXnNz4lsdajbW7qUCxtJG+zWUny7WXjzpx+qqfUHr0AJ9Y1T7VF/bGsBra1izJZ2cpxtHaeUevdVPTjv089tPHOs/8ACVQ3WjWe6xkIhWwK/PdLnmQns3U5PrzWTrmuXninUQFEr2zSZhhPDXLf329FHYdAK7LQPDsumRKI4/tmtXy4jjGVUL/eY9UiH5t+Neeqs69S1J2it338kcqnKpL3Nl17mxfR6JrM6w6Dp7rq1ySGW2mktxF/eeXyyOB+ZPArrvCfgzTfClm4t83F5NzNcyfec+g/uqOwFV/BMVpb2lxDLC0Wthv9PEuN5boCuOPLx93HGPfNddXoHUUNYVm0qVlXcYysmB32sG/pUfmp/bVtLuzHcQFY27Eghsflz+BrTIBBB5BrESwZZDprbxDGwntZR/yzweV/Dp9DjtQBt0UdqKACuc8JnZDq9n2tdSnUD0DESf8AtSujrndDHkeKfE1t/fuIbofRoVT+cZoA6Kufvf8AkfNI/wCvS4/mldBXP3v/ACPmkf8AXpcfzSgDoKKKKACiiigAooooA5rVP+Sg+Hf+ve7/AJR10tc1qn/JQfDv/Xvd/wAo66WgAooooAKKK5Dxtrc1tpkmk6Ws0+oXCfOLdcvBDn55PYgZx3J6UAeTfGPxBqmqa4uk2szHQrXDM0Odksw6qzd9vp0/Hpzb3UnjLS47Nr77JrlsFKb22xaiq9I5P9odj+de4XWmeGbrwN9kdoV0rycrMCBt4+9nsa+erPwlr2uaukPh2xuZrCS4MMGoOhWNgOrk9gP/ANXPFKUVKLi+oNJqzPSvB2m28cCTIgv9anbyxaldvlkdfMH8Ea/+PH1yK9h0XRU0uGSSWZrq/uDvuLl+rn0A7KOgHaqfhTwtbeGdM8szPeX8oU3N5L9+YgYH0A7CuipQhGEVGKshJKKsjG1jRWvZYtR0+b7Jqltnypv4XHdHH8Sn07HkUuja2uo+Za3UBstSt+J7VzyP9pT/ABKexH44PFbFZWr6JBqnlTpI9rfW53QXUXDxn0/2lPdTwaoZq0VzR1rVtHdY/EFj5tt/z/2Sl0H++n3l+oyPpW9aXlrfW63FncR3ETdHjbINAE9FFFABXNapN/YfiSLWpVP2C6jW1uZAP9SQSUc/7OWIJ7ZHaulpk0MVxA8M0YkjdSrKwyCD2oAcrBlDKcg9xWBe/wDI+aR/16XH80qLRJJtI1OTw3dSF4gplsJWOS0XeMnuU/VSPepb3/kfNI/69Lj+aUAdBRRRQAUUUUAFFFFAHNap/wAlB8O/9e93/KOulrmtU/5KB4d/697v+UddLQAUUUUAcX8TPF2o+CPBUmv6fpf9oeVMiT9f3EbHBlIHJC8cVN4bk0dfDq65a6mmoJer9pm1BmH77Izn2A6Be3SupuLeG6tpLa5iWWGRSro4yGB6givKdG+EM/h7xWy6Trzr4MmkNxLocqlgsnYK3ZM8le+AOaBktj4SuPE17qVz9se28L30odbNouZ8H5nTP3FJHHHPXvmvT7W0trGzitLSBIYIVCJGgwFA7CplVUUKoAA4AHaloEFFFFABRRRQAdetc3qOjzafdNrXh6NY7oDM9qPlju19COgf0b8DxXSUUAU9M1K21XTor60bdHIOh4KkcFSOxB4Iq5XMsF0Hxajr8ljrLbWA+6lyBkH23qCPqo9a6agAooooAyde0ptTska2k8i/tXE9rMP4HHY+qkZBHoTWFY6tHq3izSJtvlXEdtcxXEB+9DIDHlT/ADHqCDXZ1ylzp1rD8UNO1GKPZcTWM6SFeA4DJgkeo9aAOrooooAKKKKACiiigDmtU/5KD4d/697v+UddLXM6/DqsfiPR9W07S21BLWOeOSNZUjYbwmD8xAP3TTv7c8Rf9Cbc/wDgZB/8VQB0lFc3/bniL/oTbn/wMg/+Ko/tzxF/0Jtz/wCBkH/xVAHSUVzf9ueIv+hNuf8AwMg/+Ko/tzxF/wBCbc/+BkH/AMVQB0lFc3/bniL/AKE25/8AAyD/AOKo/tzxF/0Jtz/4GQf/ABVAHSUVzf8AbniL/oTbn/wMg/8AiqP7c8Rf9Cbc/wDgZB/8VQB0lFc3/bniL/oTbn/wMg/+Ko/tzxF/0Jtz/wCBkH/xVAHSUVzf9ueIv+hNuf8AwMg/+Ko/tzxF/wBCbc/+BkH/AMVQBoeINOOqaFcWqcTgCSFu6SKdyH8wKl0fUF1XRbW/XjzYwWX+63Rh+BBH4Vlf234i/wChNuf/AAMg/wDiqytJuPE+l3WpIvhCc2dxP9ohQXkOYyw+cfe6Fst/wI0AdzRXN/254i/6E25/8DIP/iqP7c8Rf9Cbc/8AgZB/8VQB0lc/e/8AI+aR/wBelx/NKj/tzxF/0Jtz/wCBkH/xVRWp1rUPFtnf3mhyadb21vLGWknjkLMxXAAUn0NAHU0UUUAFFFFABRRRQBFcXVtaoJLq4jgQnAaRwoJ9OabBe2d0zLbXcM7JjcI5AxXPTOK87+JrNqniDwb4Vt7GK+nudQbUZIJW2qYbdNxycHGXeMdKh32q6/4ZE/haCw1LX8z3VvFKUe2jtg0isSgG7BdQQeCWpJ9X3/r9fuG12PUaK8v0r4ka1rmp+Hk07RLYWmrxXNzL5srCWzhiIAMgAwrMTjB6H6VP4f8AiXPrj+HYRpsMMmq2t3qEp8wlYLWJtscnT+MlDj0J9Kf9f19z+4R6TRXmeh/EfWNW0zQ76XQYIV14bLBRcEtI+WYsRjiMRLuLevHcV1HhDxHceJNP1C8ntYoIra/ns4nik3LMIm2Fxx0LBvyp2A3pLq1hnjgmuYo5ZPuIzgM30Hepq85uLSHXvj1BNJCkqeGtJZlLLnE9w+Bz7JGf++q6u61uXRPB8uueI4Y7eW2hMk8Vs5kXd2VSQM54HQcml0uHWxt0Vxeo+L9U0W2gk1XRUV794Lexiim3NLcSk/uj6bVG4t0wDiszVviNdaTFrFu2mwXGoadqFpYLHHIds7XAQgKcZ3AMSR7Uf1/X3oD0eivJbH4sald6pbWjaJbJFJq17p0ky3BKqlvE7tIPl5AKbT7kYq1ZfEvVjaaPdarocFmmp6Vc6mFExZoFiAZS/HCsGHuCaOl/62uHW39b2PUKK81t/iB4ha+8KreeHra3tdf2tvNyS8SCB5ZXK7eFXaoGTzuHSpLD4nR3ul6ZObOOG51Q3M9sjOSPssUhVZTgZJf5MKBklvam1YV7noLXNutyls08YncFljLDcwHUgdalrxW88S663ia88XtoVtHceHdBV7q2nlIMbzN5jRggZ3bEXr03Yrq5viG93fz2Hh7TP7Qu7aeC3mhLEMJHCs44GAERssxwM8daXl/W9h/1+B39RNcW6XEdu80azSAlIywDMB1wO9c/4i8W2uh6lY6UNj3t4kkyh2IVI0xubjJJJKgAckmud0K7uvEnxJtNQ1HTxZXWlaMGlgPJhluHztJ9dkYOO26ha/16/wCQbHo9Fec+IfFkek674o1M2UUp8M6UkgmM7qGeXLeSVHy5IRSDgn5h61Hb/Ey6Op3mnXWiqLpWs7e1hhl3NJPOpfy2yBt2oN5POFPrSTuN6f1/Xc9FFzbm5a1E8ZnVd5j3DcB649KlrxCXUZ9S8V61eXem215/aWq2vhiJIZ3jDRRAyzSK64b5Sz5/654rvYfGNxdWUut2mnJ/wj1tPLFLdyTBWEUQYPMB3XchUDqevSn0u/6/pNf0hPe39f1dM7KopLi3ilihlnjSSU4jRmALnGcAd64X/hYUlrfxnVLGK00/+yZNYmkMhMlvECAgZcfebJ/Iiuc8QeLRD4u0rWdbsEjj0fT21BbWJt83nXDCCCI9gzZYf/qo62/rr/kw/r8v80exUV5pr/xKvvDo1y1vNLt2v9O0+2vkjSYlXaaVolhJxw24ceua7fRbrWLu2nl1jTorFvNxAkcvmFo9oIZuBg5J49qNwKDeErV/iDF40fUr1ruKyaxjtiY/ISNmDNgbN2SVHO7tUOv+HJJtZHi3SzJNrllYS2lpbvIFgbeysd3Gc5UdwOOal1TxZHpXi208PzWLlryxuLyCfzAEYw7N0Zz0OHBz04NZY+IltJBC0OlTvcf6Mk9tvUSRSzBSIgP4mVWy2OAO9C2Vv6vf/gg/P+rW/wCAY/hXwdr2l6hPYi/1UeHb21mW6g1Q27zJK5GDFJFlu753k9sVpWPws0DT7cW8Gpanu/sn+x97TLu8npu+7jcBx0xwOM0f8LLhWe8LaFdtZ2d7LYTXUboyCVcBVAyCxZztAA4PWs2PXI7f4ha94k1i3a1TTLW20uKFJQ/mzStvKjoN3MY9ue1C1t/XR2/O3zB6X/rqv8r/ACOo1LwNpGoP4fdJ7uwOgho7X7JIEzGybGjbg/KVA6YPHBFRWHgDR9O+Hr+CLe6vv7PZGTzTMBMNzbshgAM5Pp9c1p6Br39uG/xZtALOf7P5gcOkpCgkqw64JwfcGtqm9fmC0+Rztp4Rs7LTNRtoNQv1u9RYPcaiJFFwxAAUghQq4AAAAAA7Ve13Q7LxF4dutD1Bpfs1ygRmjba6kEEMD6ggGtSik9Q2OYuPBtre2FhDf6tqF3eWFyl3b38jR+ckiqVBACCP7rMMbOc+vNRL4A0JZtNmDXPmWV++ps5kDG5uWjZPMkJHJAckAYAwMDAArrKKP6/r7kH9f1955T4n+GsVj4PhtvC9vqF5f29vPZQqs8S5FzIGnmcttBbqeDz0wa6c+AdLuNHubG9vL24kurRLFrh2jEiQLj92u1QoBxzxk+vSuvooA5rWvBel65qWn3tzPdwmxt5bZI4JAqMkgUENxn+EdCPfI4rPh+G+l2h0OTT9W1Sxn0e1Nkk0Mqbp4DgmOTchGMqDlQpHYiu1oo/r+vvA5dfA+ji+v52kupIL+eO5ubV5A0csiKqqSSNxACL8u7HHSl03wVp+leJdS1my1C/jj1KcXU9gJV+zmfaFMgG3dkhRkbtvtXT0ULQDnNa8JWuseINP15NSv9Nv7KN4RJZuo82JyC0bhlYYyAcjBHYip9H8L2Gi63q+rWs91JPqrxvKs0m5U2RrGAvGcYUdSec+tblFAHG3Xw50S9m1iS4ur511jULfULmMyLtZofL2xgbfuHylyOvXkZqK4+GeizatNqyajqVvey6n/avnRTKCknlCEoMqRsKDHOSM8EV29FC02/rb/JA9f6/rucXp/wANtC0yTTGt7rUCNOvLi9iVpgQzzbtwbjp8xxjB9SeaWD4d6XD4e1Pw62p6lNpF+k8a2jyoFtllyX8shQ3ViRuLY7V2dFD10DbU4GX4U+H7mDVI73UNUu31TTo9NuJZZxuKISVcYUYbLfTgcVI3wu0CWe/ubm91G5ub5bXfPLMpZZLdt0cg+XG7dzyCPbHFd1RR5h5f1/WhykngHQ5pBPcvcXFy99DqFxPIyl7mSL/Vq/y42LwQqgDj656uiijyDzOe1vwnZ694i0PWLqeRTpJm2xJjbMJFAIb2+UHHeqOl+DJtJ8U6vq1rqw+zalc/a2gNspkjkKhSBLnOw7QduM+9FFAPUpf8K5WPwVpWg2+syRXdhfrqTX3khjPPvZ2Z0JwdxY9+OPSqlx8LRLpd5br4gma6m1hdZiuJoFkCSLwFdeN64yDyO2MYooo/r8v8kO9/69f82d5p1pLZWKQTXHnyDksIxGo9lUdB6Dn6mrdFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=" width="206" height="167" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><ol style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 13.25pt; text-indent:0pt; text-align:justify; padding-left:8.05pt; font-family:Times New Roman; font-size:11pt; font-weight:bold"><strong><span style="font-family:Times New Roman; font-size:11pt;">Eliminación de plumas usadas:</span></strong></li></ol><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:253.5pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Deseche las plumas usadas en un contenedor para desechar objetos punzantes (precintable y resistente a los pinchazos). Por su salud y su seguridad y las de los demás, no se deben reutilizar nunca las plumas usadas.</span></li><li style="list-style: none; display: inline"><div style="margin: 0pt; margin-left: 2em; padding-left: 0pt"><ul style="margin:0pt; padding-left:0pt"><li style="margin:0pt 0pt 0pt 10.06pt; text-indent:0pt; text-align:justify; padding-left:11.24pt; font-family:serif; font-size:11pt"><span style="font-family:Times New Roman; font-size:11pt">Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente. La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él se realizará de acuerdo con la normativa local.</span></li></ul></div></li></ul><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p></td><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:178.7pt"><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><img src="data:image/jpg;base64,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" width="131" height="252" alt="" /></p></td></tr></table><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; text-align:justify; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;"> </span></strong></p><p style="margin:0pt; line-height:115%; font-size:11pt"><strong><span style="font-family:Times New Roman; font-size:11pt;">Si tiene alguna pregunta, consulte con un médico, farmacéutico o enfermero que esté familiarizado con Hyrimoz.</span></strong></p></div></text></section></section></section></Composition></resource></entry></Bundle></resource></entry></Bundle>